BioM Biotech in Bavaria Report 2022

BioM Biotech in Bavaria Report 2022_23

Content
Greeting

Bavarian Ministry of Economic Affairs
Preface Prof. Dr. Ralf Huss

Managing Director BioM, CEO and spokesman Bavarian Biotechnology Cluster
Company Development

Bavarian biotech in numbers - Company survey on business climate and international markets
Supporting the start-up scene is very close to my heart

Interview with Prof. Dr. Ralf Huss
MAxL – Munich Accelerator Life Sciences & Medicine

Perfect conditions for successful start-ups
Next generation antimicrobials

Invitris combats increasing antimicrobial resistance
Investments into biotech

How to finance valuable innovations
We want to understand the language of cells and communicate with them

Interview with Prof. Dr. Fabian Theis
AI in radiology

deepc paves new ways in healthcare delivery
DigiMed Bayern

Future medicine, individual and data-driven
Bavarian successes in CAR-T cell therapy

New approaches against AML - Cure for two autoimmune diseases
BIO-Europe 2023 in Munich

Strong Bavarian presence
Life Science Centers in Bavaria

Regional networks
Development in Regensburg

Guest contribution from Dr. Thomas Diefenthal
Billion deal at the IZB

Important cooperations of the IZB start-ups mark a dynamic period 2022/23
Company profiles
Imprint and contact

T N E T N O C Greeting Bavarian Ministry of Economic Affairs, Regional Development and Energy Preface Prof. Dr. Ralf Huss Managing Director BioM, CEO and spokesman Bavarian Biotechnology Cluster Company Development Bavarian biotech in numbers Company survey on business climate and international markets Supporting the start-up scene is very close to my heart Interview with Prof. Dr. Ralf Huss MAxL – Munich Accelerator Life Sciences & Medicine Perfect conditions for successful start-ups Next generation antimicrobials Invitris combats increasing antimicrobial resistance Investments into biotech How to finance valuable innovations We want to understand the language of cells and communicate with them Interview with Prof. Dr. Fabian Theis AI in radiology deepc paves new ways in healthcare delivery DigiMed Bayern Future medicine, individual and data-driven Bavarian successes in CAR-T cell therapy New approaches against AML Cure for two autoimmune diseases BIO-Europe 2023 in Munich Strong Bavarian presence Life Science Centers in Bavaria Regional networks Development in Regensburg Guest contribution from Dr. Thomas Diefenthal Billion deal at the IZB Important cooperations of the IZB start-ups mark a dynamic period 2022/23 Company profiles 5 7 8 13 14 18 20 24 26 30 34 36 38 40 42 44 47 BIOTECH IN BAVARIA - REPORT 2022|23 3

GREETING BAVARIAN MINISTRY OF ECONOMIC AFFAIRS GREETING Bavarian Ministry of Economic Affairs, Regional Development and Energy In recent years, Bavaria has experienced an extraordinary development in the field of biotechnology, having now become one of the key biotech sites in Germany and Europe. Academia, science and industry have always been closely interconnected in Bavaria, delivering the ideal foundation not only for innovation and growth, but also for deployment into real-world applications. Digitization has now taken on a crucial role. Modern technologies make it possi- ble to analyze massive volumes of data quickly and efficiently in order to garner valuable insights. Enormous potential lies in digitization, and that particularly holds true for biotechnology: Examples here include the facilitation of accurate and rapid diagnosis as well as the development of active ingredients for new, more effective therapies. We believe these kinds of approaches will play an increasingly important role in the treatment of disease and illness in the future – especially when carried out in combination with artificial intelligence. Another application to highlight is the analysis of health data – be it sourced from examinations at a doctor’s office or from wearable technology. We are now able to improve the healthspan and quality of life through better prediction, diagnosis and prevention. That makes it possible to personalize therapy and treatments and tailor them to a patient’s specific circumstances. Furthermore, predictions regarding optimal therapy and treatment can also be made on the basis of genetic information and clinical data. As the Ministry of Economic Affairs, we are constantly scanning for early-stage, innovative ideas in order to nurture them during the incubation phase. In- cubators and accelerators are key to enabling young project teams to prove themselves on their way to establishing a business. That is why our efforts have included the creation of the Munich Accelerator Life Sciences & Medicine located in Martinsried, which we call “MAxL”, as well as the “BioPark Jump” accelerator in Regensburg. In addition to the office space and lab stations needed, these facilities equip founders with a catalyzing environment to expedite market access and clear a path to commercial realization through strong networking and synergies. By operating across a variety of levels and sectors while also leveraging digiti- zation, AI and Big Data, it will be possible to attain remarkable advancements in healthcare and the treatment of disease and illness. In view of the tremendous potential found in Bavaria through academia, science and private enterprise, there is no doubt we will continue to play a leading role in the future of bio- technology. Hubert Aiwanger Roland Weigert BIOTECH IN BAVARIA - REPORT 2022|23 5 © StMWi HUBERT AIWANGER Member of the Bavarian State Parliament, Bavarian State Minister of Economic Affairs, Regional Development and Energy, Deputy Minister President of Bavaria © StMWi ROLAND WEIGERT Member of the Bavarian State Parliament, State Secretary at the Bavarian Ministry of Economic Affairs, Regional Develop- ment and Energy

PREFACE PROF. DR. RALF HUSS PREFACE PROF. DR. RALF HUSS Managing Director BioM, CEO and spokesman Bavarian Biotechnology Cluster © BioM At the beginning of this year, I took over as Managing Director of BioM Biotech Cluster Development GmbH from Prof. Dr. Horst Domdey. I am pleased to be able to continue the successful work of the last 25 years. BioM has already had numerous successes in this area. An other important step is the establishment and commissioning of the new incubator MAxL – Munich Accelerator Life Sciences & Medicine. Biotechnology itself is also at a relevant turning point – facing major challenges and opportunities at the same time. The biotechnology sector in Bavaria has experienced enormous growth in recent decades, especially in the number of new companies and start-ups, and has established itself as one of the leading locations worldwide. However, in order to main- tain and expand this position, we must face up to current developments and trends. Digitization is a decisive step in medical and any other bio- technology. The increasing linkage and digitization of process- es and data, particularly in biomedical development, enables us to improve medical research and care as well as make it more individualized by means of integrated structures. Hopeful and groundbreaking achievements also result from the opportunities given by digitization through the applica- tion of artificial intelligence (AI) and Big Data. The increasing availability of large data volumes is allowing us to gain better knowledge and insights into biological processes and disease mechanisms. With the help of AI, we will be able to analyze and use these data more quickly and systematically to also develop new diagnostic and therapeutic methods. In Bavaria, we already have some outstanding projects in this field. MAxL offers young and emerging pre-seed projects and start- ups a first-class and up-to-date infrastructure to quickly turn ideas into products and services. State-of-the-art laboratories and offices, as well as BioM’s extensive network of investors, mentors and experts from the start-up and industry world, are available for this purpose. With MAxL and together with other incubators, Bavaria once again underlines its role as an important player in the field of biotechnology and biomedical innovation. We are convinced that MAxL will make a further important contribution to strengthening Bavaria as a biotechnology location and look forward to many innovative start-ups that will successfully pursue their journey in this way. Thus, with a thirst for action and many exciting and promising innovations, we and the Bavarian biotechnology are taking firm steps towards new horizons. At BioM, we work closely with our partners from industry, re- search, clinics and politics to foster and advance these trends. By promoting innovation, we aim to further expand and strengthen Bavaria as a leading biotechnology location. Prof. Dr. Ralf Huss BIOTECH IN BAVARIA - REPORT 2022|23 7

COMPANY DEVELOPMENT BAVARIAN BIOTECH IN NUMBERS After years of crisis, the current figures show that biotech- nology is not without reason considered to be an industry of the future. Just like any other industry, the Bavarian biotech ecosystem is affected by the difficult global economic situa- tion, supply chain uncertainties and the loss of international partners. The worldwide situation is particularly hard on companies that live from producing and selling their own products. Research-based companies and drug developers have also had to adapt to many changes in recent years. However, the continuity in the most important key figures also shows that the biotech sector is somewhat more resilient than others, with those major problems slowing down further growth rather than causing a decline of the industry. The total number of biotech and pharmaceutical compa- nies based in Bavaria grew from 509 to 522 last year, with 11 start-ups and three new settlements adding to the count. The number of employees in the industry has also increased. From 44,000 at last count to just over 51,000 now. It must be noted, however, that part of the gain is not only due to the growth of the companies. BioM always endeavors to include all industry representatives in Bavaria. As a result, some companies were also newly included in the count this year and late registra- tions and corrections from the past year have been included. The global crises are also having a particularly strong impact on start-ups and smaller companies, which depend on ex- ternal support from investors. However, despite the current cautious investor market, Bavarian companies have managed to raise considerable sums and land some major deals. Financing & company news In total, the funds raised in 2022 amounted to more than EUR 350 million. The companies Tubulis (EUR 60 million; Series B), ITM (EUR 58 million; equity investment), CatalYm (EUR 50 million) and Ethris (USD 26.3 million; Series B) were particularly successful with their financing rounds. Both, Immunic (EUR 60 million) and Vivoryon (EUR 21 million), raising considerable amounts of funds via stock placements. As one of the Bavarian flagships, MorphoSys in particular has undergone a year of consolidation, restructuring and repo- sitioning. Poor study results and a subsequent slump in the share price were among the factors contributing to the recent market adaptations. This development once again highlights NEW COMPANIES COMPANY AATec Medical GmbH Crane Biosciences UG Deep Piction GmbH Ellennbe GmbH Mermaid Bio GmbH Invitris GmbH Fusix Biotech GmbH OpSYon Therapeutics GmbH Plectonic Biotech CATEGORY Therapeutics Therapeutics Diagnostics Therapeutics Therapeutics Therapeutics Therapeutics Therapeutics Therapeutics NEOsphere Biotechnologies GmbH Therapeutics OmicsChart Health IT Diatech Pharmacogenetics GmbH Diagnostics Atriva Therapeutics SCG Cell Therapy Therapeutics Therapeutics 8 BIOTECH IN BAVARIA - REPORT 2022|23 LOCATION Hohenbrunn Munich Munich Heilbrunn Munich Munich Munich Munich Munich Munich Planegg Munich Planegg Planegg

COMPANY DEVELOPMENT the difficulties and risks of the market, but at the same time certainly offers sufficient opportunities for a strong comeback. On a more positive note, some of the well-established players have attracted attention with significant investments in their infrastructure in Bavaria as a business location. The Ludwig-Maximilians-Universität of Munich (LMU) is adding two key elements to its Großhadern/Martinsried campus: ICON, for research into cardiovascular diseases, and DIAG, for diagnostics at the Max von Pettenkofer Institute for Bacteriology and Virology. The Bavarian Ministry of Economic Affairs is funding the establishment of the Munich Accelerator Life Sciences & Medicine (MAxL) in Munich-Martinsried with EUR 8.5 million. The project for a new Bavarian incubator infrastruc- ture for pre-seed projects and early-stage start-ups in the biotech and health tech sector is managed by BioM Biotech Cluster Development GmbH. Pipeline Compared to 2021, the pipelines of Bavarian companies have also matured. A whole series of R&D projects have been advanced and are now in a pre-clinical phase. In contrast, the total number of projects in phases 1-3 has slightly decreased. Thus, Bavarian ideas should continue to contribute to the successful use of biotechnology to improve the health of us all. The Roche Group is investing up to EUR 250 million in its new diagnostics research building at the Penzberg site. In addition, the first laboratories of the Fraunhofer Institute for immunology, infection and pandemic research were opened in Penzberg. In a unique collaboration with Roche, the Ludwig-Maximilians-Universität of Munich and the LMU Hospital in Großhadern/Martinsried, Fraunhofer aims to ad- vance precision medicine. Construction of the 9,200-square-meter Life Science Center research building has been advancing well in Gräfelfing. By summer 2024, state-of-the-art laboratory and office space will be completed, providing sufficient room for some 400 biotechnology scientists. The site is going to be home to two very successful Bavarian companies, Crelux and GNA Biosolutions (now part of HP), as well as the European office of Crelux’s mother company, WuXi AppTec. The WACKER Group is pooling its biotechnology research activities at the Munich site. The company is investing a double-digit million euro sum in the construction of a Bio- technology Center, which is scheduled to go into operation in 2024. By founding the TUM WACKER Institute for Indus- trial Biotechnology, Wacker Chemie AG and the Technical University of Munich (TUM) also aim to raise industrial bio- technology research in Germany to a top international level. BIOTECH IN BAVARIA - REPORT 2022|23 9

COMPANY SURVEY COMPANY SURVEY ON BUSINESS CLIMATE AND INTERNATIONAL MARKETS After the coronavirus pandemic, which brought not only opportunities but also many challenges for the biotech in- dustry, as companies around the world are now struggling with supply bottlenecks and rising prices. In a survey, BioM asked the companies in the Bavarian biotech cluster what their current business situation is and how they assessed the future of their company. In the survey, 62% of respondents rated their company’s current business situation as good (48%) or even very good (14%), 29% considered it satisfactory and 9% poor. Looking ahead, 42% of respondents assessed business devel- opment up to the end of 2023 as positive, 13% expected it to deteriorate, while 45% expected no change. As many as 72% of the companies surveyed expected medi- um-term development to improve over the next three to five years; only 7% expected their company’s business situation to deteriorate. How do you assess the current business situation of your company? 9% 14% 29% 48% Very good Good Satisfactory Poor How do you think the business situation will develop in the future? Until the end of 2023 In the next 3-5 years 13% 45% 42% 7% 20% 72% Improve Stay the same Deteriorate In terms of activity on international markets, Bavarian biotechs are represented worldwide according to the survey. At the top of the list are the member states of the European Union with over 90%, followed by the U.S., where 70% of the companies that participated in the survey are active. They are followed by Switzerland (53%), Great Britain (50%) and Japan (38%). And interest in internationalization remains high. At the top of the companies’ wish list are Great Britain, Switzerland, the U.S., Japan and Israel. However, India as well as Australia, New Zealand and South Korea are also markets that interest a quarter or more of the companies. In which international markets is your company represented? 93% 50% 53% 38% 70% EU Great Britain Switzerland Israel U.S. Japan China South Korea India Africa Australia/New Zealand Gulf States South America Other 19% 23% 24% 15% 8% 9% 20% 18% 3% Which international markets are you also interested in? EU Great Britain Switzerland Israel U.S. Japan China South Korea India Africa Australia/New Zealand Gulf States South America Other 40% 49% 49% 30% 45% 36% 19% 15% 25% 26% 26% 21% 21% 4% BIOTECH IN BAVARIA - REPORT 2022|23 13

INTERVIEW BioM: Congratulations on your new job as Managing Director of BioM. Have you already had some time to settle in here in the hallways in Martinsried? Prof. Dr. Huss: Yes, first of all thanks a lot for the congratulations. I am very happy to be here at BioM and in Martinsried. For a start, of course, the surroundings are not so new to me. I have been here in the vicinity of Munich Großhadern, Martinsried on and off in various roles for almost 30 years. So, on my first day of work, I didn’t really have to search and find my way. The team has given me a great welcome, so it makes this start much easier. Your predecessor, Professor Horst Domdey, co-founded BioM and success- fully led it for 25 years. Under him, the Munich or Bavarian biotech cluster has developed into one of the leading bio- technology locations in Germany and Europe. How do you feel about following in Professor Domdey’s footsteps? It is a great responsibility for me. However, it is not a burden, but rather a joyful re- sponsibility. Horst Domdey and the team have really achieved something here, built something up, and I am of course delighted to be able to continue this now. Now I am, and I say this also quite openly, certainly not Horst Domdey 2.0. I have worked for 30 years and was active in the field of ac- ademia, in the field of large-scale indus- trial pharmaceutical research, of start-ups. I certainly bring my own ideas and percep- tions. But I believe that this is just a logical continuation of what Horst Domdey has built up here, and in that sense I will be happy to continue it. What stands out for you about Bavaria as a location? What advantages do Bavaria and Munich offer the biotech industry, and where do you still see a need for improvement? BioM and the cluster has established itself as one of the leading clusters in Germany and Europe, and this is not just only due to Horst Domdey as an individual and to BioM, but also due to the opportunities that exist here in Munich. We have at least two major universities right here on site. We have a network of other universities, medical schools, biological, and chemical departments. We have research institutes outside of the universities, we have large- scale industries, we have a spirit here, if one may say so, of starting businesses. We have Max Planck, we have Helmholtz, we have Fraunhofer. What more could you actually want if you were ready and willing to implement new ideas here? So, the basis is unique. I can hardly think of any other areas, even worldwide, that have this density. Where we could certainly do more is – now we’re looking a bit at the U.S. and perhaps also at the U.K. and other neighboring European regions – perhaps start businesses more entrepreneurially in the future, bring them a bit more directly to implementation. That’s something we’re still lacking a bit. We are strongly driven by research. Great minds here, many prize winners. We also want to implement the entrepreneurial spirit to a greater extent. BioM has an extensive support program for company founders. At the beginning of December, BioM was awarded a grant by the Bavarian Ministry of Economic Af- fairs to set up the Munich Accelerator Life Sciences & Medicine, or MAxL for short, in Martinsried. Funded with 8.5 million euros, the project is intended to be an incubator for outstanding life science and healthtech start-ups in Bavaria. What potential do you see in MAxL and in the Bavarian start-up scene? I am convinced that the founding and promotion of MAxL is the logical contin- uation of the start-up scene. With this, we are joining other large centers, innovation centers, incubators worldwide, and that was basically one of the pieces of the puzzle that we were certainly missing here. We are thus also part of a scientific network to do the last proof of concept studies be- fore it really goes into implementation. So from that point of view, I think it’s abso- lutely consistent and right and has my full support. We are also currently seeing a new start-up scene that we have to adapt to. Increasingly, millennials – the young “dig- ital natives” – are founding, and they also bring a different spirit on board. The topic of young founders and supporting young founders is something that is very close to my heart. I believe that MAxL and the close connection with what we already have and the scene here in Munich will enable us to make more use of this potential, of the – I don’t want to call them “young guns” now – but of the new spirit and also of the “digital natives”. MAxL also fits in very well here. You yourself are a pathologist. After work- ing at Roche in Penzberg and co-founding the biotech company Apceth, now Minar- is, and after working a while at Definiens you were most recently Director of the Institute for Digital Medicine and Deputy Medical Director at the Augsburg Uni- versity Hospital. From all these previous positions, what do you take with you into your new position here at BioM and to what extent will they influence your work here at BioM? To be honest, I’m really proud to have been able to take so much with me. Especially this mixture of academia, clinical opera- tions, but also the companies where I was privileged to work, and finally also the way back to the clinic with this focus on digitization. All of this has brought along experiences and developed, also in the col- laboration. The basic answer to this is: I take the best from everywhere and try to apply it here for BioM and for the start-up scene. Over the last 30 years, I have seen many things which kept coming in waves. When I started, immunology was an important, exciting topic. Cell and gene therapy was coming up. In my first years at Roche, the company had a big in-silico department, so the mindset was also there already, namely how can data, how can computers support drug development? At that time, probably the time was not ripe yet, and right now we have reached the point when we see how immunotherapies are really bringing huge clinical successes. We are increasingly understanding the complexity of disease with the support of computers and medical imaging, allowing us now to combine this with cell and gene therapies. We have new regulations and also “in silico” is no longer a separate word, but actually means the use of computers and computer-based systems up to artificial intelligence. That is an essen- tial part of any development today. I find it highly exciting to see the fruits now and I am really happy and proud to be able to accompany this now in the last years of my professional activity here at BioM. In addition to immunology and cancer and stem cell research, your pet issue is above all digitization. In your opinion, BIOTECH IN BAVARIA - REPORT 2022|23 15

INTERVIEW how important is basically the subject area of digitization in medicine? A vital part. I believe that the digital avail- ability of data, of information, the use of this data at a higher speed, the understand- ing of higher complexity is exactly what we have been lacking in recent years and where we can also be increasingly success- ful. Does this make us a leader in Bavaria and Europe? Yes, certainly to some degree. Americans are undoubtedly a bit ahead of us here, too. But we do have a strong focus in some areas, especially in the field of diagnostics – what is meant by the term digital or specialized diagnostics. Let’s just take a brief look back at the coronavirus. How quickly we were able to do not only the diagnostics that everybody knows, the rapid test that we learned, and PCR, but also through the support of various organ- izations here in Germany, we actually man- aged to bring data together, to coordinate, to understand. Where are the real hotspots now? How do we deal with a pandemic? The coronavirus has been promoting the topic of digitization, support and use of data and AI-assisted analytics. I think that’s one of the developments that we should continue to leverage in the future and learn our positive lessons. So you also see digitization as another area for start-ups? Absolutely. The topic under the keyword “Digital Health”, but also data analysis, is something that we will absolutely sup- port in the area of start-ups and the use of technologies in the future. I believe that a close connection to the technological disciplines, keyword “quantum computing”, is really beneficial for biomedical research here as well, by allowing us to use more data faster and in a more structured way, and to create start-ups with that, and to create new jobs. When you talk about digitization in med- icine, there is no getting around health data. However, the availability and thus also the use of such data for research and better medical care is a very difficult topic, especially in Germany. How can we succeed in combining data protection and data treasure together? 16 BIOTECH IN BAVARIA - REPORT 2022|23 We have a bit of a hard time here in Ger- many when it comes to data usage. At the same time, I think we have all understood that data is a real treasure. For someone like me, a pathologist, but also a physician and clinician, knowing the data of the indi- vidual patient and how it fits into a cohort, into a group of diseases, into a response to new therapies is and always has been an essential subject matter for any med- ical decision. Today we have even more possibilities – with immunotherapy, with cell therapy, with molecular analyses, I just mention cancer genome, further analyses also of protein components in the blood and the tumors – to bring all this together. I think we understand that this data usage is really the treasure for the individual patient, but also for the community of all who are making an effort to be healthy and maintain their health. Can the European Health Data Space agreed in 2022 be a possible boost here? I think it is not only a possible boost, but it is the boost. We see, especially from the European environment and with many partner organizations and consortia that we have in the European area, that this is exactly where we should join forces and where we have to learn. Let’s just look at BENELUX, let’s look at the Netherlands, let’s look at Scandinavia, even at the British, who in my view have unfortunately left the EU, are also very strong there. The short answer is: yes and absolutely. Apart from the areas already mentioned: What will be the breakthrough topics in biotechnology in the near future? Predicting the future is, of course, always difficult. So forecasts about the future, we all know that, are not so easy. But we now have possibilities to apply forms of therapy in the clinical environment that we only thought about 20 years ago. We had already men- tioned immunotherapy, cell therapy and gene therapy. The coronavirus has shown us how quickly we can implement vaccines. We started in cancer therapy, but especially German companies, like BioNtech, Curevac and others, show us how you can quickly implement that based on new technolo- gies. These are the platform technologies that are absolutely groundbreaking topics for the future. Further issues are the con- sideration of demographic change. We see an increasingly aging society. We are seeing more and more diseases that are age-associated. I’m not just talking now about cardiovascular diseases, or diabetes, or increasing cancers but also of psycho- logical, psychomental problems. According to the WHO, the leading symptom will be depression by 2030. This is also something that we need to address therapeutically and also diagnostically. I believe that the topic of regenerative medicine, which is already being approached much more actively in the U.S., will be an increasing topic for us in the future. What might be the approach for depression? First of all, how do I diagnose depression? And with regard to the topic of data recog- nition and data management: How can I engage patients who have an underlying depressive mood to a greater extent? The topic of adherence to care, to the care environment both for physicians, but also for clinics, both therapeutically, thus with novel medications, but also in the context of monitoring? And now we come back to the topic of digital health. Can we inter- vene early here, in terms of just detection and moderate treatment of depression? And in this case, we are even talking not only about old patients or an aging soci- ety, but we also see a young society that has witnessed the coronavirus crisis and has also had increasing problems at least here. Keyword burnout symptoms and also stresses. I mean, who among the younger ones among us has ever experienced a war in Europe – thank God none. But the war is now very close, and these are threatening situations that we all perceive somewhere. Where do you see the greatest challenge in medicine in the next decade? I think the biggest challenge is: How can we really advance innovation for the benefit of the patient, taking into account cost optimization, and make the best drug available to the respective patient early, at the earliest, most appropriate time? This is certainly also a task and a topic for us here at BioM and in the field of biopharmaceuti- cal innovation.

What are your visions for BioM and the Munich and Bavarian biotech ecosystem? I believe that Munich and the Bavarian eco- system are optimally positioned to face and master the aforementioned challenges. My interest is to further bring together the ecosystem, which is still fragmented to a certain extent, to integrate it, to enter into partnerships, to intensify it, and to do that from academia, from research, via the topic of start-ups, innovation with the industry. And the industry partners are not just the classic biopharmaceutical companies such as a Roche in Penzberg and other companies, which of course we will also increasingly have here. However, there are also other partners entering the market, data companies like Google and Alphabet, which are also active in this area. I believe that this ecosystem must be expanded, re- designed and integrated. For me, these are the visions I have: that we create integrative solutions here, for the benefit of the region and innovation as well. What are you most looking forward to in your new role as head of BioM? When Horst Domdey asked me, or indi- cated, whether I might be interested in becoming head of BioM, I was immediately enthusiastic, although I had only been in Augsburg for two and a half years. You INTERVIEW don’t really change jobs that quickly. But I’m looking forward to tackling these chal- lenges and the opportunities with the team that has been built up over the years, to reconnect with the clinics, but also to have this interface with pharma and the phar- maceutical industry and with biotech, with the start-up scene. It’s actually almost a bit like a wish list store that you have. You can walk through a department store, look and put together your shopping cart. It’s the colorful diversity of people, of scientists, of participants, and that is the interaction I’m most excited about. You can listen to the full interview from our BioM podcast series Biotech Talk aus Bayern in German at: www.bio-m.org/Podcast/Interview_Huss

BIOM INCUBATOR MAxL – MUNICH ACCELERATOR LIFE SCIENCES & MEDICINE Perfect conditions for successful start-ups by MAxL is BioM’s unique co-creation start-up incubator for the future of medicine and life sciences located in Martinsried/Munich, the European hotspot for biotech. Based on BioM’s strong expertise, MAxL supports selected pre-seed and early-stage start-up teams from Bavaria and beyond with an exclusive high-end infrastructure: shared and fully equipped lab space, co-working and community space, struc- tured incubation and coaching program, co-working spaces, and numerous net- working opportunities. The project is funded with EUR 8.5 million from 2023-2027 by the Bavarian State Min- istry of Economic Affairs, Regional Develop- ment and Energy and is managed by BioM. With MAxL, pre-seed projects and start-ups from life sciences and healthtech receive precisely targeted support. Furthermore, we offer partnerships with pharma, big biotech, deeptech and other industry players and strategic partners, CROs and investors. Where? P On 900 m2 in close proximity to BioM - from end of 2023 onwards What? P Innovative therapeutics – all modalities, including ATMPs such as gene therapy, cell therapy, vaccines P Platform technologies for drug discovery, drug development, drug and vaccine production P Next-generation diagnostics and diagnostic platforms P Healthtech business models based on digital health, big data, machine learning and AI P Biotechnology-based solutions in the area of bioeconomy How? P Access to equipped state-of-the-art co-lab & co-working P Interdisciplinary co-creation space where life sciences meet AI & ML Hands-on venture building support & mentoring P Bioentrepreneurship & data science training P Access to vibrant start-up community & to extensive network of BioM Interested? We are happy to get in touch with you! © BioM CHRISTINA ENKE-STOLLE Phone +49 (0) 89 / 89 96 79-26 enke-stolle@bio-m.org © BioM DR. PETRA BURGSTALLER Phone +49 (0) 89 / 89 96 79-23 burgstaller@bio-m.org 18 BIOTECH IN BAVARIA - REPORT 2022|23

k c o t s r e t t u h s © NEXT GENERATION ANTIMICROBIALS Invitris combats increasing antimicrobial resistance Antibiotic resistance is one of the biggest challenges facing global health and our society worldwide. Munich-based start-up Invitris has developed a technology that enables developing and manufacturing the latest generation of synthetic antimicrobials, such as bacteriophages, to combat antibiotic-resistant infections. After winning the m4 Award 2021, EXIST-Forschungstransfer, and other awards, the team was recently accepted into the renowned U.S. start-up accelerator Y Combinator program. In 1928, Alexander Fleming discovered penicillin, the first antibiotic, thereby tak- ing away the horror of many bacterial in- fections. Almost a hundred years after this medical history and antibiotics milestone, to which around 20% of our current life ex- pectancy is attributed, a new threat that Fleming had already warned about has emerged. Resistant bacteria are increasing- ly on the rise worldwide and pose one of the greatest challenges for current global health. According to a study financed by the Bill & Melinda Gates Foundation and Wellcome Trust, antimicrobial resistance (AMR) is now the leading cause of death worldwide. The United Nations has warned that by 2050, multi-drug resistant germs will kill ten million people each year, 25% more than die from cancer today. Novel antimicrobials are urgently needed. One promising antimicrobial approach is treating infections with bacteriophages. The idea of treating infections caused by resistant germs with bacteriophages, i.e. viruses infecting bacteria but not humans, has been around for almost 100 years – longer than antibiotic therapy. So far, however, the approach has not been able to gain acceptance because the production of phages was not previously scalable and had to take place within the pathogenic host bacteria. Virus particles produced completely synthetically Invitris has found a particularly innovative solution to this problem. Unlike other com- petitors, Invitris produces the virus parti- cles completely synthetically. Previously, phages were produced by culturing them in vivo in the target bacteria. This requires a lengthy process development that has to be repeated for each new target bacteri- um. In this way, they managed to produce phages synthetically in vitro within a single system with the highest yield and purity. With its patent-pending technology, the spin-off from the Technical University of Munich is a world leader in this field. The idea came from Invitris co-founder and CTO Dr. Kilian Vogele. The physicist had found a way to synthesize any phage in a single process, independently of its host. With other researchers, Vogele and the Phactory team won first place among 20 BIOTECH IN BAVARIA - REPORT 2022|23

ANTIMICROBIALS 350 other teams at the 2018 International Genetically Engineered Machine (iGEM) competition and were awarded several prizes, including “Best in Entrepreneurship.” Motivated by this success, a core team was formed, which Dr. Patrick Großmann then joined. The start-up Invitris was born and the road to continued success was paved. At Invitris, modular thinking and modu- lar technologies play a major role. For its product and technology optimization, Invitris also uses machine learning, for example. “Our team thinks about biology also in a highly tech-driven way because of our training in various disciplines. This differentiates us from other traditional biotech companies,” explains Großmann, bioinformatician and CEO at Invitris. With the m4 Award to the own product In 2020, EXIST funding from the German Federal Ministry of Economics and Climate Protection (BMWK) helped the young re- searchers to further develop their cell-free synthesis technology concept. “EXIST was instrumental for successfully building a Winning the valuable m4 Award allows us to advance development for our own product. team to develop a technology platform, provided us with valuable support, and helped us a lot with technology transfer,” says Großmann, highly praising the pro- gram. valuable m4 Award allows us to advance development for our own product.” Invitris also has its sights set on further developing the technology against several WHO prior- ity 1 pathogens (“ESKAPE”). Things continued rapidly: from the plat- form, Invitris also wanted to develop its own product - phages, which do not yet exist in this form - and successfully applied for the m4 Award a year later. With the pre- seed competition coordinated by BioM, the Free State of Bavaria supports academic research projects with spin-off potential in the field of biomedicine with up to EUR 500,000 per team. “We are creating novel phages that do not exist in the environ- ment in this way and cannot be developed using conventional methods. Winning the The right timing Even though several large pharmaceutical companies have resumed their programs to develop novel antibiotics, it is generally not easy to raise money for anti-infectives, according to Großmann. Antibiotics are costly to develop, but at the same time they are inexpensive drugs thus far, and the treatment period is very short. Espe- cially when they are still, at best, reserve antibiotics that may never be used, it is hard to find investors. Together against antibiotic resistance: Sophie von Schoenberg, Dr. Kilian Vogele, Dr. Viktoria Krey, Franziska Winzig, Dr. Patrick Großmann of Invitris (from left) © Invitris BIOTECH IN BAVARIA - REPORT 2022|23 21

ANTIMICROBIALS Y Combinator teams passionately care about their customers and partners. As a result, many become massively successful; our goal is to be one of them. But Großmann is optimistic: “It is difficult to become profitable with reserve antibi- otics against resistant germs. With phages, however, you decrease the likelihood to generate population-wide resistance. So phages make a lot of sense as frontline antimicrobials, while valuable antibiotics can be withheld as a last resort, further de- creasing the likelihood for resistance.” New modalities tend to be more exciting than traditional chemical molecules for raising capital. In addition, Großmann is confident about regulatory issues, saying, “I think a lot of things are changing right now. Federal governments understand that reimburse- ment models need to be adjusted. Timing is good right now, and timing is everything when building a start-up.” Prizes upon prizes By having its finger on the pulse, the start- up continued to win further prizes and awards. In addition to winning Phase 1 and 2 in BayStartUP’s Munich Business Plan Competition 2021, Invitris was selected in the INCATE (Incubator for Antibacterial Therapies in Europe) Phase I in January 2022 and advised on scaling production and company formation. In April 2022, the team impressed at Rice University’s busi- ness plan competition and was pleased to receive investment prizes totaling over USD 90,000. Then, in early May, Invitris was selected by INCATE as the first company to receive EUR 250,000 in “Phase II funding.” The funding enables the company to complete its spin-off from the Chair of Physics of Syn- thetic Biological Systems at the Technical University of Munich (TUM) and to carry out a larger-scale production of phages, phage-derived and other antimicrobial proteins in the fight against antibiotic resistance. Meanwhile, the Invitris team comprises a total of six team members. After its found- ing in October 2022, the start-up also raised an angel investment relatively quickly so it could finance its move to the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried. Invitris places great emphasis on building long-term partnerships with other bio- pharmaceutical companies working on new therapeutic approaches to combat antimicrobial resistance. In addition to its own product development, the young founding team sees its business model as having two parts: On the one hand, Invitris offers third-party companies, on a licensing basis, to improve the effectiveness of their drug candidates under development. In addition, the start-up responds to requests for biomanufacturing in order to produce products that are highly scalable for clinical trials, for example. The goal: to create value Invitris reached another milestone when it was accepted into the U.S. start-up accel- erator Y Combinator. “Y Combinator is the role model start-up accelerator worldwide. The admission was transformative for us. YC teams passionately care about their customers and partners. As a result, many become massively successful; our goal is to be one of them,” Großmann explains. The program is now helping Invitris focus the company accordingly. “We have to prove that our model works and that we are possibly in a good position that not many biotechs are at this stage.” Großmann sees the entire Y Combinator community as extremely valuable for continued suc- cess. Joining Y Combinator also includes a standard USD 0.5 million deal that will help Invitris pay its staff, keep lab operations running, and be visible beyond that. “The immediate goal now is to build com- mercial partnerships and drive process development as well,” says Großmann. His plan: “We want to move from the laboratory to the industrial scale, ideally GMP-compliant, and be financed through sales and partnerships.” The start-up also wants to broaden its reach and develop microbial proteins in general, in addition to bacteriophage- and endolysin-based antimicrobial agents. If the young team continues to pursue its journey as ambitiously as it has so far, there is nothing to stop their progress. ©shutterstock 22 BIOTECH IN BAVARIA - REPORT 2022|23

BIOTECH INVESTMENTS INVESTMENTS INTO BIOTECH How to finance valuable innovations Huge costs, enormous risk and years of testing and study cycles. On paper, the development of new therapeutics and diagnostics does not seem very enticing. However, in the event of success, comparatively attractive margins and a real profit for society beckon. In itself, biotechnology should be quite interesting for investors willing to take risks and optimistic visionaries. However, financing biotech start-ups in Germany remains a major challenge. For young, innovative companies in particular, equity financing via venture or participation capital is often the only realistic option for generating the corresponding sums. So high capital requirements can be covered, most companies focused on R&D depend on the inclusion of international investors. This automatically puts the entrepreneurs in global competition for these funds, and bureaucratic and legal hurdles can become real deal breakers. How can start-ups and young companies in medical biotechnology in Germany nevertheless succeed in obtaining sufficient financing? Do we need a change in the framework conditions to make investment in these companies fundamentally more attractive? Questions, on which we sought five opinions from different perspectives. We think more about what we can lose instead of what we can win. e k s a a B p p i l i h P . r D © We founded NanoTemper during the 2008 financial cri- sis. A business angel invested in us to counter finance a BMBF grant. The grant more than doubled his investment. This made it very attractive. Since then, we finance our growth via the revenue we earn with our products from our customers. The situation for start-ups is now orders of magnitude better than the one we had in 2008. The investors are much more professional and understand biotech better. The biggest problem for me is the risk averse German mentality: we think more about what we can lose instead of what we can win. Conditions can always be better – that’s not the thing: we must stop complaining about the boundary conditions. Instead, we must use our full power to develop and sell leading products. That’s the spirit we need. DR. PHILIPP BAASKE CEO and co-founder NanoTemper Technologies 24 BIOTECH IN BAVARIA - REPORT 2022|23 DR. DOMINIK SCHUMACHER CEO and founder Tubulis (left) DR. JONAS HELMA-SMETS CSO and founder Tubulis The current risk averse climate makes it difficult for young biotechs to secure the financing needed to become successful. Therefore, seed funding programs, govern- ment grants and awards are especially important to raise initial capital and provide a first validation for a new technology. It is also critical to attract investors that share your vision and provide strategic guidance as well as a strong network. At Tubulis, we made it our focus from the beginning to build our network and work with the right advisors to create a strong, long-term development plan as well as attract an experienced team to react to the inherent challenges of drug development. With our Series B last year and our recent partnership with BMS we are in a strong position to leverage the cur- rent momentum in the ADC space to drive our oncology pipeline forward for the benefit of patients. s i l u b u T © Seed funding programs, government grants and awards are especially important.

Biotech is currently facing one of the toughest bear markets. l m Y a t a C © While German biotech has been gaining momentum internationally, biotech as a global industry is currently facing one of the toughest bear markets and careful venture investors. Therefore, lean companies with strong execution power, convincing business models, close to clinical proof of concept have a fair chance to qualify as attractive investment. When raising our Series C at CatalYm in Q4 2022, our new investors were particularly intrigued that our lead program Visugromab already in- dicated promising results in the first clinical study in late stage cancer patients. Our highly experienced team and rapidly executed clinical activities put us in a strong posi- tion. Together, it enabled us to raise funding dedicated to broadening our phase 2 activities from strong syndicate partners to further strengthen our shareholder base. ANNE BURGER CFO CatalYm The time to invest is now! l a t i p a K n r e y a B © Precision Medicine – the future of healthcare will (also) be digital. What we are seeing could be a kind of revolution – biotech, pharma, all life sciences and even healthcare will be digitalized. Just to name a few examples: the use of artificial intelligence in drug discovery, in radiology and for the analysis of real-world data. Thus, there are plenty of new opportunities for VCs to invest. This comes with some challenges, e.g. more interdiscipli- nary expertise will be needed in VC teams. Therefore, it is even more than ever necessary to create a start-up-eco- system that works well – here are some of the major issues: improved education at universities (lectures for potential founders), TTOs with VC-compatible regulations and also a European IPO exit channel comparable to NASDAQ. Overall, the future of life sciences will be a bright one, the time to invest is now! ANDREAS HUBER Scientific Director Life Science, Bayern Kapital BIOTECH INVESTMENTS DR. FEI TIAN Principal MIG Capital Currently, there are certainly strong incentives for VC investors to invest in biotech start-ups. We have seen the trend of stabilized valuations as a basis for attractive investment returns. In addition, emerging cutting-edge technologies contribute to a new vision of biotech innovation, for instance, AI and big data analytics enable insights targeting the microbiomes as well as transformative gene editing technologies for advanced therapies. There has been a rather stable record of the biotech sector performing in difficult economic times based on the insensitivity to the economic cycle and the exit path to fuel the evolving pipeline of global pharma companies. One essential factor as an improvement offering support to these long-term tailwinds and increasing incentives is to enhance and empower the confidence in the origin of the VC funds, namely the limited partners and fund investors. They can be provided with incentives in the form of tax benefits on the initial investment. Additionally, public matching facilities would enforce higher investing capital, and give stronger support to the VC funds and biotech start-ups, eventually leading to higher financial returns and social and healthcare system impacts. n a T i i e F © Stabilized valuations are a basis for attractive investment returns. BIOTECH IN BAVARIA - REPORT 2022|23 25

WE WANT TO UNDERSTAND THE LANGUAGE OF CELLS AND COMMUNICATE WITH THEM Interview with Prof. Dr. Fabian Theis Artificial intelligence in medicine - how can we use AI and Big Data to better understand the development of common diseases such as cancer, diabetes or Alzheimer’s and ultimately also improve therapies? Prof. Dr. Fabian Theis, Director of the Institute for Computational Biology at Helmholtz Munich and Professor of Mathematical Modeling of Biological Systems at the Technical University of Munich uncovers the secrets of human cells with AI. PROF. DR. FABIAN THEIS Director of the Institute for Computational Biology, Helmholtz Munich Professor of Mathematical Modeling of Biological Systems, TU Munich © Astrid Eckert / TUM 26 BIOTECH IN BAVARIA - REPORT 2022|23 k c o t s r e t t u h s ©

INTERVIEW BioM: Professor Theis, with the help of artificial intelligence, which is your ma- jor topic, you are investigating how cells function by looking at single cells and analyzing those using algorithms or com- puter-based methods. Your work opens up groundbreaking possibilities to gain a better insight into the development of public diseases such as cancer, diabetes and Alzheimer’s disease, and ultimately to improve therapies accordingly. Can you describe your work in more detail? Prof. Dr. Theis: We are interested in how cells make decisions. You can think of these cells as little computers. They take in external information and, depending on this information, they decide whether to proliferate, whether to die, whether to divide. I still find it fascinating, first of all considering it disease-free, that humans or basically, all organisms in all their com- plexity, have emerged from a single cell, and that everything works. All these cells contain the very same program. The DNA is the same everywhere, but the execution of the program is different. Now one can ask the question: how does this work? What is the language of the cells? In prin- ciple, it is the language of the genes. After the human genome project – one of the achievements of the last 20 years – we now know the genes. But we don’t yet know the grammar of how they work together. And if you will, we are now using AI to learn that. I think all of us by now know these language models like ChatGPT. We basically want to understand the language of the cells. In “a sense” we want to communicate with them. We want to understand how cells interact. We also want to ask them what goes wrong in disease. We would like to ask them what goes wrong in cell differentiation, so that, for example, we have non-functioning beta cells in diabetes that are no longer able to secrete insulin. And: if we understand what goes wrong, we would also like to ask: can this perhaps be rewound? Can you make new functional cells again? Is it possible to maybe understand what medication could be given to make something like that? These are the big questions that might be answered one day with such methods. Can you describe the benefits of artificial intelligence for patients by giving a con- crete example? You can envision AI like this: You want to emulate how we humans think, and to do that we use machine learning. For exam- ple, we measure cells in high throughput and try to understand what is happening in these large amounts of data. Then we use machine learning methods to define groups. As an example, to come back to this differentiation system, in a diabetic or, tragically, also in lung cancer patients or also in infectious diseases, there are certain cell types in a different state. What we are doing now is to create a space for all these cells where we measure this highly parametric data. You can’t imagine this in 3 dimensions, but in 20,000 dimensions. The cells are then in certain groups and we want to find these groups, in a data-driven way. We want to find clusters. Then we have these cell types that are not okay. Now it is getting interesting: there are always a few cells that just go from healthy to sick. This means that they are not isolated, that there are transitions in between. We can learn, if you will, these high-dimensional trajectories. This is how we do it with cells. Apart from diabetics and lung diseases, here is a second example. We can actually do that for patient read- outs as well, like for back of the eye ex- aminations in ophthalmology. The main reason for blindness in adulthood is dia- betes: This is called diabetic retinopathy, when multiple little blood vessels burst in the eye. Now we have a lot of back of the eye images of people. We group them in a high-dimensional space like our cells and then see that on the one hand, there are healthy people, on the other hand there are seriously ill people, and in between there are intermediate states. If one can now imagine at what point does such a healthy eye become slightly ill? If you learn this trajectory, then you can perhaps predict early on: hey, he can get it, and then you can intervene. Will AI and modeling soon be the main deciding factors in diagnosis and ther- apy? Will doctors be replaceable in the future? One of the founding fathers of artificial intelligence made a statement like this perhaps ten or 15 years ago - always over- optimistic, of course: “I would stop training pathologists.” Of course, that’s complete nonsense. It’s similar to an achievement in medicine 250 years ago, when doctors were afraid that they would no longer be needed to detect influenza. Now we have the clinical thermometer! And of course, there is no doctor today who does not use a clinical thermometer. It will be the same with artificial intelligence, and it has already started. Every one of us, incidental- ly not just doctors, but every one of us, will be using these models very naturally in the next five to ten years. That’s how it’s also going to be in medicine. AI is a supporting tool to handle this data complexity, and not just what’s currently being observed, but often the data that’s chronologically staggered as well, the medical record data that’s still there when I’ve been to another doctor. This data will be integrated into a model and then the doctor has it available and can make a better therapy decision. Predictions for certain disease risks are already possible, such as in type I diabetes. In the future, however, such predictions via genome sequencing will also be available for other indications. Do these predictions also entail risks for people who cannot handle them? How does a patient deal with such informa- tion? Likewise, how could third parties, such as insurance companies, use this information? Yes, this is indeed a complex and not at all trivial issue from an ethical point of view. You have just spoken about the patient in question. But of course, what if we de- termine someone’s genome sequence? It costs almost nothing anymore. 20 years ago, it cost 100 million and took ten years. Now it costs a few hundred dollars and can be done in a week or even less. This means that this data, our genome sequence, is go- ing to be all over the place. Of course, our genome plays a massive role in our disease development, which means that we need to support medicine to do something with it. But now to your question, how does one deal with something like that? These are precisely the areas where legal conditions are really needed. The frame- work conditions must be clearly defined. To what extent can you actually adjust policies and so on based on previous risks? Actually, this is already the case: If you have a history BIOTECH IN BAVARIA - REPORT 2022|23 27

INTERVIEW of alcohol addiction or something like that, then it might be more difficult to get one of these things. I once tried to take out a life insurance policy. My wife said: “But then you can’t go mountain climbing or anything like that.” In my opinion, first of all, you have to be completely transparent about it, and secondly, you have to set clear legal conditions about how far you can go with the policies. That’s obviously not my area of expertise. But I think that jurispru- dence, and perhaps also medical ethics, will have to deal with this very thoroughly. What fascinates you most about your work? We were just talking about the scientific stuff, but I almost think that the coolest or most beautiful thing is to be able to work in international teams with fantastically smart PhD students from all over the world, very diverse backgrounds, but so highly intelligent and so creative. It’s really fun. First, these methodologies that I have in my lab, but then bringing them together with experimental colleagues. We always want to work on data and thereby learn new things, but also create new results along the way. That’s always exciting, you always have something new to do, and hopefully we won’t be replaced by AI any time soon. In addition to high-ranking awards, you have recently been honored with the Gottfried Wilhelm Leibniz Prize. This prize is somewhat equivalent to the German Nobel Prize. What does this award mean for you and your research? First of all, it’s a recognition of the work we do here in the lab. My staff and I are really proud when we hear something like that. Yes, we were very happy. When we arrived in Berlin together with the whole family and were able to enjoy a really nice celebration, it’s something like that when you take a deep breath. With us, everything often happens very quickly. One paper finished, the next one already in prepara- tion, and the research results are just so exciting. During the COVID pandemic, we were able – and also had – to find answers to so many new issues. That was an exciting thing in the first place. But beyond that, it is a matter of course that this prize enables me to tackle and discuss a new research topic for which I don’t have my own fund- ing. The prize is relatively well endowed… very well endowed, and so I have to think about choosing a highly exciting new field, in which I am not normally so well informed or have not yet had a chance to get to grips with, and so we are trying to do more with generative AI models. Where do you want to go from here? Is there a higher level for you? Well, scientifically speaking, there is always a progression. Scientifically, nothing rests here. Biology, biotechnology, very well sup- ported by BioM, is incredibly fast. There is always a new device, a new machine that can measure something new, and for all these new observations, maybe also chron- ologically arranged, we will maybe some- day finally have a health record in Germany. Models are needed, and all these models should perhaps also be integrated. In other words, the wave of data that is coming our way is not going away. It is getting bigger and bigger, and we want to dig through it, we want to build understandable models that can then be given to the population as interpretable results. These are really difficult issues, and we will never get bored. Since 2020, you have been co-chairing the AI Council of the Bavarian State Government to bundle and network AI expertise in Bavarian science, industry, and society. Where do we stand in terms of the use of AI for medicine in Bavaria and in Germany? First, it has to be said that we in Germany are good in all kinds of areas due to very substantial long-term science funding. A lot has been invested in AI, especially here in Bavaria, through the Bavarian high-tech agenda, and we have always had and built up very strong expertise here in Munich. We are one of the largest centers now for “Health AI”, or, as I always say, “AI in health research”, with about 250 people and 30-35 group leaders here at the Computational Health Department at Helmholtz Munich alone. In addition, we have a whole range of extremely strong colleagues and partners at the TU and LMU. In this respect, there is really bundled expertise here. It’s great to bring together, through this AI Council, all these different individual initiatives and to communicate them in a way that people see themselves reflected externally, so that when we want to bring top people from the U.S. or the whole world to us, for example, we can tell them more clearly and show them in a more focused way what expertise and opportunities are here - not only in science, but naturally in business as well. Health data play a relevant role in your work. Compared to Germany, such data are more readily available in other countries such as the USA, Finland, Great Britain or Israel. Is the situation here in Germany more of a hindrance for your research? Data availability is absolutely a hindrance. A very clear point, yes! If you are working on model organisms or cells, it doesn’t play such a big role at the moment. But as soon as we want to look at patient co-variables or something like that, we are simply not as fast or as digital as in other places. For papers, I can simply collaborate interna- tionally. For my scientific research, we work beyond that. But we don’t advance the sys- tem that much here. In this respect, I am very excited. I’m very happy that the elec- tronic health record will soon be available here as well. Honestly, I personally would love to own my data that the different doctors generate. I don’t remember when I had my last doctor’s visits. Or I would also like to be able to see on my phone what medication my parents have right now, etc. I think that’s where we need to become more digital. If we have something like that, You can listen to the full interview from our BioM podcast series Biotech Talk aus Bayern in German at: www.bio-m.org/Podcast/Interview_Theis 28 BIOTECH IN BAVARIA - REPORT 2022|23

then we can also do better research and bring something back for health research. Perhaps as a very brief note: As part of the Bavarian AI Council, we have launched the so-called “Bavarian Cloud for Health Research (BCHR)” as an initiative intended to supplement the strong “medical infor- matics initiative”, which is active not only here in Bavaria but also in Germany, very strongly with central computers. The first prototypes are underway, so to speak, and the project is also very strongly supported by BioM. What is your vision? Where will we be in ten or maybe even 20 years? What do you think you and your colleagues will be working on then? It’s difficult to predict the future so far. But I think that we can already see that these methods from artificial intelligence, ma- chine learning, will change many things, many processes and how we work. I think that ten years from now, especially in biolo- gy, we will have a very prevalent and, in my opinion, totally impressive approach: I have now finished an experiment, have a result and I talk to the colleague who then has the idea to do this new experiment, that this process is accompanied by a so-called “experimental design”. In other words, we have an artificial intelligence model that acts as a digital twin, so to speak, pre- dicting what the next potentially exciting experiment might be, and then together we make the decision on how to proceed. So this means that we’ll have a lot more guided experimentation and this will allow us to explore much better the complexity of particular diseases, and not do it any longer in such an isolated way - paper by paper by paper - but assemble it more, so to speak. That would be my hope. W H W O E S S A E N T M S S O N K S E C N E E Q U I I T C S E Y S T O RY F I L E Q U I T Y Actively managed global investor network of >1,500 investors Institutional and Family Office investors Focus on seed to crossover rounds C H I N A L I C E N S I N G Joint Venture with YAFO Capital (Shanghai) Ltd. Specialist in fundraising, licensing and M&A transactions in the Asian market Access to >500 financial and strategic investors T R P R A N S O C A C E S T I F I N A N S I O N N G S N R O O T I S T A E L I N V R E C E C E C O M P E T E N D E B T Most successful advisor in Europe Direct access to all European and US Venture Debt Providers (Commercial, EIB and KfW) Access to more than 90 Venture Debt Providers V A L U A T I O N Joint Venture with BioScience Valuation GmbH Leader in evidence-based commercial, R&D, and economic evaluations Valuable support for investment and partnering decisions FCF Fox Corporate Finance GmbH Arno Fuchs Maximilianstr. 12-14 80539 Munich, Germany T: +49-89-20 60 409-100 arno.fuchs@fcf.de www.fcf.de

AI IN RADIOLOGY deepc paves new ways in healthcare delivery c p e e d © The Munich-based, emerging start-up deepc has developed a software platform that aims to fundamentally improve the work processes of radiologists. The platform is a one-stop shop for artificial intelligence (AI) applications in the field of radiology that allows clinical institutions to seamlessly integrate AI applications into their workflows. Medical imaging such as magnetic reso- nance imaging (MRI) or computed tomog- raphy (CT) is being used more than ever before. Our growing and aging population is causing the number of chronic diseases such as cardiovascular diseases and cancer to rise. This is accompanied by an increase in the number of imaging analyses needed to diagnose these diseases. This means more work and increased time pressure for radi- ologists: the specialists simply have hardly any time left for image interpretation. AI can support them in making a faster and at the same time more reliable diagnosis. This is where the company deepc comes in. Since November 2022, the start-up deepc has been based in Munich downtown. When taking the old-fashioned paternos- ter lift to the premises on the 6th floor, it doesn’t exactly feel like digitization and AI. Once you enter the office of deepc and meet the deepc’s employees, however, you notice that this is exactly what the compa- ny has specialized in: the development of a software platform to support the entire radiology ecosystem with AI. One platform, a wide variety of applications There are already many commercial AI applications available that can support radiologists in their daily routine workflow. Interestingly, deepc had started with de- veloping AI itself, and has recognized how complex it is for clinical institutions to iden- tify AI applications fitting their needs, clar- ify regulatory status, ensure that data pro- tection requirements will be met, agree on a contractual framework and finally install and deploy a multitude of AI applications. The start-up has identified this market niche and developed a platform that clinics, hospitals and medical practices can use to easily deploy a wide variety of AI applications from globally leading com- panies. “Our product is essentially an app store designed specifically for the field of radiology, with a focus on AI applications,” explains co-founder and CEO of deepc Dr. Franz Pfister, a leading expert at the inter- face between between medicine and AI. Meanwhile, deepc has discontinued its own AI development and is fully focused on platform development. The company’s core technology, deepcOS®, is a cloud-na- tive, vendor-independent platform that can be seamlessly integrated with existing radiology workflows. The platform enables AI companies to efficiently market certified AI products. For hospitals and medical practices, the platform provides a one-stop shop for all AI-enabled radiology applica- tions and services. 30 BIOTECH IN BAVARIA - REPORT 2022|23

AI IN RADIOLOGY However, the identification of suitable investors and the financing process were complex. Here, the exchange with other stakeholders from the biotech and life science scene was especially valuable. “Having a network makes a huge difference, especially talking to other experienced founders or investors and getting their tailored advice. The development of such a network is particularly facilitated by the support of start-up network organizations and incubators,” says Moosbauer, COO of deepc. More time thanks to AI Pfister clearly sees the use of AI in reporting as an opportunity for a faster diagnosis and thus also for timely therapy: “The basic problem is that the workload of radiolo- gists is so high that they do not even have time for reporting. The number of exami- nations has doubled in Germany in the last ten years, but the number of radiologists has remained nearly the same. The issue is present in Germany, but much more dras- tic in other countries. This unsatisfactory situation is one of the first areas that can be significantly improved and optimized through AI.” Our product is essentially an app store designed specifically for the field of radiology, with a focus on AI applications. The right network led to funding Founded in 2019 by Dr. Franz Pfister and Julia Moosbauer, the young start-up was able to win several awards from the start. In 2019, for example, the Munich-based company received the Eugen Münch Prize from the Münch Foundation and the Munich Digital Innovation Award. In 2020, deepc was awarded the Founder’s Prize by the German Federal Ministry for Economic Affairs and Energy as the main prize winner and also received the special prize in the field of health care. In 2020, deepc was among the 50 German start-ups with the greatest success in founder competitions. Then, in early 2021, the start-up success- fully closed a seed funding round worth a mid-seven-figure sum. This was followed by a Series A investment of EUR 12 million in March 2023. Despite this success, Pfister also sees at the same time the difficulties of the current financing situation global- ly: “The field of software, AI and medical technology is a very new, specialized and difficult to assess area in which many in- vestors may not yet feel so comfortable.” It is also a regulated market when it comes to using patient data. “Therefore, there are challenges that some investors perceive as risks,” says the physician. Here, deepc is doing pioneering work, so to speak. This area is not yet mainstream in Germany, and the choice of potential investors is limited. In addition, due to the current macroeco- nomic situation, many investors are not active at the moment. The founders of deepc see the successful financing rounds all the more as confirmation of their path as well as for the product and the team – that meanwhile comprises 46 employees. deepc founders CEO Dr. Franz Pfister and COO Julia Moosbauer © deepc BIOTECH IN BAVARIA - REPORT 2022|23 31

AI IN RADIOLOGY Once they use an AI product, radiologists typically don’t want to work without it anymore. For a successful implementation of ad- vanced image analysis software, it is most important that radiologists do not see AI as competition but as support. According to Moosbauer, the acceptance of radiologists to use AI applications has also increased significantly: “Three to four years ago, there was still a lot of fear of the unknown. This has changed, and radiologists today see these applications as a tool that supports them in their day-to-day work. Once they use an AI product, radiologists typically don’t want to work without it anymore. It makes their job easier and makes it possi- ble to redirect their focus to other relevant things,” explains the data scientist. This also includes communication with patients and their relatives. At present, however, physicians often lack the time for this. The feedback from radiologists, who are already using the deepc platform, is very positive. Several hundred physicians are now among the users in clinics and medical practices who purchase the software either as a li- cense or by subscription. Only a one-time installation is required to use medical prod- ucts from the world’s leading AI partners. deepc also advises facilities on setting up their AI infrastructure. At the Munich Oktoberfest 2022, deepc’s AI platform was also used for the first time outside of a hospital or practice. In the first- aid area at the world’s largest public festi- val, a team of doctors from the Clinic and Polyclinic for Radiology at LMU Hospital Munich used the software for a computer tomograph directly to triage injured visi- tors. Patients with head injuries could thus be examined on site and the ambulance service did not have to bring them to the emergency room of a hospital. Data availability as a challenge An AI tool only works if it is fed and trained with the appropriate data. Compared to countries like the U.S., Estonia, or Israel, such data is available to a very limited extent in Germany. For deepc, this is an indirect challenge, as the company does not train AI models itself, but distributes AI applications provided by providers. How- ever, these partners need training data. Therefore, deepc tries to give their partners feedback from the market with as much detail as possible when a model needs to be improved. This, in turn, allows providers to add missing data to their re-training pro- cesses in the most targeted manner possi- ble. “Data access could be even easier, and many things could be faster,” Moosbauer says. But she can understand the caution in this country: “Data protection is a very important topic, especially in Germany. We give data protection and information security the highest priority.” Many people, however, do not know exactly the purpose their health data is being used for and therefore tend to react negatively. Both Pfister and Moosbauer partly see this as a matter of education. “Cloud systems are unjustifiably treated like a spectre in the health sector, which is not at all understandable from a technical or security point of view. Cloud systems mainly offer advantages: cloud-based sys- tems developed by professional providers are more secure, faster, better performing and cheaper. An educational component is needed to create an understanding of these advantages,” clarifies Pfister. 32 BIOTECH IN BAVARIA - REPORT 2022|23 Indeed, for the most accurate application, it is important to train the model with heter- ogeneous validated data from appropriate target geographies. In contrast to Germany, many countries in the European Economic Area such as Denmark, Finland, and Esto- nia − with legal requirements comparable to those in Germany − have large central register databases that can be accessed. There are also countries like the U.S. that commercialize access to health data. deepcOS® – the all-round solution In five years, deepc wants to be globally leading in the space of AI in radiology. To this end, the start-up will have developed its platform significantly further and have also provided the infrastructure so that other companies can develop new solu- tions on deepc’s platform, validate them, bring them to market and ultimately monitor them there as well. There is still no standard procedure for this post-market monitoring, especially for data-driven soft- ware in the field of AI. This is exactly what deepc wants to provide infrastructure for. For Pfister, the application of digitization in the field of medical diagnostics has only just begun. He still sees a lot of potential, especially on the product development side. Pfister is convinced that the applica- tion and use of AI-driven image recognition software will certainly change in the future. Right now, he says, it’s more point solu- tions, such as detecting fractures, a pneu- mothorax or traumatic brain injury. “We expect the wealth of diagnostic informa- tion and use cases to increase significantly. The performance of the algorithms will also improve, and more meta-information will be included. Not only radiological data, but also pathological data, clinical data, laboratory data will then be processed by those applications,” predicts Pfister. Thus, there are still many growth opportunities for the company. The founders and their team still have many plans for deepc.

DIGIMED BAYERN The DigiMed Bayern research project de- livers steps towards big data-supported healthcare in the field of cardiovascular disease, the most common cause of death worldwide. The flagship project runs from 2018 to 2024 with a total funding of around EUR 24.5 million from the Bavarian State Ministry of Health and Care. DigiMed Bayern aims to contribute to the prevention of heart attacks and strokes through improved assessment and predic- tion of disease risks, followed by targeted prevention, diagnosis and therapy. For this purpose, extensive health data are collected, enriched and analyzed. In the project, Bavarian world-leading university hospitals collaborate with research insti- tutes in the fields of epidemiology, biology and biochemistry, as well as data sciences and IT infrastructure. This is complemented by legal and privacy research and contribu- tions to ethical questions and sociological issues. Successfully implemented by DigiMed Bayern: The HerzFit App and Vroni study Within the year since its launch in April 2022, the HerzFit app has been down- loaded more than 92,000 times. This free www.herzstiftung.de/herzfit-app g n u t f i t s z r e H e h c s t u e D © www.myvroni.de 34 BIOTECH IN BAVARIA - REPORT 2022|23 DIGIMED BAYERN Future medicine, individual and data-driven tool supports citizens and patients in their effort to lead a healthier lifestyle. It is based on the individualized use of health data for risk assessment and coaching in the fields of nutrition, exercise, stress and smoking, completed by a wealth of high quality information about heart health. HerzFit brings cardiovascular prevention into everyday lives. The Vroni study has already examined over 13,000 children in Bavaria for heredi- tary familial hypercholesterolemia (FH), a frequent congenital lipometabolic disorder resulting in a significantly increased risk of serious vascular occlusion, heart attacks and strokes already in early adulthood. If recognized and treated early in life, FH car- riers can expect an almost normal life. But of the estimated approximately 270,000 FH carriers in Germany, only less than 1% are diagnosed! The Vroni study pioneers early FH identification and treatment for regular care by focusing on children aged 5 to 14 and delivers a blueprint for regular care implementation in Germany. To date (April 2023), 482 pediatricians from across Bavaria are participating, and out of over 13,000 tested children, 121 individuals were found to be FH carriers. The Vroni study will con- tinue to identify FH carriers and also their affected relatives, and to intensify the edu- cation and coaching of parents, children and pediatricians for better adherence to treatment guidelines. Further impressive project milestones with multi-omics, big data and IT infrastructure DigiMed Bayern contributes hands-on to the availability and use of patient data from clinics, epidemiological studies and health insurers. These data are enriched with large-scale molecular “multi-omics” analyses (genomics, transcriptomics, pro- teomics and metabolomics) of biosamples. Integrated data analyses already show exciting molecular findings, promising starting points for the identification, valida- tion and future medical use of biomarkers © BioM Please contact the DigiMed Bayern Executive Management at BioM: Dr. Jens Wiehler, Managing Director DigiMed Bayern and Anja Kroke, Project Manager DigiMed Bayern info@digimed-bayern.de for early and personalized diagnosis and treatment of cardiovascular diseases, up to new drug targets. DigiMed Bayern’s activities in generating, analyzing and applying big data require novel compliant, secure, performant and collaborative IT infrastructures. The pro- ject faces this challenge and makes good progress with implementing pilot data and cloud computing. This “DigiMed Bayern Cloud” will be extended and is planned to serve as the nucleus to build a sustainable and ethical long-term service for actors in the field of medical research and develop- ment. To date, DigiMed Bayern has already con- tributed to nearly 60 high-level peer-re- viewed scientific publications and to guide- lines for the treatment of hereditary FH. Stay tuned: Visit https://www.digimed- bayern.de/en/ for further information and follow us on Twitter @DigiMedBayern for news and events!

5 December 2023 Munich | TranslaTUM – Klinikum rechts der Isar DigiMed Bayern Symposium 2023 Big Data – Big Outcome? The DigiMed Bayern Symposium is the public annual conference of the flagship program DigiMed Bayern – for the medicine of the future Look & Register! @DigiMedBayern #DigiMedSymposium23 www.digimed-bayern.de/symposium-2023.html Gesund, aktiv und informiert mit der neuen HerzFit-App! Mit der neuen, kostenlosen HerzFit-App können Sie aktiv Ihre Herzgesundheit unterstützen. Sammeln Sie Ihre Gesundheits- Download unter: daten und Ihre körperliche Aktivi- Messen! tät übersichtlich an einem Ort. Lassen Sie sich von der HerzFit- Mehr Informationen unter: App aktiv bei der Verbesserung www.herzstiftung.de/ Verbessern! Ihres Lebensstils unterstützen. herzfit-app Bildnachweis: Adobe Stock © Farknot Architect Informieren Sie sich umfassend über Herzgesundheit sowie Lernen! Herz-Kreislauf-Erkrankungen.

k c o t s r e t t u h s © BAVARIAN SUCCESSES IN CAR-T CELL THERAPY New approaches against AML Cure for two autoimmune diseases CAR-T cell therapies have attracted a lot of attention in recent years and, among other things, are seen as an important advance in cancer therapy. However, not all forms of cancer can be treated alike. Bavarian scientists have now achieved important successes in this area using artificial intelligence. In addition, groundbreaking healing successes have been achieved in Bavaria in the therapy of autoimmune diseases. In CAR-T cell therapy, T cells are taken from the patient’s blood and genetically modi- fied to equip them with the CAR (Chimeric Antigen Receptor). This receptor enables T cells to recognize and attack specific cells. Munich: New targets for CAR-T cell therapy against AML through AI-assisted analysis This therapy has been shown to be particularly effective in treating certain types of blood cancers, such as acute lymphoblastic leukemia (ALL) and some non-Hodgkin’s lymphomas (NHL). However, acute myeloid leukemia (AML) is not treatable with currently approved CAR-T cell immunotherapies because they are directed against the antigen CD19, which is generally not present on the surface of AML cells. Clinical results with CAR-T cells directed against other surface molecules of AML cells were also unable to distinguish between healthy and degenerate cells - with correspondingly large side effects. Thus, the specific molecular targets by which certain immune cells specifically attack AML cells are missing. These targets have now been discovered by two research teams, one led by Prof. Dr. Sebastian Kobold with Dr. Adrian Gottschlich and Ruth Grünmeier from the Department of Clinical Pharmacology at LMU Hospital, and the other by Dr. Carsten Marr with Moritz Thomas from the Institute of AI for Health at Helmholtz Munich. The results were pub- lished in the journal Nature Biotechnology in March 2023. Using extensive bioinformatics analysis and integrating expression data from more than half a million individual cells out of 25,000 potential cell surface molecules, the scientists were able to identify two candi- dates found exclusively on the surface of AML cells: CSF1R and CD86. CAR-T cells produced in the LMU Hospital laboratory, which target precisely these molecules, were then tested on different AML models, including AML cells from pa- tients. The result: on the one hand, CAR-T cells are effective against AML, but on the other hand, they hardly attack healthy cells. AML is a treacherous disease. Five years after the initial diagnosis, only one third of patients affected by the disease are still alive. Although up to 85% of patients appear to be cured after intensive chemo- therapy, the disease returns within one to two years in more than half of them be- cause the chemotherapy has not destroyed all leukemia cells. The long-term survival probability is less than 20%, which is why innovative treatment options are urgently needed. 36 BIOTECH IN BAVARIA - REPORT 2022|23

The researchers’ current goal is to develop a process for GMP (good manufacturing practice)-capable production of these CAR-T cells for possible use in clinical trials with AML patients. This will take place as part of the “Bavarian Cell Therapy Catalyst” supported by the Bavarian Research Foun- dation. Kobold expects the first tests with patients in two to three years. In 2019, Prof. Dr. Kobold and a team of re- searchers won the m4 Award coordinated by BioM for their work on CAR-T cells in sol- id tumors. The pre-seed m4 Award is aimed at academic research projects with spin-off potential in the field of biomedicine. Up to five teams receive a maximum of EUR 500,000 for up to two years (m4-award.org). Erlangen: groundbreaking successes in the treatment of autoimmune diseases In addition to these achievements in on- cology, Bavaria also celebrated important successes in the treatment of autoimmune diseases. At the University Hospital Erlangen, a pa- tient with a severe form of muscle inflam- mation (myositis) was successfully treated for the first time worldwide. The antisynthetase syndrome belongs to the group of autoimmune muscle inflam- mations (myositis). The usually severe disease is caused by a malfunction of the immune system and affects muscles, joints, skin and lungs. The name antisynthetase syndrome is derived from the observation that in this disease, the enzymes necessary for the synthesis of amino acid building blocks (tRNA, also known as synthetases) are mistakenly attacked by the immune system. As a result, various cells are signif- icantly affected in their function. Completely cured of myositis after six months The 41-year-old man suffering from myosi- tis was successfully treated in Erlangen for his disease with the help of CAR-T cell thera- py. After infusion of the patient’s previously harvested and genetically modified T cells, the patient’s health improved immensely: the inflammation in his muscles, lungs and joints receded completely. Strength, performance and endurance returned. All immunosuppressive drugs - especially cor- tisone - could be completely discontinued without the disease flaring up again. Six months after CAR-T cell administration, the patient had completely recovered from his autoimmune disease. The work Prof. Dr. Sebastian Kobold (2nd from right) at the m4 Award ceremony 2019 with Dr. Ulrike Wolf, department head of the Bavarian State Ministry of Economic Affairs, his colleagues Prof. Dr. Stefan Endres and Bruno Cadilha from LMU Hospital and Prof. Dr. Horst Domdey, former managing director of BioM (from left). © BioM CAR-T CELL THERAPY was published by a team led by Prof. Dr. Georg Schett, Director of the Medical Clinic 3 - Rheumatology and Immunology of the University Hospital Erlangen, and Prof. Dr. Andreas Mackensen, Director of the Medical Clinic 5 - Hematology and In- ternal Oncology of the University Hospital Erlangen in the renowned journal Lancet in February 2023. This marks the second form of human autoimmune disease to be successfully treated with CAR-T cells by a team of phy- sicians and scientists at the German Centre for Immunotherapy (DZI) at the University Hospital Erlangen. Success against systemic lupus erythematosus In mid-2021, researchers reported the suc- cessful treatment of a 20-year-old woman with CAR-T cell therapy for the life-threat- ening autoimmune disease systemic lupus erythematosus. Mackensen and Schett were also involved in this project. In this disease, which mainly affects young women, the immune system attacks the body’s own cells in various organ sys- tems. Two main forms are distinguished: cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). CLE affects only the skin with typical butter- fly-shaped skin changes on sun-exposed areas of the body, especially around the eyes. SLE additionally affects internal or- gans (e.g. kidney inflammation, joint pain, inflammation of the lungs and heart). In individual cases, the disease can be fatal. After various immune-suppressing thera- pies also failed to sustainably improve her symptoms, the patient was administered a preparation with CAR-T cells by researchers at the German Centre for Immunotherapy (DZI) at the University Hospital Erlangen in March 2021. Almost six months after the cell therapy, her joint pain disappeared and the 20-year-old’s body completely recov- ered. The research results were published in the New England Journal of Medicine. For his groundbreaking research on the relationship between inflammation and autoimmune diseases, Prof. Dr. Schett was awarded the Gottfried Wilhelm Leibniz Prize, Germany’s most important research prize, at the end of 2022. BIOTECH IN BAVARIA - REPORT 2022|23 37

BIO-EUROPE © shutterstock managed by BIO-EUROPE 2023 IN MUNICH k c o t s r e t t u h s © Strong Bavarian presence For attendees who are unable to attend the face-to-face event live, EBD will still offer access to digital partnering with the Digital Ticket following the conference on November 14-15, 2023. Thanks to the support of the Bavarian Ministry of Economic Affairs, Regional Development and Energy, BioM presents the Bavarian Biotechnology Cluster with its forward-looking projects and innovative companies. Already on the first evening of the event, the Bavarian State Government invites the participants of BIO-Europe to a state reception at the Munich Residence. Here, in addition to the appreciation for the indus- try by State Secretary Roland Weigert and the welcome by BioM Managing Director Prof. Dr. Ralf Huss, there will be the perfect ambience for networking and socializing. Together with its partner Bayern Innovativ, BioM offers Bavarian companies and start- ups the opportunity to present themselves at a prominently positioned joint booth in the exhibition hall. Showing the entire Bavarian Biotechnology cluster, Bavarian research institutions and research groups will also be present. With various receptions at the booth, there will be many opportu- nities for exchange and networking here in addition to the official partnering program. Prof. Dr. Ralf Huss looks forward to the upcoming event in Munich with great expectations: “I am particularly pleased that BioM, with the support of the Bavarian Ministry of Economic Affairs, will host this partnering event, which is unique in Europe. The already large of number of registrations demonstrates that Munich is one of the most vigorous and successful German locations in all aspects of the life science industry and especially for start- up activities. We will join all our forces to present Bavarian biotechnology in all its dimensions and cluster partners to an international audience.” BIO-Europe, Europe’s largest partnering conference, is being held in Munich for the 5th time since 1997. From November 6 - 8, 2023, leading play- ers from the biotechnology and pharma- ceutical industry will meet at the Messe München exhibition center to present their innovative projects, inspire investors or find partners. By using partneringONE®, the EBD Group’s sophisticated web-based partnering sys- tem, the event will enable participants to efficiently identify and meet internationally operating corporate partners, investors and innovative start-ups from the life sci- ence value chain on-site. After its great success in 2022 in Leipzig, where BIO-Europe was held in attendance for the first time since the coronavirus pandemic, the EBD Group expects another increase for Munich: more than 5,000 par- ticipants from 60 countries and more than 2,220 companies are awaited, making this event the largest industry gathering of the biopharma sector in Europe, according to the organizers. 38 BIOTECH IN BAVARIA - REPORT 2022|23

GUEST CONTRIBUTION NOVEMBER 68, 2023 | MUNICH, GERMANY Your gateway to the global biopharma community After being delivered virtually for two years, the event returned face-to-face in 2022 breaking all records—becoming the biopharma reunion of the year. In 2023, BIO-Europe will continue to raise the bar with another record-breaking year. The 29th annual BIO-Europe will take place November 6–8, 2023 in Munich, Germany, and it will convene over 5,000 life science professionals representing more than 2,220 companies from over 60 countries. Attendees will take part in 27,000 one-to-one meetings over the course of the event. Access the global biopharma community all under one roof only at BIO-Europe. Produced by: In collaboration with: BIOTECH IN BAVARIA - REPORT 2022|23 39 Register before July 28, 2023 to receive the best registration rates!bioeurope.com

LIFE SCIENCE CENTERS IN BAVARIA LIFE SCIENCE CENTERS IN BAVARIA Regional networks Bavaria is home to a dynamic, innovative, and highly successful biotech scene that never fails to impress, with hubs in Munich, Regensburg, Würzburg, Straubing, and the Nuremberg metropolitan region. Biotech companies – start-ups and established enterprises alike – benefit from the region’s optimal conditions: proximity to academic re- search institutions, service providers and technology parks. In addition, they can rely on the support of the respective cluster organizations regarding any biotech-related topic. The cluster organizations support the biotech community with their extensive network of companies, universities, research institutions, university hospitals, chambers and associations, investors, funding agencies, consultants, and other stakeholders in the respective clusters and beyond. Würzburg The Innovation and Start-up Center close to the Julius-Maxi- milians-University offers lab space and has developed a comprehen- sive program for promoting start- up activities in the region. Cluster organization: Innovation- and Start-up Center (IGZ) Würzburg Incubator: IGZ Würzburg (>5,000 sqm) www.igz.wuerzburg.de Regensburg The Innovation Center and Start-up Center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services. Cluster organization: BioPark Regensburg for BioRegio Regensburg / Healthcare Regensburg managed by BioPark Incubator: BioPark Regensburg (>18,000 sqm) www.bioregio-regensburg.de Munich The cluster organization BioM is the central point of contact for the biotechnology sector in Munich and Bavaria and is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personal- ized medicine. BioM offers a wide range of services and events and has developed the comprehensive incubation program “inQlab” for company founders in the field of biotechnology. Incubator: MAxL (900 sqm) www.bio-m.org by Industrial Biotechnology in Bavaria Managed by IBB Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes in industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint R&D projects in Industrial Biotech nology and sustainable economy. www.ibbnetzwerk-gmbh.com 40 BIOTECH IN BAVARIA - REPORT 2022|23

LIFE SCIENCE CENTERS IN BAVARIA Erlangen and Nuremberg The European Metropolitan Region Nuremberg is an inter- nationally leading location for medical technology. As one- stop-shop Medical Valley offers a broad variety of services to accelerate time-to-market for healthcare innovations. Cluster organization: Medical Valley Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm) www.medical-valley-emn.de Straubing The BioCampus in the port of Straubing focuses on creating value from biobased resources, BioMass logistics and start-up management. In close vicinity to the TUM Campus Straubing for sustainability and biotechnology, it offers lab space, offices, start-up and business support and industrial plots. Cluster Organization: BioCampus Straubing GmbH Incubator: TGZ Straubing (4,000 sqm) www.hafen-straubing.de Würzburg Erlangen Nuremberg Regensburg Straubing Munich Freising- Weihenstephan Martinsried IZB Martinsried and Freising The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on life sciences) has developed into one of the leading biotechnology centers in Europe and offers young biotech start-ups 26,000 sqm of modern building infrastructure for biotechnology. www.izb-online.de BIOTECH IN BAVARIA - REPORT 2022|23 41

GUEST CONTIRBUTION DEVELOPMENT IN REGENSBURG Guest contribution from Dr. Thomas Diefenthal Current BioPark Annual Report 2022 The companies in the cluster from the fields of biotechnology, pharmaceuticals, medical engineering, diagnostics, analytics and the healthcare industry were able to continue to significantly expand their busi- ness in Eastern Bavaria in the post-Corona period and have increased their staff sub- stantially. The total number of companies in the cluster increased slightly compared to the previous year to 66 companies (+3). The total number of employees increased strongly from 4,504 to 5,340 (+16%). © BioPark Regensburg The BioPark is currently fully booked. The technology and start-up center accom- modates 35 leaseholders with almost 676 employees in its three buildings on a gross area of 18,000 m2. These include start-up companies, university and non-university institutions, companies from Germany and abroad, as well as service providers and our own daycare center. Healthcare Regensburg – managed by BioPark Today, a total of 21,600 employees with social security were working in the health sector in the Regensburg region. That is a good 33.8% more than in the 2011 census. At 55%, the largest proportion is employed in five hospitals. 80% of the employees work in the urban area and 20% in the rural district. There are currently 831 companies in the health sector in the Regensburg 42 BIOTECH IN BAVARIA - REPORT 2022|23 area, 60% of them in the city and 40% in the district. These generated sales of EUR 2.7 billion in the last year, which is almost twice as much as in 2011 with a rate of increase of 92.9% and corresponds to an annual growth rate of 7.6%. The RCI becomes a Leibniz Institute in Regensburg The Regensburg Center for Interventional Immunology (RCI) was founded in 2010 as a central institution of the University of Regensburg to bundle all university research areas working on the develop- ment of new immunotherapies. In 2022 the RCI was included in the federal-state funding of the Leibniz Association. The new LIT (Leibniz-Institute for Immunotherapy) focuses on translational immunology in the fields of cancer immunotherapy, chronic inflammation and autoimmunity. Regensburg clusters bundle AI expertise In Regensburg - a high-tech and science location where artificial intelligence shows itself in all its facets - BioPark Regensburg has been working together with the Mo- bility & Logistics clusters, the IT Security Cluster and the Sensor Technology Cluster in the joint AI initiative AIR (Artificial Intel- ligence Regensburg). AIR is a clear com- mitment from the regional networks for “their” region to jointly deliver a future-ori- ented, regional development concept that actively involves and mobilizes their respec- tive stakeholders. The aim is to better net- work the stakeholders in the clusters and thus enable an optimized transfer of knowl- edge and technology. Industry affiliations DR. THOMAS DIEFENTHAL is Managing Director of BioPark Regensburg GmbH and Vice President of the German Association of Innovation, Technology and Business Incubation Centres (BVIZ) in Berlin. play a subordinate role, especially in cross- sectional technologies such as artificial intelligence. BioPark Jump Accelerator gets started in Regensburg To further expand start-up support, BioPark Jump has launched on its own premises and with many supporters at BioPark Re- gensburg. The project will be funded by the Bavarian Ministry of Economic Affairs for the next three years. With BioPark Jump, a previously non-existent contact point has been created specifically for those inter ested in founding a company in the healthcare sector in the region. It supports prospective start-ups in the ear- ly founding phases on their way into the healthcare market, from the idea and the development of a functioning business model to team building and raising funds to commercialization. BioPark Jump will work closely with the ex- isting start-up networks, the BioPark Brain 8 Network, the BioPark Innovation Award, the technology and transfer facilities of the universities and regional industrial partners and the TechBase (digitalization). BioPark Regensburg www.biopark-regensburg.de BioPark Jump www.biopark-jump.de BioPark Award www.biopark-innovationspreis.de i r e n s e W h t e b a s i l E , H b m G g r u b s n e g e R k r a P o B © i

The Top Region for excellence in science and innovative companies RESEARCH 2 Universities, Cell therapy Immunology, Oncology DEVELOPMENT 80 Companies, Biotech, Medtech,Health IT HEALTHCARE Over 20,000 employees 2.7 billion Euro turnover MAIN FOCUS Digitalization & AI, Innovation in Nursing, Hygiene and Infection Prevention START-UP BioPark Jump Accelerator program and BioPark Brain 8 Network for founders Proﬁ t from the Healthcare Network with over 80 companies, ﬁ ve hospitals and two universities. BioPark Regensburg GmbH | Am BioPark 13 | D-93053 Regensburg | Phone: +49 941 92046-0 | Fax: -24 info@biopark-regensburg.de | www.biopark-regensburg.de

LIFE SCIENCE CENTERS IN BAVARIA BILLION DEAL AT THE IZB Important cooperations of the IZB start-ups mark a dynamic period 2022/23 The Innovation and Start-up Center Bio- technology (IZB) in Martinsried by Munich, one of Europe’s leading biotechnology centres with almost 50 resident biotech start-ups, provides a positive overview of the second half of 2022 and early 2023. “I am proud that our start-ups, first and fore- most Tubulis, were able to enter top-class partnerships,” said Dr. Peter Hanns Zobel, Managing Director of the IZB. “In addition, I am pleased that several infrastructure projects have finally begun that will further strengthen our research location.” Financings and partnerships In April 2023, Tubulis, a company focused on generating uniquely matched protein-drug conjugates by combining novel propri- etary technologies with disease-specific bio logic insight, entered a strategic part- nership with Bristol Myers Squibb (BMS) to develop differentiated antibody-drug conjugates (ADCs). Through this license agreement, Tubulis will receive an upfront payment of USD 22.75 million and is eligible to receive milestone payments potentially totalling over USD 1 billion plus tiered roy- alties on net product sales. Earlier this year, Secarna Pharmaceuticals and SciNeuro announced their partnership to research and develop therapies directed at targets that play a substantial part in diseases of the Central Nervous System (CNS). In October 2022, adivo (now an IZB alumnus) received a EUR 2.5 million EU grant, which will be used to accelerate the development of new therapies for inflammatory bowel diseases in pets. CatalYm raised EUR 50 million in an oversubscribed Series C financing. The funding will support the clinical develop- ment of lead candidate visugromab in pa- tients with solid tumors in November 2022. New start-ups in the IZB In 2022, seven companies moved into the IZB with SCG Cell, Insempra, Tubulis, T-Curx, Klifo, Atriva and Andera Partners. Early this year, Invitris, a start-up with a universal plat- form technology that can generate in vitro synthetic proteins at the highest yields and purity in a single process, moved into the IZB with the goal of scaling up both drug discovery and production. The company is focusing on antimicrobial proteins like bac- teriophages and endolysins to battle the most serious health and economic threat to develop over the next decades: multi- drug-resistant diseases. Leon-nanodrugs (LEON), a pharmatec company, selected the R&D capacities at the IZB as the optimal place for the completion of product devel- opment for LEON’s manufacturing devices. Innovative discoveries originating at IZB In early 2023, Neuron23, Inc., a San Fran- cisco-based clinical-stage biotechnology company announced the start of its first- in-patient Phase I clinical treatment with NEU-723 in patients with Parkinson’s disease. The company was co-founded by IZB start-up Origenis and is focused on developing precision medicines for genetically defined neurological and immunological diseases. Thermosome, a drug development company spe- cializing in targeted tumor therapies, received regulatory approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the Ethics Commission to conduct the first-in-human trial of its lead program, THE001 in March. Eisbach Bio achieved an important mile- stone in the end of April with the start of a Phase I, first-in-human clinical trial for EIS- 10700, a small molecule that targets the RNA helicase of SARS-CoV-2. The COVID-19 antiviral, which emerged from Eisbach’s drug discovery platform, will be tested in healthy volunteers to assess the safety, tolerability, and pharmacokinetics of the helicase inhibitor. Strong foundations for growth In the first half of 2023, some long-awaited infrastructure developments were kicked off. In February, the expansion of the so- called subway “science line” was started and will link the Martinsried campus to other Munich science locations such as the Tech- nical University (TU) and LMU. Only a few meters away from the IZB, the construction for LMU’s state-of-the-art University Hospi- tal for Paediatric and Youth Medicine started in March this year. The Free State of Bavaria is funding the EUR 550 million-budget. DR. PETER HANNS ZOBEL Dr. Peter Hanns Zobel has been Managing Director of the IZB since 1996 and has turned the 26,000 sqm Innovation and Start-up Center Biotechnology into one of the major biotech centers in Europe. © IZB © IZB © IZB 44 BIOTECH IN BAVARIA - REPORT 2022|23

21Dx GmbH LIFE SCIENCE / TECHNOLOGY TRANSFER Keywords: Infectious Diseases, Molecular Diagnostics, Vaccines 21Dx GmbH is a pioneer helping to fight the pandemic with high-quality test and vaccination services in Germany. Entrepreneurship and experience enable a com- bination of a fast and custom-fit implementation of all available technologies and end-to-end quality managed processes. We continue to develop and provide future pandemic solutions, but also offer further services in the healthcare sector, such as medical call centers and low threshold, highly localised medical services. 2bind GmbH BIOTECH DNA & PROTEIN ANALYTICS Keywords: Small Molecules, Molecular Diagnostics, Peptide/Protein, Bioanalytics, Drug Development, R&D Service 2bind is a provider for biophysical services in early drug development (hit ID, hit validation and characterization) and antibody Characterization based on the core technologies MST, Dianthus, nanoDSF, BLI and ITC.Our Biotech and Pharma customers benefit from a strong expertise in biophysical methods (certified by NanoTemper for MST, Dianthus and nanoDSF), from customized milestone-based projects with clear timelines and reliable cost structures. Be smart – work with the experts! 4SC AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Rare Disease, Orphan Drug, Drug Development, Small Molecules, Oncology 4SC is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical need. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: resminostat. 4SC had 46 employees as of 31 December 2021 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C4). ABF GmbH CRO Keywords: Metabolomics, Analytical Chemistry, Biomarker Discovery & Development ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and applica- tion in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS(/MS). Since end of 2001, ABF provides its services to corre- sponding industry, academic and governmental institutions. Kreillerstrasse 210 D-81825 München Phone: +49 (0) 163 874 79 75 E-Mail: Internet: www.21dx.de kontakt@21dx.de Am BioPark 11, BioPark II D-93053 Regensburg Phone: +49 (0) 941 20000890 E-Mail: info@2bind.de Internet: www.2bind.de Fraunhoferstraße 22 D-82152 Martinsried Phone: +49 (0) 89 700763-0 E-Mail: public@4sc.com Internet: www.4sc.com Raiffeisenstraße 34 D-82152 Planegg-Steinkirchen Phone: +49 (0) 89 535395 E-Mail: max.scherer@abf-lab.com Internet: www.abf-lab.com 48 BIOTECH IN BAVARIA - REPORT 2022|23

abf diagnostics GmbH PHARMA SUPPLIER & TRADE abf diagnostics develops, manufactures and markets products and solutions for the collection, storage and onsite analysis of biological traces and samples. Our strate- gic focus lies on innovations in pre-analytics and decentralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces. Gewerbepark 14 D-85402 Kranzberg Phone: +49 (0) 8166 9986 130 E-Mail: info@abfdiagnostics.com Internet: www.abfdiagnostics.com Actarmo Medical GmbH BIOTECH DEVICES & REAGENTS Keywords: Respiratory Diseases, Devices, Drug Delivery, Drug Development, Laboratory Actarmo is a technology focused Contract Research Organisation supporting small to mid size pharmaceutical, biopharmaceutical and device companies in development of respiratory products. With our highly experiencend team we offer GMP laboratories as well as consultancy activities. Robert-Koch-Allee 29 D-82131 Gauting Phone: + 49 (0) 89 614233 0 Internet: www.actarmo.com adivo GmbH PHARMA ANIMAL HEALTH Keywords: Pain, Oncology, Inflammation, Antibody, Drug Development adivo is at the forefront of a new era for companion animal health. Our proprietary phage display antibody libraries for cats and dogs deliver species-spe- cific drugs for a growing market need. We apply our extensive drug discovery and protein engineering know-how to address cancer, chronic inflammatory diseases and other serious conditions in pets. Together with our partners, we create the best possible therapeutics for our beloved furry friends. advanceCOR GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Personalized Medicine, Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation Am Klopferspitz 19 D-82152 Planegg-Martinsried Phone: +49 (0) 89 - 588 08 84 71 E-Mail: info@adivo.vet Internet: www.adivo.vet advanceCOR is a biotech company focusing on personalized medicine in cardiovascu- lar diseases. Revacept, a biological drug ( lesion specific inhibitor of atherothrombosis) has completed a phase II trial in patients with stroke and cerebral vascular syndromes and a phase II clinical trial for the treatment of coronary artery disease. Further preclinical candidates are under development. advanceCOR is financed by MIG AG, KfW, Bayernkapital, HTGF, Occident and BioM. Fraunhoferstraße 9a D-82152 Martinsried Phone: +49 (0) 89 2000 204-10 E-Mail: info@advancecor.com Internet: www.advancecor.com BIOTECH IN BAVARIA - REPORT 2022|23 49

Stäblistraße 10 D-81477 München Phone: +49 (0) 89 45470050 E-Mail: info@advancedbiolabservice.com Internet: www.advancedbiolabservice.com Agnes-Pockels-Bogen 1 D-80992 München Phone: +49 (0) 89 4111842-00 E-Mail: info@advitos.com Internet: www.advitos.com advanced biolab service Gesellschaft für Laborgeräte, Beratung und Support mbH DEVICES advanced biolab service GmbH based in Munich provides maintenance, repair and troubleshooting service for capillary electrophoresis sequencers, Real Time and stand- ard PCR instruments ABI 377, ABI 310, ABI 3100(-Avant), ABI 3130(xl), ABI 3500(xl), ABI 3730(xl), ABI 7300, ABI 7500(Fast), ABI 2700, ABI 2720 and GeneAmp 9700. Remanu- factured instruments, service contracts or individual repairs, software and computer upgrades, user training and reagents offered by a small and highly professional team. ADVITOS GmbH MEDTECH Keywords: Multi organ failure, Respiratory Diseases, Hepatology, Devices ADVITOS has developed the CE-marked & globally patented ADVOS technology (ADVanced Organ Support) the only therapy worldwide offering multi-organ sup- port integrated in one single device, supporting all 3 main detoxification organs simultaneously: liver, lung and kidney. ADVITOS was founded near Munich in 2005 by renowned nephrology & multi-organ support expert Dr. Bernhard Kreymann who was instrumental in establishing the pervious gold standard of organ support by single-pass albumin dialysis. Aenova Holding GmbH BIOTECH & PHARMA PRODUCTION, CMO Keywords: Laboratory, Regulatory Affairs, R&D Service Berger Straße 8 - 10 D-82319 Starnberg Phone: +49 (0) 8151 9987-001 E-Mail: Internet: www.aenova-group.com info@aenova.de The Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group’s portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. Aenova operates 15 manufacturing facilities located within Europe and the United States. More than 4300 employees contribute to the group’s success. Agrobiogen GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Agrobiotechnology, Bioanalytics, Laboratory Larezhausen 3 D-86567 Hilgertshausen Phone: +49 (0) 8250 9279040 E-Mail: info@agrobiogen.de Internet: www.agrobiogen.de Agrobiogen focuses on and is experienced in the application of molecular- genetic techniques in livestock animals (especially moleculargenetic diagnostics). Detection of pathogens like BVDV, as well as parentage control of animals, SNP geno- typing and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. 50 BIOTECH IN BAVARIA - REPORT 2022|23

Agrolytix GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services. Cauerstraße 4 D-91058 Erlangen Phone: +49 (0) 9131 85-29452 E-Mail: info@agrolytix.com Internet: www.agrolytix.com Alexion Pharma Germany GmbH PHARMA & CHEMICAL INDUSTRY Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion Pharma Germany GmbH is based in Munich, Germany. Landsberger Straße 300 D-80687 München Phone: +49 (0) 89 45 70 91 300 E-Mail: Internet: www.alexion.de alexion.germany@alexion.com ALGORA Gesellschaft für Medizin statistik und Vertriebssysteme mbH CRO Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Infectious Diseases, Oncology, Autoimmune Diseases Algora offers a broad range of services for phase II-IV clinical trials as well as for observational studies in Germany, with key competencies in study start-up, clinical monitoring, data management, and statistical analysis. Experienced in oncology and infectious diseases since the first days of the company in 1989, we later gained additional expertise in immunology and entered the field of nutritional studies while we continued to cultivate strong relations with the medical community. Altmann Analytik GmbH & Co. KG PHARMA SUPPLIER AND TRADE Keywords: Laboratory, Fine Chemicals/Reagents, Devices, Analytical Chemistry Specialized distributor for chromatography & lab supply. We provide consumables for HPLC & GC, Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps) as well as chemicals and products for dairy and food industry. On www.analytics-shop.com you can find more than 200,000 lab supply products from high-quality manufacturers, such as Agilent, Chiral Technologies, Grace, Hamilton, Macherey-Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC. Münchner Straße 11 D-85540 Haar Phone: +49 (0) 89 613727-0 E-Mail: cro@algora.de Internet: www.algora.de Rupert-Mayer-Straße 46 D-81379 München Phone: +49 (0) 89 724805-90 E-Mail: info@altmann-analytik.de Internet: www.analytics-shop.com BIOTECH IN BAVARIA - REPORT 2022|23 51

AMGEN GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Nephrology, Bone/Joint Diseases, Oncology Riesstraße 24 D-80992 München Phone: +49 (0) 89 149096-0 E-Mail: Internet: www.amgen.de corinna.jacob@amgen.com Amgen is one of the worlds leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history. Worldwide, millions of pa- tients with serious or rare diseases benefit from our therapies every year. Our drugs are used in nephrology, cardiology, hematology, oncology, bone health and chronic inflammatory diseases. In addition to original products, our portfolio also includes biosimilars. We have a diverse pipeline. Amgen GmbH in Munich was founded in 1989. Today, almost 650 employees work here with a focus on clinical research, regulatory affairs and the distribution of pharmaceuticals. AMGEN Research (Munich) GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Immune Therapy, Drug Development, Antibody, Oncology Staffelseestraße 2 D-81477 München Phone: +49 (0) 89 895277-0 E-Mail: Internet: www.amgen.de susanne.sporer@amgen.com Amgen Research (Munich) GmbH (formerly Micromet GmbH) located in Munich, Germany has been part of Amgen since March 2012 and is Amgen`s largest R&D site outside of the U.S. The site has about 200 employees and is specialized in the devel- opment of the “Bispecific T cell Engager” (BiTE®) antibody constructs for innovative cancer therapies. Amgen is one of the world’s leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history. Werkstraße 2 D-83555 Gars-Bahnhof Phone: +49 (0) 8073 91693-50 E-Mail: Internet: www.eazyplex.com info@amplexdiagnostics.de AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, In-Vitro-Diagnostics, Molecular Diagnostics, Clinical Diagnostics, PCR Founded 2002, AmplexDiagnostics is one of the first suppliers for CE IVD diagnostics based on a real-time isothermal amplification technique in a portable device (GENIE II) using lyophilized test reagents for a maximum on user-friendliness and a minimum of hands-on time. With the new eazyplex® system you identify pathogenic bacteria within 15 min, screen swabs for multi-resistant bacteria within 20 min or realise Meningitis diagnostics directly from CSF in 30 min. 52 BIOTECH IN BAVARIA - REPORT 2022|23

AMS Advanced Medical Services CRO Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service, Regulatory Affairs, Data Management, Pharmacovigilance AMS specialises in Global Drug Development, are market leaders in Health Economics and Public Health Benefit Assessments of pharmaceuticals, as well as HTAs and Rela- tive Effectiveness Assessments for medical devices. AMS can provide market access programs in Europe and field force services in German speaking countries. The com- prehensive suite of AMS services also include ePRO solutions, strategic consultancy and staff development training. AMSilk GmbH BIOTECH NEW MATERIALS AND COMPOUNDS Keywords: New Materials, Industrial Biotechnology Rosa-Bavarese-Straße 5 D-80639 München Phone: +49 (0) 89 2000074-100 E-Mail: Medical.Science@ams-europe.com Internet: www.ams-europe.com AMSilk GmbH is the world’s first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers com- bine the advantages of natural products with the possibility of large scale, industrial production processes. AMSilk´s high-performance biopolymers are distributed in the form of Biosteel® fibers or as a coating solution for medical devices. Anna-Sigmund-Straße 1-3 D-82061 Neuried Phone: +49 (0) 89 579 5393-0 E-Mail: info@amsilk.com Internet: www.amsilk.com Birkerfeld 11 D-83627 Warngau Phone: Internet: www.a-m-w.eu +49 (0) 8024 470999 0 AMW GmbH, Arzneimittelwerk Warngau PHARMA & CHEMICAL INDUSTRY Keywords: Drug Delivery AMW GmbH is an innovative, and steadily growing pharmaceutical company situated nearby Munich, the capitol of the Free State of Bavaria in Germany. Although still a small to medium-sized enterprise, we already act globally by providing licensees to partners throughout the world. Our partnering resp. licensing focus is the develop- ment, manufacture and distribution of medicinal products for indications such as oncology, neurology and pain treatment. What drives us at AMW is the fact, that despite significant progress in the treatment of severe diseases with highly active drugs, there are still several unmet needs in various therapeutic areas. Thus we strive for the development of a leading technology platform to achieve the maximum benefit for the patient by significantly improving the patients adherence to the prescribed course of treatment. The base of our technology is to provide a prolonged therapeutic effect with the benefit of having lesser side effects and lower consumption of the active pharmaceutical ingredients. One example from our portfolio is a biodegradable implant, that will be applied subcutaneously by an applicator with an automatic needle-retraction mechanism. BIOTECH IN BAVARIA - REPORT 2022|23 53

Am Mittleren Moos 48 D-86167 Augsburg Phone: +49 (0) 151 50516119 E-Mail: info@afin-ts.de Internet: www.afin-ts.de Analytisches Forschungsinstitut für NonTarget Screening GmbH LIFE SCIENCE / CHEMICAL INDUSTRY Keywords: Bioanalytics, R&D Service, Laboratory, Analytical Chemistry, Metabolomics, Natural Compounds, Small Molecules AFIN-TS was founded in 2018 as spin-off from TUM and provides research as well as important services and consulting around MS based non-target screening (NTS). Drug production processes as well as drug production origins/sources can be monitored by NTS. Thus, NTS can be used to characterize unknown/unexpected organic compounds in these or to track changes in the chemical composition (e.g. impurities, fake compounds, etc.) along treatment processes. R&D for (plant) metabolomics offered in own lab. anteris medical GmbH CRO CONSULTANTS Keywords: Regulatory Affairs, R&D Service, In-Vitro-Diagnostics, Clinical Diagnos- tics, Molecular Diagnostics, Devices, Drug Delivery Münchner Straße 47e D-83607 Holzkirchen +49 (0) 8024 4686 652 Phone: E-Mail: info@anteris-medical.com Internet: www.anteris-medical.com anteris medical supports Pharma and Biotech companies with the development, quality control and approval of their products. Our expertise in the fields of requirements management, quality control and risks management, usability engineering, Alliance Management as well as approval accompanies the products through the entire product life cycle. anteris medical brings together the experience of its founders and employees with medical products, combination products and in vitro diagnostics under one roof. Birkerfeld 12 D-83627 Warngau Phone: +49 8024 46869 70 E-Mail: info@apurano.de Internet: www.apurano.de Apurano Pharmaceuticals GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Pain, Nanobiotechnology The future of chronic pain with Adezunap. Apurano is a bio-nanotech company in Warngau/Bavaria with its late stage lead candidate ADEZUN-AP (nano CB1 receptor agonist) against chronic pain. 1.7B people suffer from chronic pain globally and 78% are unsatisfied with their treatment. FDA and EMA have declared it as unmet medical need. Apurano’s nano production technology PuranoTec allows best-in-class bioavail- ability of insoluble APIs. Apurano is vertical integrated with own GMP production, R&D, GLP lab & clinical Phase 1 center. Apurano gained 5 research grants. 54 BIOTECH IN BAVARIA - REPORT 2022|23

ASPHALION, S.L., Zweigniederlassung München CRO Keywords: Regulatory Affairs, Pharmacovigilance, Data Management and Biostatis- tics, Clinical Trial Management and Monitoring, Medical Writing ASPHALION is a Scientific and Regulatory Affairs consultancy firm with offices in Bar- celona, Madrid, Munich and London. Founded in 2000, ASPHALION now consists of a team of over 100 professionals offering services to Pharma and Biotech companies in Drug Development, Regulatory Strategy, Medical and CMC Writing, Regulatory Submissions, eSubmission, Pharmacovigilance and Training. ASPHALION operates in a global environment with regulatory submission expertise mostly in EU and North America. Leopoldstrasse 244 D-80807 München Phone: +49 (0) 89 208 039 280 E-Mail: munich@asphalion.com Internet: www.asphalion.com Assay.Works GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Tissue Engineering/Cell Culture, Automation, Small Molecules, Laborato- ry, Pharmacology, R&D Service, Drug Development Our mission is to accelerate our partner‘s research programs by developing and exe- cuting predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results. Am BioPark 11 D-93053 Regensburg Phone: +49 (0) 941 2000 1240 +49 (0) 941 2000 1241 Fax: E-Mail: contact@assay.works Internet: www.assay.works Astellas Pharma GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to changing tomorrow by improving the health of people around the world. We focus on oncolo- gy, anti-infectives, urology and transplantation as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies and modalities. The German headquarters are based in Munich. Located here are sales, marketing and medical. Ridlerstraße 57 D-80339 München Phone: +49 (0) 89 4544-01 E-Mail: communications.de@astellas.com Internet: www.astellas.com/de BIOTECH IN BAVARIA - REPORT 2022|23 55

Aurigon GmbH BIOTECH PRECLINICAL SERVICES Keywords: Pharmacology, Toxicology, Pharmacokinetics, ELISA/EIA, Bioanalytics, Drug Development, R&D Service AURIGON is an independent CRO offering a full range of in vivo and in vitro non-clinical services. These services include, but are not limited to: PK/PD, ADME, bioanalytics, toxicology and safety pharmacology in all species used in toxicity testing. We’re big enough to provide a full service, but small enough to fully adapt to your needs. AURIGON operates offices in Munich and state-of-the-art GLP- and GMP-compliant facilities at its ATRC Aurigon Toxicological Research Center near Budapest. Axolabs GmbH BIOTECH PRECLINICAL SERVICES Keywords: RNAi & Antisense, Antisense/Nucleotides, Pharmacology, Bioinformatics, Bioanalytics, Aptamer Technology, Pharmacokinetics Axolabs is the leading research and development organization for oligonucleotide therapeutics and nucleic acid medicines. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 20 years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs. BAP Pharma GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Clinical Trial Management and Monitoring, Logistics BAP Pharma Group are global leaders in clinical trials supply, specializing in comparator sourcing and secondary packaging/labelling. BAP Pharma is well placed to understand your clinical trial needs, deliver on our promises and known for innovation, expertise, ethics and dedication to providing excellent and bespoke customer service. With the newly founded site in Höchstädt, Bavaria, BAP Pharma is even closer to serve customers of the pharma and biotech- nology communities. baseclick GmbH BIOTECH DEVICES & REAGENTS Keywords: PCR, Nanobiotechnology, Chip/Array Technology Baseclick GmbH was founded in 2008 as a spin out of the LMU in Munich by Prof. Dr. Thomas Carell. Baseclick utilizes the “click chemistry”, discovered by the Nobel laureate Prof. Dr. Barry Sharpless, and developed a wide range of nucleic acid modification products, e.g. EdU proliferation kits, labeling of nucleotides and preparation kits for “Next Generation Sequencing” (NGS) and for the development of RNA-based drugs. baseclick GmbH out-licensed this technology to leading companies worldwide. Planegger Straße 9a D-81241 München Phone: +49 (0) 89 780 720 010 E-Mail: info@aurigon.de Internet: www.aurigon.de Fritz-Hornschuch-Straße 9 D-95326 Kulmbach Phone: +49 (0) 9221 82762-0 E-Mail: info@axolabs.com Internet: www.axolabs.com An der Kohlplatte 23 D-89420 Höchstädt a.d.Donau E-Mail: DEoperations@bappharma.com Internet: www.bappharma.com Floriansbogen 2-4 D-82061 Neuried Phone: +49 (0) 89 9699 3401 E-Mail: info@baseclick.eu Internet: www.baseclick.eu 56 BIOTECH IN BAVARIA - REPORT 2022|23

Bavarian Nordic GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox and monkeypox vaccines. Our commercial product port- folio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. BN was founded in 1994 and is headquartered in Denmark. The company has more than 500 employees in Europe and USA and is listed on the Copenhagen Stock Exchange. Baxter Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Beckman Coulter Biomedical GmbH BIOTECH - THERAPEUTICS AND DIAGNOSTICS Keywords: Devices, Nanobiotechnology, Automation, PCR Fraunhoferstraße 13 D-82152 Martinsried Phone: +49 (0) 89 255446-030 E-mail: hho@bavarian-nordic.com Internet: www.bavarian-nordic.com Edisonstraße 4 D-85716 Unterschleißheim Phone: +49 (0) 89 31701-0 E-Mail: Internet: www.baxter.de info_de@baxter.com Beckman Coulter develops, manufacturers and markets products that simplify, auto- mate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor pa- tients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs. Sauerbruchstraße 50 D-81377 München Phone: +49 (0) 89 579589-0 E-Mail: info@beckmancoulter.de Internet: www.beckmancoulter.de Bencard Allergie GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Allergy Bencard Allergie GmbH is the Munich based, German subsidiary of Allergy Thera- peutics plc. (Worthing/UK). As a global company, we specialize in the research and development of allergy treatments since 1934. We constantly aim to improve the quality of life of people suffering from allergies. Our strong portfolio offers specific immunotherapies to treat allergies such as pollen, pets, wasps or bees. Additionally we provide prick-tests for diagnostic purposes and OTC products (e.g. immunoBON®). Leopoldstraße 175 D-80804 München E-Mail: Internet: www.bencard.de info@bencard.com BIOTECH IN BAVARIA - REPORT 2022|23 57

beneArzneimittel GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Pain, Drug Development Herterichstraße 1 D-81479 München Phone: +49 (0) 89 74987-0 E-Mail: contact@bene-arzneimittel.de Internet: www.bene-arzneimittel.de bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for our most important goal: human health! betapharm Arzneimittel GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Pain, Drug Development Kobelweg 95 D-86153 Augsburg Phone: +49 (0) 821 74881-0 E-Mail: info@betapharm.de Internet: www.betapharm.de Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one oft the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m. Bicoll GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Natural Compounds, Nutraceuticals, Medicinal Chemistry, Oncology, R&D Service, Agrobiotechnology, Small Molecules Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 820106-30 E-Mail: Internet: www.bicoll-group.com contact@bicoll-group.com Bicoll offers novel patentable and biologically relevant structures for pharmaceutical, nutraceutical, and agricultural industry. Used proprietary, efficient and multi-discipli- nary technology approach to the discovery of novel potent molecules shortens the process from initial screening to animal test to 9 months. It has 20 years experience in dealing with plant natural products: extraction, isolation and synthesis. Bicoll is an expert in high tech natural product and in medicinal chemistry. BindX GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: New Materials, Agrobiotechnology, R&D Service, Industrial Biotechnology Am Klopferspitz 19 D-82152 Planegg-Martinsried Phone: +49 (0) 89 2620344-0 E-Mail: info@bind-x.com Internet: www.bind-x.com Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. Bind-X products are capable of solidifying almost any permeable material and provid- ing additional functional properties. Foremost they always increase the sustainability of Bind-X clients in the worldwide mining, agriculture and construction industry. 58 BIOTECH IN BAVARIA - REPORT 2022|23

BIOBANK der Blutspender Blutspendedienst des BRK BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology With innovative products and services, the Bavarian Red Cross (BRK) Blood Donor Service (BSD) secures around 75 percent of the Bavarian-wide supply of blood prepara- tions essential for survival and promotes health care. With its “Blood Donor BIOBANK”, the BSD also offers a unique and innovative resource for biomarker research. BioClinica GmbH CRO Keywords: Drug Development, Oncology, Neurology, Cardiovascular Diseases, Imaging, Metabolic Diseases, CNS Bioclinica is the global leader in medical imaging core lab services, providing life-sci- ence companies with clinical trial support for all phases and across all major indica- tions. Our commitment to service and scientific excellence is focused on advancing our clients’ drug development process. Bioclinica’s services create a unique and scalable platform and include Medical Imaging, Cardiac Safety Services, Clinical Event Adju- dication Services, Software Solutions, and Drug Safety Solutions. Biogen GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases or related therapeutic areas. Founded in 1978 as one of the first biotechnology companies we offer the leading portfolio of medicines to treat multiple sclerosis, have introduced the first approved treatment for spinal muscular atrophy, are commercializing biosimilars and focusing on advancing the industry’s most diversified pipeline in neuroscience. Biogen Germany is located in Munich. Biogents AG BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organizations (e.g. CDC, USA), several armed forces and other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Biogents also offers a fee-for-service business for insect repellents and attractants. Herzog-Heinrich-Straße 2 D-80336 München Phone: +49 (0) 89 5399-0 E-Mail: biobank@blutspendedienst.com Internet: www.biobank.de Landsberger Straße 290 D-80687 München Phone: +49 (0) 89 202 444 97-0 Internet: www.bioclinica.com Riedenburger Straße 7 D-81677 München Phone: +49 (0) 89 99617-0 E-Mail: stefan.schneider@biogen.com Internet: www.biogen.de Weißenburgstraße 22 D-93055 Regensburg Phone: +49 (0) 941 5699 6947 E-Mail: biogents@biogents.com Internet: www.biogents.com BIOTECH IN BAVARIA - REPORT 2022|23 59

Lochhamer Straße 9 D-82152 Martinsried Phone: +49 (0) 89 741595-0 E-Mail: info@biolink.de Internet: www.biolink.de Robert-Koch-Straße 2 D-82152 Martinsried Phone: +49 (0) 89 895574-0 E-Mail: info@biomax.com Internet: www.biomax.com Bruckmannring 32 D-85764 Oberschleißheim Phone: +49 (0) 89 3157000 E-Mail: info@biomed.de Internet: www.biomed.de BioLink Informationstechnologie GmbH BIOTECH BIOINFORMATICS Keywords: Laboratory The BioLink GmbH, an information-technology company, was founded in 1997 to serve as High Security Internet Provider and as Software Developer for Laboratory-In- formations-Management-Systems (LIMS). It was specifically the software-developing business which evolved over the last years. Based on the concept to design and develop personalized LIMS solutions, BioLink put forth a number of softwares aimed to support laboratory processing as well as certain aspects of genetic engineering. Biomax Informatics AG BIOTECH BIOINFORMATICS Keywords: Bioinformatics, Industrial Biotechnology, Data Management, Personalized Medicine, Agrobiotechnology, Informatics, Data Management and Biostatistics Biomax provides software solutions for efficient decision making and knowledge management. All products are based on the BioXM technology platform: • AILANI provides unique semantic integration and search capabilities that catalyze digital change and accelerate the innovation cycle. • NICARA is a knowledge hub for brain image assessments. In addition, Biomax offers solutions for Industrial Biotech and Systems Medicine. Biomax was founded in 1997 and is certified according to ISO 9001 and ISO 27001. Biomed Labordiagnostik GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: In-Vitro-Diagnostics, Bioanalytics BIOMED has been known for decades as a reliable manufacturer for lab diagnostics. Our core competences are diagnostic products, staining solutions and staining devices for routine and special laboratories for the detection and prevention of diseases. Whether immunology, infectiology, cytology, haematology, safe screening methods or the automation of staining for your different sample materials we offer solutions for many clinical and laboratory challenges. 60 BIOTECH IN BAVARIA - REPORT 2022|23

bioMérieux Deutschland GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, Peptide/Protein, Infectious Diseases, Proteomics BioMérieux’s Endotoxin Center of Excellence in Bernried, Germany. Our ENDONEXT™ range of recombinant Factor C assays and our ENDOXPERTS™ services provide innovative solutions for endotoxin detection. We aim at revolu- tionizing the endotoxin detection market through the replacement of historical animal-source based methods by modern, sustainable and ecological techniques, leveraging significant advantages such as accuracy, sensitivity, lot-to-lot consistency, and easy automation. Am Rusgraben 1 D-82347 Bernried Phone: +49 (0) 8158 9009 900 E-Mail: Internet: www.biomerieux.de Info.DE@biomerieux.com Biometric GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Analytical Chemistry Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food. Im Gewerbepark B49 D-93059 Regensburg Phone: +49 (0) 941 454 41 E-Mail: info@biometric-gmbh.de Internet: www.biometric-gmbh.de Bionorica SE PHARMA & CHEMICAL INDUSTRY Keywords: Neurology, Pain, Respiratory Diseases, Oncology, Analytical Chemistry, Drug Development Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders. Phytoneering combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern phar- maceutical research (engineering) in order to develop efficient and safe preparations. Kerschensteinerstraße 11-15 D-92318 Neumarkt Phone: +49 (0) 9181 231-90 E-Mail: info@bionorica.de Internet: www.bionorica.de BioNTech SE – Munich Small Molecules BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Immune Therapy, Medicinal Chemistry, in silico Predictions, Analytics, Preclinical Research, Oncology The department Munich Small Molecules (MSM) of BioNTech is focused on the identifi- cation and chemical synthesis of new molecular entities in support of the development and advancement of BioNTech’s next-generation cancer immunotherapy candidates. MSM consists of five research units, Chem- & Bioinformatics, Medicinal Chemistry, Analytical Chemistry, Pharmaceutical Research and Preclinical Development covering the small molecule drug discovery process starting from computer-based hit iden- tification up to preclinical assessment. BioNTech’s most advanced small molecule product candidate BNT411 which was developed at MSM department has entered clinic in July 2020. Am Klopferspitz 19 a D-82152 Planegg-Martinsried Phone: +49 (0) 89 8188802-0 Internet: www.biontech.de BIOTECH IN BAVARIA - REPORT 2022|23 61

BioNTech SE – Munich Antibody Platform BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Antibody The department Munich Antibody Platform (MAP) of BioNTech applies the company’s proprietary antibody and nanobody discovery platforms to generate and develop highly specific, functional monoclonal antibodies and nanobodies which serve as building blocks for many of BioNTech’s technologies. MAP consists of five functional units covering B cell cloning, phage display technology, Molecular Biology, Protein Expression & Purification and the screening and characterization of candidates. These units build the foundation of a high quality, fit-for-purpose discovery of therapeutic antibodies and nanobodies for the application in therapy and diagnostics. Biontex Laboratories GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents Biontex Laboratories GmbH is an innovative biotech company with focus on trans- fection technology, covering the introduction of genetic material and proteins into eukaryotic cells by synthetically produced carrier systems. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects. BioRad Laboratories GmbH BIOTECH DEVICES & REAGENTS Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service Bio-Rad was founded in 1952. The headquarter is in Hercules, California. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms and classrooms around the world. Bio-Rad’s key competencies incl. separation, purification and analysis. The com- pany is a leader in electrophoresis, protein assays, gel image analyis, quality controls, diabetes monitoring, autoimmune testing, blood typing and BSE. Biosepar Ges. für Medizin und Labortechnik mbH PHARMA ANIMAL HEALTH BIOSEPAR is driving excellence in sample preparation for parasitologic diagnostics since 1987. With the vision to make parasitologists’ life easier, BIOSEPAR has revolu- tionized parasitological stool diagnostics with standardized, hygienic, ready-to use kits and non-toxic, environmentally friendly reagents in both, human and veterinary medicine. The flagship product ParasiTrap® was followed by FixSepar® ECO and while increasing its global reach the company continues driving innovation. Forstenrieder Straße 8-14 D-82061 Neuried Phone: +49 (0)89 89990178-0 Internet: www.biontech.de Landsberger Straße 234 D-80687 München Phone: +49 (0) 89 324799-50 E-Mail: contact@biontex.com Internet: www.biontex.com Kapellenstraße 12 D-85622 Feldkirchen Phone: +49 (0) 89 31884-0 E-Mail: Internet: www.bio-rad.com info@bio-rad.de Adolf-Kolping-Strasse 34 D-84359 Simbach am Inn E-Mail: mail@biosepar.de Internet: www.biosepar.de 62 BIOTECH IN BAVARIA - REPORT 2022|23

Biophyll GmbH SUPPLIER & ENGINEERING Biophyll has over 25 years of experience in sourcing and manufacturing of biological products of animal, human, and plant origin. We assess the specific needs of our customers to provide tailored product solutions for pharmaceutical, diagnostic, and scientific purposes. - Access to new and rare biological products sourced worldwide - Supply of quality and traceability documentation - Regulatory support in import, export, and registration matters - Individually designed transport logistics concepts. Winkl 4 D-84378 Dietersburg Phone: +49 (0) 8565 964961 Internet: www.biophyll.com bioVariance GmbH BIOTECH BIOINFORMATICS Keywords: Genomics, Bioinformatics, Personalized Medicine, Biomarker Discovery & Development, Informatics, Pharmacogenomics, NGS BioVariance GmbH offers biomedical data analyses and related software development in the area of precision medicine for the healthcare, pharma and biotech sector. To accelerate the data analytics, we use special algorithms and machine learning to automate complex analytical processes in a customized software pipeline and to develop prediction models. We develop user-friendly interfaces including mobile apps to simplify data collection, processing, visualization and research. BIOZOL Diagnostica Vertrieb GmbH BIOTECH DEVICES & REAGENTS Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search. BristolMyers Squibb GmbH & Co. KGaA PHARMA & CHEMICAL INDUSTRY Keywords: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Rheumatoid Arthritis, Hematology Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease and rheumatoid arthrittis. Kornbühlstraße 28 D-95643 Tirschenreuth Phone: +49 (0) 9631 30 89 200 E-Mail: info@biovariance.com Internet: www.biovariance.com Obere Hauptstraße 10 b D-85386 Eching Phone: +49 (0) 89 3799666-6 E-Mail: info@biozol.de Internet: www.biozol.de Arnulfstraße 29 D-80636 München Phone: +49 (0) 89 12142-0 E-Mail: Internet: www.bms.com/de info-bms-germany@bms.com BIOTECH IN BAVARIA - REPORT 2022|23 63

Behringstraße 6 / 8 D-82152 Planegg-Martinsried E-Mail: info@bioservice.com Internet: www.bioservice.com BSL BIOSERVICE Scientific Laboratories Munich GmbH CRO Keywords: Toxicology, Pharmacology BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering biological testing services for Pharmaceuticals, Chemicals and Medical Devices. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A experienced team guarantees acceptance by authorities and supports customers from research until finalization. BSL is certified in accordance with GLP/GMP. We are listed by the WHO and been audited by the FDA. Carl Zeiss Microscopy GmbH BIOTECH DEVICES & REAGENTS Keywords: Imaging, Molecular Diagnostics, Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture, Toxicology, Genomics Kistlerhofstraße 75 D-81379 München Phone: +49 (0) 89 909000-0 E-Mail: microscopy@zeiss.com Internet: www.zeiss.com/microscopy ZEISS Research Microscopy Solutions is the world’s only one-stop manufacturer of light, electron, X-ray and ion microscope systems and offers solutions for correlative microscopy. The portfolio comprises of products and services for life sciences, ma- terials and industrial research, as well as education and clinical practice. The unit is headquartered in Jena. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment. CASCAT GmbH INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consul- tation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus. CatalYm GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Oncology CatalYm is developing innovative immunotherapies to transform cancer patients lives by effectively engaging their own immune systems to combat this malignant disease. Targeting novel mechanisms that lead to a potent and sustained activation of the immune system within the tumor microenvironment, CatalYms goal is to ridly bring its next-generation immuno-oncology products to patients in need. Europaring 4 D-94315 Straubing Phone: +49 (0) 9421 7855 20 Internet: www.cascat.de Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 2000 664-40 E-Mail: info@catalym.com Internet: www.catalym.com 64 BIOTECH IN BAVARIA - REPORT 2022|23

Celgene GmbH a BMS company PHARMA & CHEMICAL INDUSTRY Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de Joseph-Wild-Straße 20 D-81829 München Phone: +49 (0) 89 451519-010 E-Mail: info@celgene.de Internet: www.celgene.de cellasys GmbH BIOTECH DEVICES & REAGENT Keywords: R&D Service, Bioanalytics, Laboratory, In-Vitro-Diagnostics, Biochips, Devices, Toxicology cellasys delivers systems for microphysiometry. Microphysiometry measures the functions and activities of life or of living matter and of the physical and chemical phenomena involved. The technology is used to monitor changes in the metabolism and the morphology of living cells in real-time. Its applications range from basic re- search to risk assessment. cellasys offers all services around installation & maintenance as well as contract research. CellTool GmbH BIOTECH DEVICES & REAGENTS Keywords: Multi-omics single Cell Analysis, Raman Laser Trapping Spectroscopy, Microscopy CellTool is a company that develops, manufactures and distributes Raman laser microscopes for single cell analysis in suspension, tissue and organoids, 2D and 3D. Multi-omics read out from functional genomics to functional metabolomics (DNA, proteins, lipids, sugars, small molecules). Centronic GmbH BIOTECH DEVICES & REAGENTS Keywords: Analytical Chemistry, Medicinal Chemistry, In-Vitro-Diagnostics, Clinical Diagnostics Illerstrasse 14 D-87758 Kronburg Phone: +49 (0) 8394 257929 E-Mail: info@cellasys.com Internet: www.cellasys.com Lindemannstraße 13 D-82327 Tutzing Phone: +49 (0) 8158 906400 E-Mail: Internet: www.celltool.de info-celltool@celltool.de Centronic GmbH is a german manufacturer and distributor of a big range of high qualitative clinical chemistry and immunoturbidimetric reagents for the medical di- agnosis of enzymes, electrolytes, substrates, lipids and specific proteins. The portfolio is completed with corresponding controls, calibrators, Latex and Salmonella reagents and cleaning solutions for many analysers. Our Quality Management System is certified according EN ISO 13485:2016 by the TÜV. Am Kleinfeld 11 D-85456 Wartenberg Phone: +49 (0) 8762 7243-00 E-Mail: info@centronic-gmbh.com Internet: www.centronic-gmbh.com BIOTECH IN BAVARIA - REPORT 2022|23 65

Adalbert-Zoellner-Straße 1 D-95615 Marktredwitz Phone: +49 (0) 9231 9619-0 E-Mail: info@cfmot.de Internet: www.cfmot.de Sandhofer Weg 7 D-97633 Sulzfeld Phone: +49 (0) 9761 406 0 Fax: +49 (0) 9761 406 60 E-Mail: dbestell@de.crl.com Internet: www.criver.com Cfm Oskar Tropitzsch GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Pharmacology, AntibodyDrugConjugate ADC, Antibiotics, Natural Compounds, Drug Development, Drug Delivery, Fine Chemicals/Reagents We support the chemical, pharmaceutical and biotechnological industry in the pro- curement and production of chemical specialties. We deliver the product with the right documentation, the right quantity and quality - for projects from RnD stage to commercial production. Our products: ADCs, Metals and Metal Compounds, Fermentation, Medicinal Plants, Phytochemicals, Toxins, Pharmaceutical Products, Laboratory Chemicals, Contract Fermentation, Enzymatic Development Projects, Tailor Made Enzymes. Charles River Laboratories, Research Models and Services, Deutschland GmbH CRO Keywords: Drug Delivery At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - bi- osecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future. Cherry Biolabs GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Friedrich-Bergius-Ring 15 97076 Würzburg Phone: +49 (0) 931 201 444 23 E-Mail: info@cherrybiolabs.com Internet: www.cherrybiolabs.com Cherry Biolabs GmbH has developed a novel antibody-based platform technology for the treatment of cancers, not amenable by current immune therapies. This is achieved by the combination of two complementary antibody fragments (hemibodies) that assemble on target and thus specifically tag tumor cells for lysis by the patients killer T cells. While distinct hemibody-combinations against certain tumor types have already been identified, the platform is continuously expanded. 66 BIOTECH IN BAVARIA - REPORT 2022|23

ChromoTek GmbH BIOTECH DEVICES & REAGENTS Keywords: Antibody, Proteomics, Imaging, Laboratory ChromoTek is an internationally growing life science tools company based in Martins- ried, Germany’s leading biotech cluster. We are part of the international Proteintech Group in Illinois, USA. As a group, we produce and distribute more than 15,000 anti- bodies, nanobodies, bioactive proteins and kits under the Proteintech, ChromoTek and HumanKine brands. All products meet the highest standards of validation and quality control. With more than 130,000 scientific publications, our products set new standards for research applications. Technical know-how and first-class service are our hallmarks. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 124 148 8 - 0 E-Mail: info@chromotek.com Internet: www.chromotek.com Cipla Europe NV PHARMA & CHEMICAL INDUSTRY Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe. Cipla offers a range of products in Europe – Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products. Inselkammerstraße 4 D-82008 Unterhaching Phone: +49 (0) 89 6242208 10 E-Mail: Internet: www.cipla.com europe@cipla.com Clariant Produkte (Deutschland) GmbH, Group Biotechnology PHARMA & CHEMICAL INDUSTRY Keywords: New Materials, Agrobiotechnology Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth. The main focus of Clariant Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio- based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues. Climedo Health GmbH BIOTECH BIOINFORMATICS Keywords: Automation, Cell Therapy, Oncology, Clinical Trial Management and Monitoring, Devices, Regulatory Affairs, Data Management Climedo provides a secure, modular and easy-to-use digital platform for clinical trials and observational studies. Their solutions, including EDC, ePRO and Telemedicine, help pharma and medtech companies validate medical innovations more efficiently in real-world settings. This approach saves costs, accelerates studies, and improves data flow. By connecting stakeholders in a cloud-based system, Climedo is revolutionizing clinical research and making trials more accessible patient-centric. Semmelweisstraße 1 D-82152 Planegg b. München Phone: +49 (0) 89 710 661-0 E-Mail: biotech@clariant.com Internet: www.clariant.com Schellingstraße 109a D-80798 München Phone: +49 (0) 89 32209394 0 E-Mail: info@climedo.de Internet: www.climedo.de BIOTECH IN BAVARIA - REPORT 2022|23 67

Clinrex GmbH CRO Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the of areas GCP, Quality Management and Project Management for clinical trials. GCP/Quality Management Consulting - GCP gap analyses - Inspection readiness/ Audits - SOP development/streamlining - Interface sponsor/CRO - Investigator Initi- ated Trials (IITs) Training (Smart Training® or customised in-house training) - GCP for Sponsors, CROs or On-site Personnel - Project Management/Working with CROs - NIS. PF 1223 D-85572 Neubiberg Phone: +49 (0) 89 9292 87-0 E-Mail: info@clinrex.com Internet: www.clinrex.com COLORIMETRIX GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Oskar-von-Miller-Ring 20 D-80333 München E-Mail: Internet: www.colorimetrix.com contact@colorimetrix.com Colorimetrix GmbH – The lab in your pocket - We turn any smartphone into a portable laboratory using its camera to read diagnostic tests at home. No hardware needed, iOS and Android compatible, very competitive pricing, cloud analytics, trends, insights on the measurements, etc. Check out our first products: https://pearlfertility.app and https://covidrapidtest.app – happy to discuss opportunities, info@colorimetrix.com. Conreso GmbH CRO Keywords: Vaccines, Data Management and Biostatistics, veterinary clinical trials, Devices, Oncology, Infectious Diseases, Clinical Trial Management and Monitoring Conreso, established in 1990, BVMA member, CIR accredited, offers consulting and operational clinical development services, including clinical, non-interventional and epidemiological studies for pharmaceuticals, vaccines, medical devices and IVDs. Your need for temporary insourcing can be met with the permanent permission to temporarily lend staff. We serve as “Legal Representative” for non-EU sponsors. We also offer courier services for escorted time and temperature sensitive shipments. Coriolis Pharma Research GmbH CRO Keywords: Peptide/Protein, Antisense/Nucleotides, Vaccines, Antibody, Viruses, Drug Development, R&D Service Coriolis Pharma is a globally operating contract research organization (CRO) and a leader in formulation research and development of biopharmaceutical drugs, including proteins, peptides, RNA/DNA, viral vectors and ATMPs (up to BSL-2). We offer early and late-stage formulation development for liquid and lyophilized drug products, lyophilization process development and analytical method development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service portfolio. Neuhauser Straße 47 D-80331 München Phone: +49 (0) 89 236650-0 E-Mail: info@conreso.com Internet: www.conreso.com Fraunhoferstraße 18b D-82152 Martinsried Phone: +49 (0) 89 41 77 60-0 E-Mail: Internet: www.coriolis-pharma.com contact@coriolis-pharma.com 68 BIOTECH IN BAVARIA - REPORT 2022|23

CRELUX GmbH a WuXi AppTec company BIOTECH PRECLINICAL SERVICES Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis CRELUX, a WuXi AppTec company, is a provider of high-quality solutions for early stage drug development, supporting 1000+ partners from global pharma to biotech and academic institutions. As part of the WuXi AppTec HitS platform, CRELUX contributes a portfolio of state-of-the-art and cost-effective hit-to-lead technologies, including high quality protein production, fragment and DEL (DNA-Encoded Library) screening, biophysical validation and structural characterization (crystallography, cryo-EM). Am Klopferspitz 19 a D-82152 Martinsried Phone: +49 (0) 89 700760-0 E-Mail: crelux_office@wuxiapptec.com Internet: www.crelux.com CRI – The Clinical Research Institute GmbH CRO Keywords: Clinical Trial Management and Monitoring, Data Management and Bio- statistics, Logistics, Pharmacovigilance, Regulatory Affairs, Clinical Studies, Medical devices, Post-Marketing Surveillance, Post-Market Clinical Follow-up We are a full-service Contract Research Organization for clinical studies - controlled trials and observational studies - in all medical indications. We perform clinical projects primarily within Europe with currently >500 contracted hospitals in about 25 countries. The special competence of our 50+ team is large-scaled non-commercial trials, studies with medical devices, and supportive IT solutions like App-based follow-up of patients or data exchange with remote clinical monitoring services. Arnulfstraße 19 D-80335 München Phone: +49 (0) 89 9901649-0 E-Mail: info@cri-muc.eu Internet: www.cri-muc.eu Cryondo GmbH OTHER SERVICES Keywords: Logistics CRYONDO offers the (back-up) storage of biological/medical samples, reagents and retained samples. The samples can be stored at temperatures from -196 °C to room temperature, secured by a 3D security concept. Cryondo is certified according to DIN EN ISO 9001 and has the permits to store for instance samples of genetically modified organisms or samples that are subject to infection protection. In addition, Cryondo offers various services, logistics and products around cryo storage. Schlosserstraße 4 80336 München Phone: +49 (0) 89 / 540435-72 E-Mail: info@cryondo.de Internet: www.cryondo.de BIOTECH IN BAVARIA - REPORT 2022|23 69

WerkStadt Sendling / Haus 2 Flößergasse 4 D-81369 München Phone: +49 (0) 89 63 899 012 +49 (0) 89 892 94 31 Fax: E-Mail: einfachcool@cryoshop.de Internet: www.cryoshop.de Bachbauernstrasse 1 D-81241 München Phone: +49 (0) 89 20335359 E-Mail: info@cso-pharma.eu Internet: www.cso-pharma.eu CryoShop SUPPLIER FOR LIQUID NITROGEN EQUIPMENT Keywords: Logistics CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. We are supporting, serving and supplying customers in the healthcare and medical research sector. Over the years we developed an expertise in projects for ultra-cold and cryogenic preservation and storage of biological specimen. Futhermore our ‘cryo’ experienced technical crew offers services, support and maintenance, when and wherever needed. We are a reliable and skilled partner for liquid nitrogen and cold storage equipment for biotech, pharmaceutical and research companies. CryoShop is offering value added cryogenic solutions; according to our customers individual requirements it is our aim to recommend the most suitable products/ solution. Our portfolio allows us to provide products and solutions along the cryopres- ervation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/ automated thawing devices. Furthermore we care about your staff’s safety while working in deep cold environ- ments, offering special cryogenic personal protective equipment as well as training courses. CSO Pharma Consulting GmbH CRO Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigil- iance, Medical Writing, Laboratory CSO Pharma provides reliable pharmacovigilance services, professional medical affairs support and successful QM/GDP consulting. We run our own quality management system and offer our customers reliable services and processes based on international standards. You can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements. Curadis GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Henkestraße 91 D-91052 Erlangen Phone: +49 (0) 151 228 060 68 E-Mail: info@curadis.eu Internet: www.curadis.eu The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer. 70 BIOTECH IN BAVARIA - REPORT 2022|23

Cytophorics GbR BIOTECH DEVICES & REAGENTS Keywords: Molecular Diagnostics, Devices, Chip/Array Technology, In-Vitro-Diagnostics The Cytophorics technology enables a variety of applications in the pharmaceutical industry, clinical diagnostics and basic research. Wherever a living cell sample is in interest of investigation, the patented sensor-equipped multi-well plate is able to capture high quality, relevant vital data in real time. The integrated fluidic system allows long-term studies for all kind of cell based assays. The main areas of interest are in personalized medicine in drug developing and in research to investigate basic cell mechanisms. An der Rehwiese 20 D-81375 München Phone: +49 (0) 89 30725921 E-Mail: Internet: www.cytophorics.de info@cytophorics.com CYTOX, biologische Sicherheitsprüfungen BIOTECH DEVICES & REAGENTS Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications. Gottlieb-Keim-Straße 60 D-95448 Bayreuth Phone: +49 (0) 921 1511-254 E-Mail: info@cytox.de Internet: www.cytox.de DAIICHI SANKYO EUROPE GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Cardiovascular Diseases, Oncology, AntibodyDrugConjugate ADC Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical therapies. In addition to a strong portfolio of medicines for cardiovascular diseases, the Group’s 2025 vision is to become a Global Pharma Innovator with Competitive Advantage in Oncology. Our European headquarters are in Munich, Germany and we have affiliates in 13 European countries. Zielstattstraße 48 D-81379 München Phone: +49 (0) 89 7808-0 E-Mail: Internet: www.daiichi-sankyo.eu service@daiichi-sankyo.eu Data Matrix GmbH CRO Keywords: Data Management and Biostatistics, Medical Writing Data MATRIX was established in 2014. With its high-quality software products and professional team Data MATRIX has already successfully completed over 200 projects. Our products automate the processes of clinical trials, and users manage and monitor its progress online. We adjust and validate our software before the project starts in order to do it in the best way. With Data MATRIX products, 6 out of 10 TOP Big Pharma companies reduced their R&D costs by 15%. Neuhauserstraße 25 D-80331 München E-Mail: info@dm-matrix.com Internet: www.dm-matrix.com BIOTECH IN BAVARIA - REPORT 2022|23 71

Davids Biotechnologie GmbH BIOTECHNOLOGY THERAPEUTICS AND DIAGNOSTICS Keywords: Biotechnology Therapeutics and Diagnostics High quality polyclonal and monoclonal antibody production in Germany with eco- logical methods from the beginning in 1996. We offer you all services from the antigen design and production to the immunization and purification of the antibodies from sera and cell culture supernatants. The development of monoclonal antibodies with your antigen including the production and purification of your antibodies. 3D-Or- ganoid-Cell-Cultures as in-vitro replica of immune systems for the determination of personalized activity of immune modulators and for the determination of the activity of substances on the human immune system in vitro. Extraction and chromatogra- phy of proteins, nucleic acids, conjugates and other molecules. Most methods under physiological conditions. DelphiTest GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry The company’s core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest focussed on family relationship testing and has an ISO/IEC17025 accreditation. Additional services are paternity tests and genetic tests for dogs, as well as some antibody tests for humans and dogs. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe. Denk Pharma GmbH & Co. KG PHARMA & CHEMICAL INDUSTRY In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany. Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally operating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948. DEOXY GmbH BIOTECH Keywords: In-Vitro-Diagnostics, Clinical Diagnostics, Molecular Diagnostics, Genomics, Microscopy, Nanobiotechnology DEOXY develops nanometer-scale, DNA-based barcodes for quantitative and ultra-sen- sitive detection of biomolecules with applications in research and clinical diagnostics. Roentgenstraße 3 D-93055 Regensburg Phone: +49 (0) 941 948 228 E-Mail: info@davids-bio.de Internet: www.davids-bio.de Unter den Schwibbögen 23 D-93047 Regensburg Phone: +49 (0) 941 2986615 E-Mail: info@delphitest.de Internet: www.delphitest.de Prinzregentenstraße 79 D-81675 München Phone: +49 (0) 89 2300 29-0 E-Mail: mathias.seidel@denkpharma.de Internet: www.denkpharma.de Prinzregentenplatz 15 81675 München Phone: +49 (0) 89 2180 5301 E-Mail: info@deoxy.bio Internet: www.deoxy.bio 72 BIOTECH IN BAVARIA - REPORT 2022|23

DiaServe Laboratories GmbH BIOTECH DEVICES & REAGENTS DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and man- ufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories. Seeshaupter Straße 27 D-82393 Iffeldorf Phone: +49 (0) 8856 80360 E-Mail: Internet: www.diaserve.de contact@diaserve.de Dojindo EU GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Fine Chemicals/Reagents Dojindo produces over 500 well-known products used by research organizations in the world. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for offering state-of-the-art prod- ucts because our creative researchers are working continuously to meet tomorrow’s research needs. Leopoldstraße 254 D-80807 München Phone: +49 (0) 89 3540-4805 E-Mail: info@dojindo.eu.com Internet: www.dojindo.eu.com DoNatur GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Rheumatoid Arthritis DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 856625-55 E-Mail: info@donatur.de Internet: www.donatur.de Dr. Nibler & Partner CRO Keywords: Medical Writing, Pharmacology, Devices, Drug Development We provide a complete pharmacovigilance full-service solution: 24-hours availability - Literature screening and -review - Data entry and MedDRA coding - Scientific assessment by experienced physicians - Authority reporting - SUSAR reporting - Periodic reports: ASR, DSUR, PSUR - Risk management plans - Implementation of pharmacovigilance systems - Audits and guidance through inspection. Fürstenriederstraße 105 D-80686 München Phone: +49 (0) 89 56823726 E-Mail: mail@dr-nibler.de Internet: www.dr-nibler.de BIOTECH IN BAVARIA - REPORT 2022|23 73

Dr.-Robert-Pfleger-Straße 12 D-96052 Bamberg Phone: +49 (0) 951 6043-0 E-Mail: info@dr-pfleger.de Internet: www.dr-pfleger.de Perchtinger Straße 8/10 D-81379 München Phone: +49 (0) 89 897 4544-0 E-Mail: info@dynamic-biosensors.com Internet: www.dynamic-biosensors.com Dr. Pfleger Arzneimittel GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Dermatology, Pain, Drug Development Dr. Pfleger Arzneimittel GmbH is a medium-sized pharmaceutical company with 350 employees and a sales turnover of nearly 100 million EUR. Dr. Pfleger markets non-prescription and prescription medicines for indications in urology, gyneacology, dermatology and areas of self-medication in Germany and selected territories world- wide. The financial surpluses generated by the company are passed onto the Doktor Robert Pfleger-Stiftung. Dynamic Biosensors GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Proteomics, Drug Development, Antibody, Peptide/Protein, Small Molecules, Devices, Chip/Array Technology, Realtime Interaction Cytometry Dynamic Biosensors provides instruments and consumables for the advanced analysis of biomolecular interactions on biochips and single cells, which enable breakthroughs in drug discovery, life science research, and cell & gene therapies. Dynamic Biosensors commercializes switchSENSE® and Real-Time Interaction Cytome- try (RT-IC) technologies. switchSENSE® is a unique platform technology for the analysis of molecule-molecule interactions. RT-IC is a groundbreaking technology enabling the real-time measurement of molecules binding to membrane targets on cells. The company is headquartered in Munich, Germany, and runs offices in the United States, the United Kingdom, France, Japan, and Singapore. Ebenbuild GmbH DIGITAL HEALTH Schinkelstraße 44 c/o Dr. Kei Müller D-80805 München Phone: E-Mail: Internet: www.ebenbuild.com/index.html +49 (0) 89 289 15265 info@ebenbuild.com Keywords: Personalized Medicine, Respiratory Diseases, Pneumology, Biomarker Discovery & Development, Informatics, Imaging, R&D Service Leveraging more than 15 years of bleeding edge research at TUM, we use these pa- tient-specific models to predict and optimize therapy both in clinical as well as R&D settings in MedTech/Biotech/Pharma. Our use cases span digital trials in pulmonary drug delivery, image-based biomarker tracking in clinical trials, and on-site critical care decision support. Eisbach Bio GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Eisbach Bio develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR) pathways. Its proprietary platform creates targeted therapies that exploit disease-rel- evant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, their impactful medicines prevent thereorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors. Am Klopferspitz 19 D-82152 Martinsried Internet: www.eisbach.bio 74 BIOTECH IN BAVARIA - REPORT 2022|23

Electrochaea GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Electrochaea is an energy company with an innovative solution for storage of in- termittent renewable energy and generation of synthetic methane. Electrochaea’s proprietary technology converts renewable electricity and carbon dioxide into BioCat Methane, a low-carbon intensity synthetic methane. For this process we use Electro- chaea’s patented biocatalyst – methanogenic archaea. BioCat Methane is reliable, practical, and a safe replacement for natural gas. It can be stored in the existing gas grid infrastructure for use in days, weeks or months. Semmelweisstraße 3 D-82152 Planegg Phone: +49 (0) 89 3249 3670 E-Mail: info@electrochaea.com Internet: www.electrochaea.com ELLA Biotech GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip/Array Technology, PCR, In-Vitro-Diagnostics Our expertise is the synthesis of special oligoribonucleotides for random mutagenesis, in-vitro diagnostics, epigenetic sequencing, Aptamer technology and many more following quality standards which you would appreciate and expect in your own lab. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners. EMFRET Analytics GmbH & Co. KG BIOTECH DEVICES & REAGENTS emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology. Am Kugelfang 39 D-82256 Fürstenfeldbruck Phone: +49 (0) 89 1413 66360 E-Mail: info@ellabiotech.com Internet: www.ellabiotech.com Am Morgenroth 6 D-97246 Eibelstadt Phone: +49 (0) 9303 984 964 E-Mail: service@emfret.com Internet: www.emfret.com EMP Genetech BIOTECH DNA/PROTEIN ANALYTICS Keywords: Drug Development, Biomarker Discovery & Development, R&D Service EMP Genetech is a CDMO in the field of recombinant protein production. Recombinant proteins are expressed from mammalian cells. We develop stable high producer cell lines mainly of human (HEK293 EBNA) origin cells. Protein production is conducted by bioreactor driven high cell cultivation up to 10 L scale with serum free conditions. Gene cloning and single cell clone selection as well as downstream processing are well established methods in our lab. We work successfully since 2000. Straussenlettenstrasse 7b D-85053 Ingolstadt Phone: +49 (0) 841 3796013 E-Mail: info@empgenetech.com Internet: www.empgenetech.com BIOTECH IN BAVARIA - REPORT 2022|23 75

Hohenbachernstraße 19-21 D-85354 Freising Phone: +49 (0) 8161 4990-80 E-Mail: Internet: www.epigene.de Friedrich.Felsenstein@EpiLogic.de Am Klopferspitz 19 D-82152 Planegg-Martinsried Phone: +49 (0) 89 2153 5730 E-Mail: Internet: www.epiqmax.com info@epiqmax.de EpiGene GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Agrobiotechnology, Genomics EpiGene GmbH is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecu- lar characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents and the identification of mutations or differentially expressed genes in pathogens as potential new targets. EpiQMAx GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: R&D Service, Clinical Diagnostics, Molecular Diagnostics, Proteomics, Personalized Medicine Since 2018, EpiQMAx is a partner for the development of epidrugs and biomarker research in the epigenetic and proteomic field. Headquartered nearby Munich, we operate a state-of-the-art mass spectrometer to facilitate epigenetic screenings into clinical applications. Our technology platform comprises a KIT for quick sample preparation, a mass spectrometer for a unique quantitative analysis of modifications and software programs for intuitive and visual reporting of the results. essentim GmbH BIOTECH DEVICES & REAGENTS Schragenhofstraße 35 D-80992 München Phone: +49 (0)1608093076 E-Mail: info@essentim.com Internet: www.essentim.com essentim sensors provide a scalable method for secure data acquisition and real-time monitoring of temperature, pressure, humidity, motion, light and many other variables. Benefit from fast implementation, transparent monitoring and digital documentation. Do you need a scalable solution for sensors, cloud-based apps and web technology? We realize your IoT projects, from hardware to software, from sensors to gateway technology and apps for smartphones and web. ethris GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and de- velop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients’ lives. Semmelweisstrasse 3 D-82152 Planegg Phone: +49 (0) 89 8955 788-0 E-Mail: info@ethris.com Internet: www.ethris.com 76 BIOTECH IN BAVARIA - REPORT 2022|23

eticur) GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Cell Therapy Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute) and extensive testing by highly qualified personnel. Landsberger Straße 406 D-81241 München Phone: +49 (0) 89 12 59 81-0 E-Mail: info@eticur.de Internet: www.eticur.de Eurofins BioPharma Product Testing Munich GmbH BIOTECH PRECLINICAL SERVICES Keywords: Pharmacology, Small Molecules, Bioanalytics, Laboratory, Medicinal Chemistry, Toxicology Eurofins BioPharma Product Testing Munich is part of the world’s largest network of testing laboratories providing comprehensive laboratory services to pharmaceutical, biopharmaceutical and medical device companies. Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, medical devices, chemicals and cosmetics. The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at Planegg near Munich. Eurofins Genomics Germany GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Genomics, NGS, PCR, Antisense/Nucleotides Behringstraße 6/8 D-82152 Martinsried Phone: +49 (0) 89 899650-0 E-Mail: Internet: www.eurofins.de info-munich@eurofins.com Eurofins Genomics is an international provider of genomic products and services including DNA sequencing, next generation sequencing, genotyping, DNA synthe- sis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. Anzinger Straße 7a D-85560 Ebersberg Phone: +49 (0) 8092 8289-0 E-Mail: Internet: www.eurofinsgenomics.com info-eu@eurofins.com Evanium Healthcare GmbH PHARMA & CHEMICAL INDUSTRY Evanium Healthcare develops consumer health solutions based on secondary plant compounds for the pharmaceutical industry as well as the food sector. In addition to a platform technology for increasing the solubility of flavonoids, this also includes branded ingredients and fully developed product solutions, especially for the private label sector. The current focus here is primarily on supporting liver function and the nervous system. Am Biopark 13 D-93053 Regensburg E-Mail: Internet: www.evanium.de kontakt@evanium.de BIOTECH IN BAVARIA - REPORT 2022|23 77

Anna-Sigmund-Straße 5 D-82061 Neuried Phone: +49 (0) 89 452 4465-0 E-Mail: info@evotec.com Internet: www.evotec.com Evotec (München) GmbH BIOTECH PRECLINICAL SERVICES Keywords: Cell Therapy, Metabolomics, Biomarker Discovery & Development, Bioinformatics, Small Molecules, Proteomics, Genomics Evotec (München) GmbH Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. With more than 4,500 employees globally, we provide highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. Evotec (München) GmbH is the Company’s centre of excellence for proteomics, biomarker and metabolomics services. ExB Health GmbH BIOINFORMATICS St.-Martin-Straße 63 D-81669 München Phone: +49 (0) 89 55067340 E-Mail: Internet: www.exb-health.com contact@exb.de ExB Health is a subsidiary of the ExB Labs GmbH, a Germany based technology incu- bator and research company in the field of unstructured big data, natural language processing, Cognitive Computing and deep learning. ExB Health draws on the labs mature developments and adapts them for the use in lifescience and healthcare. The knowledge discovery and decision support systems help pharma and healthcare industries to lower costs, speed up the drug-development cycle and improve patient outcomes. EXCELLA GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology Excella GmbH & Co. KG has been serving the pharmaceutical industry for more than 35 years with high quality API’s and finished dosage forms. Focused towards high containment manufacturing Excella supplies products to the generic industry and big pharma but also develops processes for innovative API’s and novel solid dosage forms. Services offered from our globally registered and approved site range from early product development through registration support to state-of-the-art manufacturing. Eximmium Biotechnologies GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Eximmium is a new antibody company located in Munich and Singapore. By using an innovative platform technology, Eximmium focuses on identification of novel tu- mor targets and generation of first-in-class antibodies for both cancer therapy and diagnostics. Nürnberger Straße 12 D-90537 Feucht Phone: +49 (0) 9128 404-0 E-Mail: info@excella-pharma-source.de Internet: www.excella-pharma-source.de Feodor-Lynen-Strasse 21 D-81377 München E-Mail: info@eximmium.com Internet: www.eximmium.com 78 BIOTECH IN BAVARIA - REPORT 2022|23

FSelect GmbH PHARMA & CHEMICAL INDUSTRY The element fluorine plays an increasingly important role in the field of high-per- formance materials and pharmaceuticals. The production of the necessary chem- ical substances remains a challenge and F-Select has the solution. F-Select offers selected fluorinating agents as well as a comprehensive know-how in the handling and production of fluorinating agents. The methods developed by F-Select provide resource-saving methods for the production of pharmacological building blocks. Semmelweisstrasse 5 D-82152 Planegg Phone: +49 (0) 89 74032330 E-Mail: info@f-select.de Internet: www.f-select.de FGK Clinical Research GmbH CRO Keywords: CRO/CMO, Drug Development, Regulatory Affairs, Devices, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Pharmacovigiliance FGK is a Europe-based CRO with offices in DE (HQ), PL, CZ and HU, offering full service for all phases of clinical trials. Our international client base includes biotech, medical device and pharma companies. With extensive experience in all major therapeutic areas and 150+ highly qualified medical, scientific and regulatory experts we can guide you through the clinical development process, from planning and approval up until the final report. FGK Pharmacovigilance GmbH CRO Keywords: CRO/CMO, Medical Writing, Clinical Trial Management and Monitoring, Drug Development, Pharmacovigilance, Data Management and Biostatistics FGK Pharmacovigilance GmbH is a service provider offering vigilance services in support to pharmaceutical, biotech, and medical device companies’ obligations in managing risk-benefit profile of their products. Services can be added to existing vigilance system of a client on a modular basis or comprise a stand-alone center of product vigilance on national, international or global level. Heimeranstraße 35 D-80339 München Phone: +49 (0) 89 893 119-0 E-Mail: info@fgk-cro.com Internet: www.fgk-cro.com Heimeranstraße 35 D-80339 München Phone: +49 (0) 89 893 119-0 E-Mail: info@fgk-pv.com Internet: www.fgk-pv.com FLUICS GmbH BIOTECH DEVICES & REAGENTS Keywords: sample tracking, inventory management, QR code printing, IoT, mobile app development FLUICS CONNECT is a mobile solution that helps innovative research labs to improve efficiency and reproducibility by keeping their sample inventory up to date. With our mobile app and an internet-ready printer connected to an online database we offer a convenient solution to print and track smear proof, QR-coded cryo labels. Watch our 1 min video to see how it works: go.fluics.com/teaser. Fürstenstraße 15 D-80333 München Phone: +49 89 71690877 E-Mail: Internet: www.fluics.com connect@fluics.com BIOTECH IN BAVARIA - REPORT 2022|23 79

FoodChain ID Testing GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Agrobiotechnology, NGS FoodChain ID Testing GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, genotyping, custom contract assay development) and immunological detection of allergens in food and feed. Formycon AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Inflammation, Dermatology, Ophtalmology, Drug Development Formycon (ISIN: DE000A1EWVY8 / WKN: A1EWVY) is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosim- ilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has six biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207. Freeline Therapeutics GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Gene Therapy, Industrial Biotechnology, Drug Development Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US. FRIZ Biochem Gesellschaft für Bioanalytik mbH BIOTECH DEVICES & REAGENTS Keywords: Molecular Diagnostics, PCR, Infectious Diseases, Chip/Array Technology, In-Vitro-Diagnostics, Clinical Diagnostics, Devices We provide novel, disruptive and fastest quality molecular diagnostics with special emphasis on near-patient applications which require as little laboratory equipment and training as possible. Our two unique patented technology platforms Lab-direct- RT-PCR and Cycle® Diagnostics cover both microbiological and viral applications for clinical diagnostics as well as for R&D. Am Mittleren Moos 48 D-86167 Augsburg Phone: +49 (0) 821 74776-30 E-Mail: info@foodchainid.de Internet: www.foodchainid.com/de Fraunhoferstraße 15 D-82152 Martinsried Phone: +49 (0) 89 864667-100 E-Mail: info@formycon.com Internet: www.formycon.com Fraunhoferstraße 9b D-82152 Planegg E-Mail: Internet: www.freeline.life infode@freeline.life Floriansbogen 2 - 4 D-82061 Neuried Phone: +49 (0) 89 7244 09-25 E-Mail: info@frizbiochem.de Internet: www.frizbiochem.de 80 BIOTECH IN BAVARIA - REPORT 2022|23

Galapagos Biopharma Deutschland GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Rheumatoid Arthritis, Small Molecules, Colitis ulcerosa, Immunology, Oncology Galapagos is a pioneering biotech with a pipeline of innovative therapies to address unmet medical needs. We built an innovative, integrated model that takes us from target discovery, through the discovery of molecules addressing targets, all the way to the development of those molecules into potential medicines, helping people worldwide with severe diseases, including inflammation and fibrosis. Luise-Ullrich-Straße 8 c/o Design Offices NOVE D-80636 München Phone: +49 (0) 89 262 013 09 E-Mail: deutschland@glpg.com Internet: www.glpg.de GATTAquant GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy The worldwide first commercial DNA origami application: The key innovation behind our nanorulers is the application of an elaborate nanotechnology method, which serves as a breadboard to position dye-molecules on the nanometer scale. The used technique, where DNA is folded into predefined shapes, is called DNA origami and allows to attach dye-molecules at will. Am Schlosshof 8 D-91355 Hiltpoltstein Phone: +49 (0) 9192 243 99 44 E-Mail: info@gattaquant.com Internet: www.gattaquant.com GBA PHARMA GmbH PHARMA & CHEMICAL INDUSTRY Keywords: R&D Service, Regulatory Affairs, Laboratory, Analytical Chemistry GBA Pharma Labs run three GMP-certified and FDA-inspected sites in Germany with more than 160 highly qualified employees and over 4,500 m2 of lab space. Our loca- tions for analytical services support domestic and international customers, whether from the private industry or research institutions, with scientific and technical solutions for the development, approval process, and quality control throughout every step of the product lifecycle. Additionally we offer regulatory affairs services. Anna-Sigmund-Straße 7 D-82061 Neuried Phone: +49 (0) 89 899 229 200 E-Mail: info@gba-pharma.com Internet: www.gba-pharma.com BIOTECH IN BAVARIA - REPORT 2022|23 81

GBN Systems GmbH BIOTECH DEVICES & REAGENTS For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conductor industry and automation technology. From the very start our experienced team of electro technology engeneers and preci- sion mechanics develops and manufactures a wide product range. From customized components to complete assemblies and machines including a fulfilment from initial vision to serial end production. Let your idea, vision turn into a serial product. Use the GBN Systems engineering- and manufacturing competence since 1989 for “Performing Mechatronics – Made in Bavaria”. The facilities are centrally located facilities near Bavarian capital and airport of Munich. This enables business partner to find the logistically ideal sparring for expansions in southern Germany, Austria and Switzerland. Key competencies in : Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics. Genedata Bioinformatik GmbH BIOTECH BIOINFORMATICS Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company‘s solutions are key for moving the focus of life science research from high- throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan). Genedia AG BIOTECH DNA/PROTEIN ANALYTICS Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry Genedia AG Biotec Services and Products is a provider of DNA testing services in- cluding private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services Another area is DNA genealogy and antropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analy- sis. The forensic area includes DNA identification and banking services DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). Fellnerstrasse 2 D-85656 Buch am Buchrain Phone: +49 (0) 8124 5310-0 E-Mail: info@gbn-systems.com Internet: www.gbn-systems.com Fürstenrieder Straße 281 D-81377 München Phone: +49 (0) 89 4581901-0 E-Mail: Internet: www.genedata.com administration@genedata.com Untere Grasstraße 6 D-81541 München Phone: +49 (0) 89 543448-0 E-Mail: info@genedia.de Internet: www.genedia.de 82 BIOTECH IN BAVARIA - REPORT 2022|23

GeneSurge GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS GeneSurge is your access to individualized diagnostics. Even though we classify tumors according to their place of origin and appearance, each one remains somewhat differ- ent at the molecular level. And that is exactly what makes each cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specific to the individual patient. We provide 3 tests to reach your individual profile. Ottostraße 3 D-80333 München Internet: www.genesurge.com GENidee BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Molecular Diagnostics, PCR GENidee is a young and innovative biotech company specialized in the development, production and sales of molecular biological diagnostic kits for the rapid detection of food-borne pathogens in food. Fast and reliable real-time PCR diagnostics is guar- anteed by simultaneous analytics suited to the individual customer requirements. GENidee offers DNA-based detection systems of highest quality. Using our kits directly in the production facilities enables the results of molecular food analytics to be sup- plied much sooner than by conventional diagnostics. Individual customer support and consequent customer satisfaction is our top priority. Lise-Meitner-Straße 30 c/o IZB D-85354 Freising/Weihenstephan Phone: +49 (0) 8161 8068186 E-Mail: info@genidee.eu Internet: www.genidee.eu GenPlus GmbH CRO Keywords: Laboratory, R&D Service, Drug Development Gen-Plus GmbH & Co.KG provides solutions for challenging needs in pharmaceutical development and is a state-of-the-art CRDO. We develop tailor-made formulation and technology concepts (NCE, value-added-Generics, OTC) for solid/semisolids, non-steril liquids, patches and thin films from early idea to IMP production under GMP. Further in-house capabilities: narcotics & high potent handling (isolators), 2D&3D API printing, high-tech analytics incl. skin permeation. Gen Plus is a member of the vertically integrated service provider Conscio group (consciogroup.com). With HQ in Munich and operations in several CEE (Germany, Czech Republic, Austria and Slovakia), Conscio is a fully certified (GCP, GLP, GMP) top provider for pharma and biotech industries with solutions spanning across the entire drug development process: Innovation and Pharmaceutical technology, Formulation development, Clinical Studies, Bioanalytical testing and GMP production & testing. Staffelseestraße 6 D-81477 München Phone: +49 (0) 89 780 179 40 E-Mail: info@gen-plus.de Internet: www.gen-plus.de BIOTECH IN BAVARIA - REPORT 2022|23 83

Gilead Sciences GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Fraunhoferstraße 17 D-82152 Martinsried Phone: +49 (0) 89 899890-0 E-Mail: info@gilead-sciences.de Internet: www.gileadsciences.de Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. Friedrich-Bergius-Ring 15 D-97076 Würzburg Phone: +49 (0) 931 907056-78 E-Mail: info@gilyos.com Internet: www.gilyos.com Weihenstephaner Berg 4 D-85354 Freising/Weihenstephan Phone: +49 (0) 8161 986 4480 E-Mail: info@gimbio.de Internet: www.gimbio.de GILYOS GmbH CRO Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development GILYOS is a contract development solution provider with more than 20 years of ex- perience in pharmaceutical freeze drying. GILYOS` key business is consultancy and hands-on development services. Typical services include formulation development of small molecules and proteins, process optimization and analytical characterization. Further, GILYOS has a very strong expertise in scale-up and technical transfer of freeze drying cycles, including troubleshooting of established products (scale down). gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie BIOTECH BIOINFORMATICS Keywords: Automation, Data Management Gimbio GmbH offers innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for bi- otechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses. 84 BIOTECH IN BAVARIA - REPORT 2022|23

GKM Gesellschaft für Therapieforschung mbH CRO Keywords: Regulatory Affairs, Data Management and Biostatistics, Medical Writing, Pharmacovigiliance, Clinical Trial Management and Monitoring GKM Gesellschaft für Therapieforschung is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for non-interventional studies. GKM also provides services for early benefit anal- yses (AMNOG), vigilance, and medical writing. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible, cost-effective services with expert knowledge and dedication to your projects. Lessingstraße 14 D-80336 München Phone: +49 (0) 89 209 120-0 E-Mail: science@gkm-therapieforschung.de Internet: www.gkm-therapieforschung.de GlaxoSmithKline GmbH & Co. KG PHARMA & CHEMICAL INDUSTRY Keywords: Pneumology, Oncology, Respiratory Diseases, Vaccines, Antibiotics GSK is a science-led, globally operating healthcare company with a special purpose: to help people do more, feel better, live longer. Our goal is to be one of the worlds most innovative, best performing and trusted healthcare companies. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines, respiratory and additionally in Oncology. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV. Prinzregentenplatz 9 D-81675 München Phone: +49 (0) 89 360 440 E-Mail: Internet: www.de.gsk.com service.info@gsk.com GWK Präzisionstechnik GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices, Analytical Chemistry, Regulatory Affairs, In-Vitro-Diagnostics, Microscopy, Chip/Array Technology, Automation GWK Precision Technology offers development and manufacturing of laboratory equipment and medical devices. Being a team of 20 specialists, we serve industry and scientific institutions since 1991. We provide special know-how in technical fields as well as the certification of equipment and production systems following ISO 13485. For the detection of Covid and Legionella we offer a differential diagnostik system using microarray-chip-technology, also see www.LegioTyper.de. Gollierstraße 70 D-80339 München Phone: +49 (0) 89 7264960-0 E-Mail: Internet: www.gwk-munich.de info@gwk-munich.com Hema.to GmbH BIOTECH BIOINFORMATICS Keywords: AI/Dx hema.to is a software service that reduces essential time to diagnosis, inter- and intraobserver variability, and expensive dyed antibodies for hematological laborato- ries. Besides a substantial reduction in misdiagnosis, we believe that we can provide patients with certainty much earlier than is the case today. Ainmillerstraße 22 D-80801 München Internet: www.hema.to BIOTECH IN BAVARIA - REPORT 2022|23 85

Professor-Messerschmitt-Straße 3 D-85579 Neubiberg Phone: +49 (0) 89 6008761-0 E-Mail: bertsch@hematris.de Internet: www.hematris.de Industriestraße 18 D-83607 Holzkirchen Phone: +49 (0) 802 4908-0 E-Mail: Internet: www.hexal.de service@sandoz.com Wilhelm-Wagenfeld-Straße 20 D-80807 München +49 (0) 89 36090200 Phone: E-Mail: info@hmnc.de Internet: www.hmnc.de Hematris Wound Care GmbH MEDTECH Keywords: Devices Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area. HEXAL PHARMA & CHEMICAL INDUSTRY Hexal is the leading German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. Hexal brings (next to classical chemical generics, OTC products, respiratory devices or patches) biosimi- lars to the German market. Biosimilars are highly-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using “recombinant DNA” technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to “traditional”, chemically synthesized medicines. In Germany Hexal employs more than 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006. HMNC Brain Health GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development HMNC is a biopharma company developing novel treatments for depression and anxiety: Proprietary gene-based companion tests support the decision which drugs optimize treatment effects. Our portfolio includes investigational drugs targeting stress systems in the brain. A novel formulation of ketamine holds promise to become prime option for treatment resistant depression. The myGeneCode1-test informs whether a given antidepressant passes the blood-brain barrier. The test is already on the market. 86 BIOTECH IN BAVARIA - REPORT 2022|23

HP Health Solutions Germany GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Clinical Diagnostics, In-Vitro-Diagnostics, Bioanalytics, Molecular Diagnostics, Devices, New Materials, Other Diagnostics HP Health Solutions was founded as GNA Biosolutions GmbH in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich. The company employs 40 people today. HP Health Solutions develops instruments, consumables and tests for fast molecular diagnostics, based on its proprietary technology, Pulse Controlled Amplification (PCA). PCA can transform molecular diagnostics by enabling the development of testing platforms that can be used outside of the traditional laboratory setting. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 998 207-180 E-Mail: info@gna-bio.com Internet: www.gna-bio.com HTI Automation GmbH BIOTECH DEVICES & REAGENTS Keywords: In-Vitro-Diagnostics, Laboratory, Clinical Diagnostics, Devices, Automation For more than 20 years, we at HTI have been developing customized solutions for laboratory and production automation. Our engineering services and products con- tribute significantly to the success of our customers. With the X-TubeProcessor®_Series, we have created the possibility to flexibly combine established technologies and processes such as liquid handling, capping or labelling in one device. Thanks to high quality standards, innovative solutions and many years of expertise, we are now a partner for companies all over the world. Human Tissue and Cell ResearchServices (HTCR) GmbH BIOTECH PRECLINICAL SERVICES Keywords: Biomarker Discovery & Development, Bioprocessing, Tissue Engineering/Cell Culture, Toxicology, In vitro Diagnostics, R&D Service, Autoimmune Dieseases, Dermatology, Hepatology HTCR Services enables basic research and drug development with specialized services and an experienced team of scientists and managers. Supported by a growing net- work of hospitals and clinical experts, HTCR offers a wide range of services including healthy and pathological bio-samples (e.g. fresh/cryo/FFPE tissue, plasma, serum, cell preparations) with clinical longitudinal data. This enables academic and industrial partners to advance their pre-clinical research pipeline and clinical development of innovative medicines and personalized treatment applications. Am Forst 6 D-85560 Ebersberg Phone: +49 (0) 8092 2092-0 E-Mail: info@hti-automation.com Internet: www.hti-automation.com Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 440076442 E-Mail: Internet: www.htcr-services.com info@HTCR-services.com BIOTECH IN BAVARIA - REPORT 2022|23 87

HWI regulatory services GmbH CRO Keywords: Drug Development, Analytical Chemistry, Medical Writing, Pharmacology, Toxicology, Devices, Regulatory Affairs Fraunhoferstraße 9 D-82152 Martinsried Phone: +49 (0) 89 200 0203-50 E-Mail: Internet: www.hwi-group.de s.oettl@hwi-group.de HWI regulatory services GmbH provides regulatory services for drug substances, drug products and medical devices (strategic consultancy, procedure- and life-cycle management). For medical devices and drug-device combination products we offer clinical evaluation, biological safety assessments and technical documentation writing for certification. The HWI group provides innovative services for pharma, biotech and medtech, par- ticularly for API, medicinal products and medical devices. Hyperthermics Regensburg GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Hyperthermics Regensburg is developing applications in renewable energy solutions. We use hyperthermophilic microorganisms to increase the biogas yield. Our bioactive pre-treatment plant pre-treats the substrate before it enters the biogas reactor. This process provides increased biogas production and can also replace a conventional hygienisation/pasteurization plant. In addition, we use hyperthermophilic microor- ganisms to produce green hydrogen from industrial organic waste streams. ibidi GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices The ibidi product lines include dishes, slides, and plates for the cultivation and high-res- olution microscopy of cells, and also cell-based assays for investigating angiogenesis, chemotaxis, wound healing, and cells under flow. Specialized labware products and Collagen Type I, Rat Tail, providesolutions for3D spheroids and organoids. ibidi also specializes in instruments, such as stage top incubators for live cell imaging, plus a unique perfusion system for the simulation of blood vessels. ImevaX GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, Industrial Biotechnology, In-Vitro-Diagnostics, Clinical Diagnostics, Biomarker Discovery & Development ImevaX GmbH, founded in 2013, is a Munich based life science company focussed on nov- el infection diagnosis. Current product in development is an innovative H. pylori rapid test that combines unprecedented sensitivity, specificity and speed. It determines the pres- ence of two specific antibodies to H. pylori, FliD and CagA, that allow a risk-stratification into low- and high-risk groups for development of gastric cancer. ImevaX owns the global patent for the detection of antibody marker FliD. Am BioPark 9 D-93053 Regensburg Phone: +49 (0) 941 4612531 E-Mail: stefan.miller@hyperthermics.com Internet: www.hyperthermics.com Lochhamer Schlag 11 D-82166 Gräfelfing Phone: +49 (0) 89 520 46 17-0 E-Mail: info@ibidi.de Internet: www.ibidi.de Sendlinger Straße 60 D-80331 München Phone: +49 (0) 89 4140 2477 E-Mail: info@imevax.com Internet: www.imevax.com 88 BIOTECH IN BAVARIA - REPORT 2022|23

IMGM Laboratories GmbH BIOTECH & PHARMA PRODUCTION Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics, Pharmacogenomics IMGM Laboratories are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover biomarker discovery, pharmacogenetics, metagenomics and biodistribution studies of nucleic acid com- pounds. In close collaboration to our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification. immatics biotechnologies GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Cell Therapy, Personalized Medicine, Immune Therapy, Oncology, Genomics, Proteomic Lochhamer Straße 29a D-82152 Martinsried Phone: +49 (0) 89 452 4667-0 E-Mail: info@imgm.com Internet: www.imgm.com Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells - unlocking new avenues for patients in their fight against cancer. Machtlfinger Straße 11 D-81379 München Phone: +49 (0) 89 540415-0 E-Mail: info@immatics.com Internet: www.immatics.com Immumed GmbH Gesellschaft für angewandte Immunologie BIOTECH PRECLINICAL SERVICES Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics Applied Immunology – Testing Services. We offer testing services for scientific samples: • Analysis of cytokines, chemokines and hormones • Cell-characterization • Cytotoxicity. Our team is specialized in measuring multiplex-parameter analysis with Luminex-Tech- nology in various samples like serum, cell cultures, saliva, urine. We perform many applications for flow-cytometry analysis, for example cell phenotyping or cytotoxicity assays, as well as a broad range of metabolic and aging parameters. Karlstrasse 46 D-80333 München Phone: +49 (0) 89 5432177-89 E-Mail: info@immumed.de Internet: www.immumed.de BIOTECH IN BAVARIA - REPORT 2022|23 89

Lochhamer Schlag 21 82166 Gräfelfing Phone: +49 89 2080 477 00 E-Mail: info@imux.com Internet: www.imux.com Immunic AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Small Molecules, Autoimmune Diseases, Inflammation, Drug Development, Immune Therapy Immunic is a biotechnology company developing a clinical pipeline of orally adminis- tered, small molecule therapies for chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York and listed on NASDAQ (ticker: IMUX). Its subsidiary, Immunic AG, is based in Gräfelfing, Germany, where the company’s research and development activities are conducted. immunoGlobe Antikörpertechnik GmbH BIOTECH DEVICES & REAGENTS Keywords: Laboratory, Antibody Production Service, Antibody Rudolf-Diesel-Straße 8a D-97267 Himmelstadt Phone: +49 (0) 9364 810-610 E-Mail: info@immunoglobe.com Internet: www.immunoglobe.com immunoGlobe® GmbH, established in 1997, is a privately owned antibody manu- facturer. Full service custom antibody services are supplemented by epitope mapping (single amino acid precision) and recombinant antibody technologies in cooperation with different partners. A special focus is on antibodies to posttranslational modifica- tions (PTM), such as combinations of different (de)phosphorylation states of neighbor- ing sites, neo-epitopes (e.g. cleavage sites), isoforms, variants, and point mutations. Implen GmbH BIOTECH DEVICES & REAGENTS Schatzbogen 52 D-81829 München Phone: +49 (0) 89 7263718-0 E-Mail: info@implen.de Internet: www.implen.de Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical labora- tories in industry and research. INCYTON GmbH BIOTECH DEVICES & REAGENTS Keywords: Oncology, Drug Development, Toxicology, R&D Service, In-Vitro-Diagnostics, Imaging, Bioanalytics INCYTON multi-sensor systems monitor different cellular key parameters simulta- neously, in real time and label free. Our technology records each event, giving the user full control at every time-point without the need to be constantly present. A highly automated testing process reduces the time spent carrying out even the most complex assays. INCYTON smart technologies are combined in one housing creating a global environment control and reducing the risk of contamination and variations. Am Klopferspitz 19a D-82152 Planegg-Martinsried E-Mail: info@incyton.com Internet: www.incyton.com 90 BIOTECH IN BAVARIA - REPORT 2022|23

Independent Data Lab BIOTECH BIOINFORMATICS Genomic data has become an essential part of almost every project in molecular biology and medicine. Unfortunately, high rate of rotation of personnel in academic environment has made it difficult to maintain collaborations for projects that often can last for years. At IDL we are committed to making sure every dataset receives the most thorough attention, and makes it’s contribution to the progression of science. Josef-Frankl-Straße 5A D-80995 München E-Mail: info@independentdatalab.com Internet: www.independentdatalab.com Infors GmbH BIOTECH DEVICES & REAGENTS INFORS HT is your specialist for bioreactors, shaker incubators and bioprocess software. We offer the right solutions for the cultivation of microorganisms and cell cultures: Customer specific bioreactors and incubation shakers including qualification, parallel bioprocesses, and integration of all your bioprocesses in one software platform. Close customer relationships, high quality, innovation and flexibility are our greatest strengths. Dachauer Straße 6 D-85254 Einsbach Phone: +49 (0) 8135 8333 E-Mail: Internet: www.infors-ht.com infors.de@infors-ht.com NEU: ScaleUp-Fonds Bayern Tickets 10–25 Mio. EUR W W W. BAY E R N K A P I TA L . D E Bayern Kapital GmbH | Ländgasse 135 a | 84028 Landshut Telefon 0871 92325-0 | info@bayernkapital.de Ihr Hightech-Unternehmen sucht Eigenkapital? Bayern Kapital bietet: • Eigenkapital für Start-Up, Expansion, Later-Stage und Growth • Co-Investments mit Partnern von 0,25 bis 25 Mio. EUR • Langjährige Finanzierungserfahrung BIOTECH IN BAVARIA - REPORT 2022|23 91

InGeneron GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Pain, Inflammation, Bone/Joint Diseases, Cell Therapy Sonnenstraße 24-26 D-80331 München E-Mail: Internet: www.ingeneron.com contact@ingeneron.com InGeneron is elevating the field of regenerative medicine by translating robust sci- ence into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields. Balanstraße 6 D-81669 München Phone: +49 (0) 89 48777-4 E-Mail: info@I-A-Z-zellkultur.de Internet: www.I-A-Z-zellkultur.de Friedrich-Bergius-Ring 19 D-97076 Würzburg Phone: +49 (0) 931 3045-0 E-Mail: info@virion-serion.de Internet: www.virion-serion.de Institut für angewandte Zellkultur Dr. Toni Lindl GmbH BIOTECH DEVICES & REAGENTS Keywords: Antibody Production Service, Tissue Engineering/Cell Culture The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies. Institut Virion\Serion GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Automation, Respiratory Diseases, Infectious Diseases, ELISA/EIA, Clinical Diagnostics Institut Virion\Serion GmbH, founded in 1978 in Germany, is one of the leading com- panies specializing in the manufacture of in vitro diagnostic products for infectious disease serology and major supplier of raw materials to the diagnostic industry. SERION Diagnostics provides a selection of analytical methodologies, such as SERI- ON ELISA classic, SERION ELISA agile and SERION ELISA antigen products as well as laboratory automated systems and software solutions. SERION Immunologics offers a broad portfolio of raw materials, including antigens, antibodies and plasma products. Intana Bioscience GmbH BIOTECH PRECLINICAL SERVICES Keywords: Drug Development, R&D Service Lochhamer Straße 29 a D-82152 Martinsried Phone: +49 (0) 89 895 572-80 E-Mail: Internet: www.intana-bioscience.de info@intana.de Intana Bioscience GmbH is a privately owned service provider company. We con- tribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candidates, and by supporting drug discovery and development efforts from target validation to clinical testing. Our services cover target validation, assay development, screening, support of PK/ PD studies and target occupancy measurements. 92 BIOTECH IN BAVARIA - REPORT 2022|23

Intercept Pharma Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Intercept is a biopharmaceutical company focused on the development and commer- cialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, Intercept now has operations in the United States, Europe, Canada, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the ‚liver community‘. Rosenheimer Straße 52 D-81669 München Phone: +49 (0) 89 4111 124 11 E-Mail: info-DE@interceptpharma.com Internet: www.interceptpharma.com/ about/germany iOmx Therapeutics GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, RNAi & Antisense, Immune Therapy iOmx Therapeutics is a clinical-stage biopharmaceutical company focused on devel- oping first-in-class cancer immunotherapies addressing novel immune-checkpoints hijacked by cancer cells. Using the foundational iOTarg discovery platform, iOmx has identified several new tumor-associated immune-checkpoints and is advancing a pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. For more details, please visit iomx.com. Fraunhoferstraße 13 D-82152 Planegg-Martinsried Internet: www.iomx.de inveox GmbH IT, DIGITAL HEALTH Keywords: Other Diagnostics, Data Management, Devices, Clinical Diagnostics, Laboratory, Imaging, Tissue Engineering/Cell Culture inveox has the goal of making cancer diagnosis faster, safer, and more reliable. In todays labs, tissue samples (biopsies) are at risk of being mixed-up, contaminated or lost. But our products are designed to work as a cohesive unit to make this a thing of the past. We help patients and doctors. In addition, we create the lab of the future by bringing big data, artificial intelligence, and machine learning to labs. This provides better research data for scientists so they can eradicate cancer. Lichtenbergstraße 8 D-85748 Garching bei München Phone: +49 (0) 89 57847601 E-Mail: info@inveox.com Internet: www.inveox.com Invitrocue Europe AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Oncology, Personalized Medicine, 3D-Structural Analysis, Other Diagnostics, Tissue Engineering/Cell Culture, Laboratory Invitrocue Europe AG is an innovative leading healthcare bio-analytic company, that specialises in ex-vivo 3D cell culture models such PDOs as well as in-vivo models by producing HiMice™ as promising tools for personalized cancer treatment. IVQ imparts to the industry valuable knowledge in creating better, faster and more affordable disease treatments. Hildegardstraße 9 D-80539 München Phone: +49 (0) 89 998209483 E-Mail: Internet: www.invitrocue.com contact.de@invitrocue.com BIOTECH IN BAVARIA - REPORT 2022|23 93

Ipsen Pharma GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Ipsen Pharma GmbH, subsidiary of the Ipsen Group for Germany, Austria and Switzer- land, has been commercializing various drugs in the fields of oncology, neuroscience and rare diseases in Germany for more than 40 years. Since 2019, the company’s headquarters are located in the competence center Munich. Ipsen strives to utilize the vibrant research landscape, with its numerous universities and clinics, to further promote the innovative spirit and the biotech mindset of within the company. Iris Biotech GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds Empowering Peptide Innovation – with this guiding theme in mind, Iris Biotech’s mission is to support researchers by providing building blocks and reagents for • Synthesis, Modification and Purification of Peptides (e.g. amino acids, coupling reagents, resins, solvents) • Drug Delivery (e.g. PEGs, poly amino acids) • Linkerology® (e.g. functionalized permanent or cleavable linkers, partial PROTACs) • Life Sciences (e.g. Maillard reaction products, fluorescent labels) as well as Custom Synthesis in all areas mentioned above. IRUBIS GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices, Vaccines, Bioanalytics, Bioprocessing IRUBIS offers an innovative analytical device for online monitoring of upstream and downstream processing in the production of biopharmaceutical drugs. Applications are in metabolite monitoring and control, as well as in downstream bioprocessing to aid in aggregation studies, contaminant detection or monitoring of target proteins and excipients. ISAR Bioscience GmbH BIOTECH PRECLINICAL SERVICES Keywords: Neuro-Degeneration, Cell Therapy, Industrial Biotechnology, Drug Development, Tissue Engineering/Cell Culture, Nutraceuticals ISAR Bioscience GmbH is a translational research company. We overcome current limitations of stem cell research in order to advance development of novel therapeu- tics and industrial biotechnology products. We use human iPSC and genome editing technologies to build the next generation of disease models and cell-based models for biotechnology applications. ISAR forges strategic partnerships with industry partners and translates academic achievements and ideas into industrial solutions and products. Einsteinstraße 174 D-81677 München Phone: +49 (0) 89 262036100 E-Mail: contact.ipsen.germany@ipsen.com Internet: www.ipsen.com/germany Adalbert-Zoellner-Straße 1 D-95615 Marktredwitz Phone: +49 (0) 9231 97121-0 E-Mail: info@iris-biotech.de Internet: www.iris-biotech.de Bayerstraße 85a D-80335 München Phone: +49 (0) 89 21539016 E-Mail: info@irubis.com Internet: www.irubis.com Semmelweisstraße 5 D-82152 Planegg Phone: +49 (89) 3564 754-00 E-Mail: info@isarbioscience.de Internet: www.isarbioscience.de 94 BIOTECH IN BAVARIA - REPORT 2022|23

iThera Medical GmbH BIOTECH DEVICES & REAGENTS Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology iThera Medical develops and markets a novel in-vivo biomedical imaging technology, “MSOT” = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics. ITM Isotope Technologies Munich SE BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology Zielstattstraße 13 D-81379 München Phone: +49 (0) 89 700 7449-0 E-Mail: info@ithera-medical.com Internet: www.ithera-medical.com ITM Isotopen Technologien München AG is a privately owned biotechnology and radiop- harmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. ITMs main objectives are to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies. Lichtenbergstraße 1 D-85748 Garching Phone: +49 (0) 89 329 8986 600 E-Mail: info@itm-radiopharma.com Internet: www.itm-radiopharma.com Kalbitzer Innovations UG BIOTECH DNA/PROTEIN ANALYTICS Keywords: 3D-Structural Analysis, Bioinformatics, Bioanalytics, Drug Development, Oncology Kalbitzer Innovations is a spin-off from the Institute of Biophysics and Physical Bio- chemistry (University of Regensburg) that provides novel experimental as well com- putational methods. It is focused on the application of high pressures on proteins in drug design, drug screening and protein refolding/renaturation. Kalbitzer Innovations develops software for specific application in NMR.based analytics as AUREMOL, a software package for automated protein structure determination. Am BioPark 9 D-93055 Regensburg Phone: +49 (0) 941 30798265 E-Mail: kalbitzer-innovations@t-online.de Internet: www.kalbitzer-innovations.de BIOTECH IN BAVARIA - REPORT 2022|23 95

Heimeranstraße 35 D-80339 München Phone: +49 (0) 89 895286-0 E-Mail: Internet: www.klifo.com info-de@klifo.com Geyerspergerstraße 27 D-80689 München Phone: +49 (0) 89 580 082-0 E-Mail: info@klifovet.com Internet: www.klifovet.com KLIFO GmbH CRO Keywords: Medical Writing, Devices, Drug Development, Regulatory Affairs, Clinical Trial Management and Monitoring, Pharmacovigilance, Data Management and Biostatistics KLIFO is an integrated North-European drug and device development consultancy with significant experience in partnering with biotech and pharmaceutical companies. We provide strategic advice and end to end operational solutions spanning all areas of clinical research, clinical trial supply, QA, CMC development, regulatory affairs, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices. We have offices in four European life science hubs. KLIFOVET GmbH CRO Keywords: Data Management and Biostatistics, Drug Development, Regulatory Affairs, Pharmacovigiliance, Clinical Trial Management and Monitoring KLIFOVET AG is a full service veterinary CRO and Regulatory Consultancy and provides the following services: evaluation of research projects, Regulatory Consultancy, Life Cycle Management & PhV, Preclinical and Clinical Studies, Quality Assurance, Data Management and more. Experienced in all species, we manage the development of VMPs & Feed/Feed Additives in every step. Multiple Animal Pharm Awards in 2006, 2015 and “Best Service Company“ for 2019 show our long term commitment to our customers. kmbs BIOTECH DNA/PROTEIN ANALYTICS Keywords: Genomics, PCR Ferdinand-Zwack-Straße 39 D-85354 Freising Phone: +49 (0) 8161 205957 E-Mail: info@kmbioservices.de Internet: www.kmbioservices.de kmbs care for organismic studies e.g. in Wildlife Biology, Phylogeny, Taxonomy, and Conservation Biology to clear up specimens’ identities by means of DNA analyses (sample preparation, PCR, DNA sequencing) for purposes like identifying species, detecting animal pre-/absence, delimiting species boundaries, resolving species relations a.s.o. Off the lab, mapping species inventories or searching for organisms including electro fishing is our business. Knowing01 GmbH BIOTECH BIOINFORMATICS Keywords: Data Management and Biostatistics, Bioinformatics Am Stadtpark 66 81243 München Phone: +49 89 74678081 E-Mail: Internet: https://knowing01.com support@knowing01.com knowing01 is a deep tech start-up challenging the status quo of disease research. Our analytics as-a-service solution masters the high complexity of molecular research data using knowledge graphs, machine learning and AI. At knowing01, we developed an elastic biodata model that links all Multiomics data while preserving a Biotech’s unique data composition. Our solution was designed to elastically align novel and established data to quickly unlock encapsulated data potential in early R&D. 96 BIOTECH IN BAVARIA - REPORT 2022|23

Laboklin GmbH & Co KG – Unternehmensbereich Labogen BIOTECH THERAPEUTICS & DIAGNOSTICS Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more. Steubenstraße 4 D-97688 Bad Kissingen Phone: +49 (0) 971 7202-0 E-Mail: mueller@laboklin.de Internet: www.laboklin.com Labor Friedle GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy Labor Friedle GmbH is an internationally active residue analysis laboratory based in Tegernheim near Regensburg. It focuses on chemical, chemical-physical, microbio- logical and mycological analyses of food samples, especially fruits and vegetables. Consumer goods, cosmetics, pharmaceuticals, cleaning products and animal feed (pet food) as well as environmental medical issues from human biological matrices are also examined. Von-Heyden-Straße 11 D-93105 Tegernheim Phone: +49 (0) 9403 967 98-0 E-Mail: info@labor-friedle.de Internet: www.labor-friedle.de Labor LS SE & Co. KG BIOTECH DNA/PROTEIN ANALYTICS Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry Labor LS is one of the leading European CROs for analytical and consulting for phar- maceuticals and medical devices. More than 1.000 customers trust the company’s ex- perience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials ad on finished products. In addition, services in industrial hygiene and clinical-microbiologocal diagnostics are offered. LabPMM GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, Molecular Diagnostics LabPMM (an Invivoscribe® company) is your partner of choice for diagnostic, research, and clinical trial services. Our network of laboratories located in the USA, Europe and Asia specialize in internationally harmonized molecular testing and collectively have CLIA and ISO15189 certifications via CAP and DAkkS. We offer an ever expanding menu of molecular assays, including NGS gene and MRD panels, FLT3 and NPM1 mutation assays, and B- and T-cell clonality and MRD assessment. Mangelsfeld 4, 5, 6 D-97708 Bad Bocklet-Großenbrach Phone: +49 (0) 9708 9100-0 E-Mail: service@labor-ls.de Internet: www.labor-ls.de Zeppelinstraße 1 D-85399 Hallbergmoos Phone: +49 (0) 89 899 480 780 E-Mail: Internet: www.invivoscribe.com/clinical-services szorbas-seifried@labpmm.de BIOTECH IN BAVARIA - REPORT 2022|23 97

Lead Discovery Center GmbH, LDC Abteilung Antikörper BIOTECH PRECLINICAL SERVICES Semmelweisstraße 5 D-82152 Planegg Phone: +49 (0) 231 97 42 70 00 E-Mail: info@lead-discovery.de Internet: www.lead-discovery.de Lead Discovery Center GmbH (LDC) was founded by Max Planck Innovation in 2008 to take promising projects from academic research and develop them into pharmaceuti- cal leads. Together with leading partners from academic research and industry, LDC is working on an extensive portfolio of projects in the field of small molecule drugs as well as therapeutic antibodies with exceptionally high medical and commercial potential. leonnanodrugs GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Drug Development, Drug Delivery, R&D Service, Liposomes, Small Molecules, Peptide/Protein LEON utilises its’ proprietary nano technology platform for the continuous manufactur- ing of SMART nanoparticles, ranging from surface stabilised polymeric nanoparticles through to lipid nanoparticles (LNP’s) and liposomes. LEON´s technology enables efficient, flexible, and scalable manufacturing of nanopar- ticles with nucleic acid payloads and by this accelerates access to important vaccines and innovative cancer therapies. LEON works with a network of leading pharmaceutical companies to take our customers’ nanoparticle projects to the next level. LEUKOCARE AG BIOTECH DEVICES & REAGENTS LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics. Our technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and bi- ologic device combination products. They provide manifold benefits as improved shelf-life, terminal sterilization and significant production cost savings. LEUKOCARE provides development services based on fee for service during implementation of its technologies. lifespin GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: In-Vitro-Diagnostics, R&D Service, Analytical Chemistry, Agrobiotechnology, Laboratory, Bioanalytics, Biomarker Discovery & Development Lifespin is building a highly scalable, automated diagnostics technology platform based on digitized metabolomic data even suitable for population health manage- ment. We are merging biology, deep data, and AI to enable digital metabolic insights for a new field of precision diagnostics that will improve the gold standard and will bring about new diagnostic products for general health, neurology and oncology, precision drug monitoring for clinical, and precision nutrition for diabetes, obesity, dietary and lifestyle interventions. Kopernikusstraße 9 D-81679 München Phone: +49 (0) 89 4142 4889-0 E-Mail: info@leon-nanodrugs.com Internet: www.leon-nanodrugs.com Am Klopferspitz 19 D-82152 Martinsried/Munich Phone: +49 (0) 89 7801665-0 E-Mail: info@leukocare.com Internet: www.leukocare.com Am BioPark 13 D-93053 Regensburg Phone: +49 (0) 941 942 898 0 E-Mail: info@lifespin.de Internet: www.lifespin.de 98 BIOTECH IN BAVARIA - REPORT 2022|23

LINDIS Biotech GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Antibody Lindis Biotech is a clinical stage bio-pharmaceutical company, committed to devel- op innovative T- cell engaging trifunctional bispecific antibodies, Triomab® to turn malignant cancers into manageable and possibly curable diseases. Triomab® antibodies offer a unique patient-specific therapeutic vaccine effect together with its potent direct, tumor-cell-killing activity that is unrivaled by current cancer therapies. For details please visit our website: www.lindisbiotech.de LivImplant GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture LivImplant GmbH develops innovative cell based therapies for leasons and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Ludwig-Max- imilians-University of Munich and a close collaboration with the Veterinary Clinic of the University of Giessen, LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs. Loewe® Biochemica GmbH BIOTECH DEVICES & REAGENTS Keywords: Agrobiotechnology, ELISA/EIA LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nema- todes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR). LRE Medical GmbH MEDTECH Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics LRE Medical is a leading provider of contract engineering and manufacturing of complex, highly integrated instrumentation for IVD, MedTech and Life Sciences. The spectrum of instruments ranges from PoC, field-testing systems through analyzers based on a variety of technologies including solutions for molecular diagnostics. LRE offers one-stop shop solutions from feasibility, product development, manufacturing, after-safter-sales service to lifetime support. 60 years of expertise and continuity. Am Klopferspitz 19 a D-82152 Martinsried Phone: +49 (0) 89 700 766 24 Internet: www.lindisbiotech.com Truhenseeweg 8 D-82319 Starnberg Phone: +49 (0) 8151 5590291 E-Mail: info@livimplant.de Internet: www.livimplant.de Mühlweg 2 a D-82054 Sauerlach Phone: +49 (0) 8104 616-20 E-Mail: Internet: www.loewe-info.com service@loewe-info.com Georg-Brauchle-Ring 89 D-80992 München Phone: +49 (0) 89 354803-47 E-Mail: info@lre.de Internet: www.lre.de BIOTECH IN BAVARIA - REPORT 2022|23 99

100

Luye Pharma AG PHARMA & CHEMICAL INDUSTRY Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry Am Windfeld 35 D-83714 Miesbach Phone: +49 (0) 8025 2867-0 E-Mail: info@luyepharma.eu Internet: www.luyepharma.eu Luye Pharma AG Miesbach is one of the largest independent manufacturers of trans- dermal delivery systems in Europe with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone treatments. Luye Pharma AG also acts as the EU hub for Luye Pharma Groups development efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards. Am BioPark 13 D-93053 Regensburg Phone: +49 (0) 941 28096-208 E-Mail: info@lysando.com Internet: www.lysando.com Lilienthalstrasse 4 D-82205 Gilching Phone: +49 (0) 8105 7783 30 E-Mail: pr@mdservices.de Internet: www.mdservices.de Lochhamer Straße 11 D-82152 Martinsried Phone: +49 (0) 89 2000 33-0 E-Mail: medigene@medigene.com Internet: www.medigene.com Lysando Innovations Lab GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Lysando AG is the market leader for antimicrobial proteins, so-called Artilysin® molecules. These can effectively eliminate problem-causing bacteria without high risk of resistance development and imbalances. Artilysin® represents an innovative, patent-protected and also environmentally friendly technology with diverse Possible uses. The research facility of Lysando AG is the Lysando Innovations Lab GmbH based in the Regensburg BioPark. Medical Device Services GmbH PHARMA & CHEMICAL INDUSTRY Medical Device Services GmbH has been qualifying the biological safety of medical devices for their producers for more than 25 years and represents the holistic partner on the path to certification and beyond. Experienced specialists identify the optimal approach while always following the latest standards. The lab is internationally reputed for its expertise, GLP-certified as well as accredited by DAkkS and ZLG. Medigene AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Immune Therapy, Gene Therapy Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunothera- pies to target various forms of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development. 100 BIOTECH IN BAVARIA - REPORT 2022|23

101

Medizone Germany GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Clinical Trial Management and Monitoring, Logistics, R&D Service Medizone Germany is your trusted and reliable partner regarding sourcing of compar- ator products for clinical trials and analytical samples for biosimilar development. We are authorized to import comparators into the EU with proper certification through our Qualified Person. With an extensive network of well-established approved suppli- ers, Medizone prides itself with meticulous quality standards when providing global sourcing services. Medpace Germany GmbH CRO Keywords: Oncology, Metabolic Diseases, Cardiovascular Diseases, Imaging, Pharmacovigiliance, Drug Development, Regulatory Affairs Medpace is a global, full-service clinical CRO providing Phase I-IV clinical develop- ment services to the biotechnology, pharmaceutical and medical device industries. Medpaces mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, endocrinology, central nervous system and anti-viral. MedPharmTec GmbH CRO Keywords: Medical Writing, Pharmacovigilance, Regulatory Affairs MedPharmTec is a service provider for pharmaceutical medicine. Our customers: pharmaceutical industry and companies in the biotechnology, medical technology and food industries. Our services: Proofreading of special and product information // Creation/maintenance of drug information // Authorization maintenance (e.g. creation of PSURs) // Consulting for pharmacovigilance and Clinical Trials/NIS // Preparation/ Submission of Ethical Applications and official registrations. metabion GmbH BIOTECH DEVICES & REAGENTS Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Metabion offers production of a wide range of synthetic DNA and RNA oligonucleotides according to customers’ needs as well as the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion’s business philosophy and key to its popularity at the same time. Keltenring 15 D-82041 Oberhaching Phone: +49 (0) 89 12 11 26 36 E-Mail: info@medizone.com Internet: www.medizone.com Theresienhöhe 30 D-80339 München Phone: +49 (0) 89 895 5718-0 E-Mail: info.de@medpace.com Internet: www.medpace.com Neuhauser Straße 47 / IV D-80331 München Phone: +49 (0) 89 354 998-0 E-Mail: office@medpharmtec.de Internet: www.MedPharmTec.de Semmelweissstraße 3 D-82152 Martinsried Phone: +49 (0) 89 899363-0 E-Mail: Internet: www.metabion.com info@mymetabion.com BIOTECH IN BAVARIA - REPORT 2022|23 101

102

Metabolon GmbH BIOTECH DNA/PROTEIN ANALYTICS Zeppelinstraße 3 D-85399 Hallbergmoos Phone: +49 (0) 89 99017752 E-Mail: Internet: www.metabolon.com rpfister@metabolon.com Keywords: R&D Service, Agrobiotechnology, Nutraceuticals, Metabolomics, Drug Development Metabolomics in the heart of Europe. Where other „omics“ technologies reach their limits, Metabolon‘s strength begins. With results close to the phenotype, we open doors that other technologies cannot. We welcome you at any time in our International HQ in Hallbergmoos. Metronomia Clinical Research GmbH CRO Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service Metronomia is a specialized CRO for biostatistical consulting, biostatistics, clinical data management and medical writing in Munich. Experience: > 600 projects since foundation in 1990, proven track record in all major therapeutic areas and all clinical phases / NIS. Customers: Biotech-, pharma- and medical device companies, universities, CROs. Commitment: High-quality and reliability of our data, outstanding flexibility and personal service through stable teams, competitive cost-benefit ratio. MGZ Medizinisch Genetisches Zentrum BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Personalized Medicine, Oncology, Bioinformatics, Genomics, Laboratory, Clinical Diagnostics The MGZ, Medical Genetics Center is one of the leading laboratories for human genet- ics in Europe and combines interdisciplinary medical expertise with a cutting-edge, accredited (DIN EN ISO 15189) laboratory. With a team of physicians, scientists and bio-informaticians as well as a broad spectrum of methods such as short- and long-read sequencing, array,conventional cytogenetics, molecular combing, polygenic risk scores and liquid biopsy, the MGZ serves patients, physicians and pharmaceutical companies. Microcoat Biotechnologie GmbH BIOTECH DEVICES & REAGENTS Keywords: In-Vitro-Diagnostics, Bioanalytics, PCR, Laboratory, Pharmacokinetics, ELISA/EIA Custom Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits. Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating. Biomarker Services, PK/ PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, GLP, GC(L)P, cGMP. Paul-Gerhardt-Allee 42 D-81245 München Phone: +49 (0) 89 829265-100 E-Mail: info@metronomia.net Internet: www.metronomia.net Bayerstraße 3-5 D-80335 München Phone: +49 (0) 89 30 90 886-0 E-Mail: info@mgz-muenchen.de Internet: www.mgz-muenchen.de Am Neuland 3 D-82347 Bernried Phone: +49 (0) 8158 9981-0 E-Mail: info@microcoat.de Internet: www.microcoat.de 102 BIOTECH IN BAVARIA - REPORT 2022|23

103

MIKROGEN GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Autoimmune Diseases, Infectious Diseases, Clinical Diagnostics, ELISA/ EIA, Automation, PCR, Chip/Array Technology MIKROGEN is a global provider of system solutions for medical laboratory diagnostics. We combine excellent genetic engineering know-how with scientific background and consistent customer orientation. The extensive and efficient evaluation of system solutions in collaboration with scientific experts and institutes is the basis for reliable diagnoses. MIKROGEN offers a wide range of system solutions for the indirect detection (antibodies) and direct detection (PCR) of pathogen. Minaris Regenerative Medicine GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Gene Therapy, Cell Therapy, R&D Service, Gene Transfer Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years experience providing outstanding quality and reliability. Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. MINITÜB GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Minitüb is an international established system supplier for assisted reproduction of domestic animals, notably in the areas of A.I., cryobiology and E.T. Through its par- ticipation in MWM Biomodels GmbH, a spin-off company of LMU Munich, Minitüb is also engaged in the development and characterization of transgenic large animal models for biomedical research. Current projects focuse on genetically modified pigs for xenotransplantation, transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. mk2 Biotechnologies GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Industrial Biotechnology, Bioanalytics, R&D Service Anna-Sigmund-Strasse 10 D-82061 Neuried Phone: +49 (0) 89 54801-0 E-Mail: meyer@mikrogen.de Internet: www.mikrogen.de Haidgraben 5 D-85521 Ottobrunn Phone: +49 (0) 89 700 9608-0 E-Mail: Internet: www.rm.minaris.com contact@rm.minaris.de Haupstraße 41 D-84184 Tiefenbach Phone: +49 (0) 8709 9229-664 E-Mail: csimmet@minitube.de Internet: www.minitube.de mk2 Biotechnologies develops, produces and investigates peptides at highest purity and quality standards using a revolutionary synthesis technology. We are able to synthesize any kind of peptide, regardless of its physical or chemical properties. We are strongly convinced, that our process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 160 777 0880 E-Mail: info@mk2.bio Internet: www.mk2.bio BIOTECH IN BAVARIA - REPORT 2022|23 103

104

Max-Lebsche-Platz 31 D-81377 München Phone: +49 (0) 89 990 17-0 E-Mail: info@mll.com Internet: www.mll.com MLL Münchner Leukämielabor GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, NGS, Laboratory, Oncology, Hematology, PCR, Genomics MLL Munich Leukemia Laboratory is a leading institution for leukemia diagnostics and research. An interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis and includes: cytomorphology, chromosome analysis, immunophenotyping, cytogenetics, FISH, and molecular genetics. MLL performs also WGS. Several workflows are already supported by AI. This combination gives medical professionals an essential foundation to ensure ideal patient care. Moderna Germany GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Rosenheimer Straße 143 c 81671 München Internet: www.modernatx.com Moderna Inc. is a biotechnology company pioneering messenger RNA (mRNA) ther- apeutics and vaccines. Our mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, in the area of immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Molecular Machines & Industries GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy, Molecular Diagnostics, Devices Breslauer Strasse 2 D-85386 Eching Phone: +49 (0) 89 319 048 40 E-Mail: info@molecular-machines.com Internet: www.molecular-machines.com MMI Microdissection, Micromanipulation and Imaging MMI is the leading provider of unique technologies for microdissection, micromanipulation, and imaging with a wide range of clinical and research applications. I.e. Capillary-based selective isolation of single cells (CellEctor), Pico-cut laser microdissection to isolate cells in tissue (CellCut), Microscopy-integrated Whole Slide Imaging (CellScan), Optical tweezers to quantify biological forces (CellManipulator). Molecular Networks GmbH Computerchemie BIOTECH BIOINFORMATICS Keywords: Molecular Modelling, Toxicology, Small Molecules Molecular Networks and Altamira (MN-AM) offer innovative approaches and solu- tions for chemoinformatics, computational toxicology and safety/risk assessment of chemical compounds. The ChemTunes·ToxGPS® software platform provides a unique combination of expert-reviewed toxicity databases, MoA-based in silico predictions for human health endpoints and workflows to support, e.g., Read-Across and ICH M7 GTI studies. A rigorous decision theory approach delivers weight of evidence-based final outcomes. Neumeyerstraße 28 D-90411 Nürnberg Phone: +49 (0) 911 597 424 00 E-Mail: info@mn-am.com Internet: www.mn-am.com 104 BIOTECH IN BAVARIA - REPORT 2022|23

105

Molekula GmbH BIOTECH DEVICES & REAGENTS Keywords: Antibiotics, Analytical Chemistry, New Materials, Medicinal Chemistry, Peptide/Protein, Fine Chemicals/Reagents Molekula is a leading chemical supplier offering research chemicals and biochemicals sourced from production sites across the globe. Our clients ranging from university labs to big industrial players. With offices in the UK, USA, China, Germany and Italy, our global insight into the market keeps us firmly at the forefront of this industry. We hold over 8000 ex-stock products and also have in-house production of tailor-made gases in solutions and Grignard reagents. MorphoSys AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Autoimmune Diseases, Small Molecules, Nephrology, Oncology, Antibody At MorphoSys, we are driven by our mission: More life for people with cancer. As a glob- al commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn. MSAID GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Proteomics, Machine Learning, Deep Learning, Bioinformatics Landshuter Allee 12 D-80637 München Phone: +49 (0) 89 360 900 900 E-Mail: dinfo@molekula.com Internet: www.molekula.com Semmelweisstraße 7 D-82152 Planegg Phone: +49 (0) 89 89927-0 E-Mail: info@morphosys.com Internet: www.morphosys.com MSAID is a bioinformatics spin-off from the Technical University of Munich, Germany. It was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. The company’s approach is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper, and more reliable way of interrogating proteomic data. Lichtenbergstraße 8 D-85748 Garching b. München Phone: +49 (0) 89 215 366 18 +49 (0) 89 215 366 19 Fax: E-Mail: info@msaid.de Internet: www.msaid.de MSD SHARP & DOHME GMBH PHARMA & CHEMICAL INDUSTRY Keywords: Infectious Diseases, Oncology, Diabetics, Cardiovascular Diseases, Antibiotics, Vaccines MSD Merck & Co., Inc., in the USA and Canada, with headquarters in Kenilworth, NJ, USA is a leading global healthcare company. MSD‘s core business is the discovery, development, production and distribution of prescription medicines, vaccines, bio- logic therapies and animal health products. In 2017, the company generated sales of approximately 40.1 billion US dollars with approximately 69,000 employees in more than 140 countries. The company has its German headquarters in Haar near Munich. Twitter: @MSD_Deutschland Lindenplatz 1 D-85540 Haar Phone: +49 (0) 800 673 673 673 E-Mail: Internet: www.msd.de infocenter@msd.de BIOTECH IN BAVARIA - REPORT 2022|23 105

106

Ahornweg 8 DE-93176 Beratzhausen Phone: +49 (0) 9493 95 92 966 E-Mail: info@multi-service-monitoring.de Internet: www.multi-service-monitoring.de multiservicemonitoring CRO Keywords: Regulatory Affairs, Devices, Autoimmune Diseases, Clinical Trial Management and Monitoring, Oncology, Drug Development multi-service-monitoring CRO (founded in 2003) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and “DIN ISO 14155”. multimmune GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Imaging, Antibody, Oncology, Immune Therapy, Drug Development, Personalized Medicine, Cell Therapy Kirchenstrasse 82 D-81675 München E-Mail: graham.pockley@multimmune.com Internet: www.multimmune.com multimmune GmbH is a clinical stage company delivering innovative theranostics for tumors expressing the tumor-specific marker membrane Hsp70. Pipelines include autologous and allogeneic natural killer (NK) cells that have been activated using a proprietary process, and a pipeline of cell and molecular therapeutics based on unique proprietary monoclonal antibodies that detect membrane Hsp70, all of which are supported by a proprietary blood test for determining the status of a patient’s tumor. MVZ Martinsried GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, NGS, Genomics, Bioinformatics, Oncology, Personalized Medicine, Laboratory Lochhamer Straße 29 D-82152 Martinsried Phone: +49 (0) 89 895578-0 E-Mail: info@medizinische-genetik.de Internet: www.medizinische-genetik.de The Center for Human Genetics and Laboratory Diagnostics in Martinsried continues to broaden its expertise and competencies. The interdisciplinary collaboration between five medical specialist areas - Human genetics, Laboratory Medicine, Microbiology/ Virology, Transfusion Medicine, Molecular Oncology/Pathology - enables diagnostic questions to be more efficiently, comprehensively and accurately resolved. Accredited according to DIN EN ISO/IEC 17025 and ISO 15189. MWM Biomodels GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases MWM Biomodels GmbH is specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies. Hauptstraße 41 D-84184 Tiefenbach Phone: +49 (0) 8709 9229-0 E-Mail: Internet: www.mwm-biomodels.com csimmet@minitube.de 106 BIOTECH IN BAVARIA - REPORT 2022|23

107

Nanion Technologies GmbH BIOTECH DEVICES & REAGENTS Keywords: Nanobiotechnology, Devices Nanion Technologies combines exceptional instrumentation with trusted support and decades of scientific expertise, to accelerate successful drug development and scientific research. As a world leading provider of automated patch clamp systems with a wide range of throughput capabilities and formats, we have expanded our product range to in vitro systems for membrane pump/transporter, bilayer recordings, and confluency and contractile force measurements from cell monolayers. Ganghoferstraße 70a D-80339 München Phone: +49 (0) 89 2190 95-0 E-Mail: info@nanion.de Internet: www.nanion.de nanoSaar AG NANOTECHNOLOGY Keywords: Nanobiotechnology THE POWER OF NANO! nanoSaar AG is a leading provider of tailor-made nanotech- nology solutions that give a wide range of partners from the chemical industry a competitive advantage. • Very homogeneous, superior product quality • Continuous, cost-effective production process • Fast, simple scale-up for industrial chemical production • Business opportunities with license or joint venture models You can find out more at: www.nanosaar.com NanoTemper Technologies GmbH BIOTECH DEVICES & REAGENTS Keywords: Automation, Devices, Bioanalytics, Drug Development, Bioprocessing, Vaccines NanoTemper provides biophysical instruments, kits & software. We have a strong customer focus and stand for strong commitment to quality, ease of use and high precision instrumentation. Our globally operating team of experts strongly focuses on the users benefits by ensuring maximum efficiency for the Pharmaceutical and Biotech industries as well as academic research. With our optical technologies like MST, TRIC, nanoDSF and DLS, we provide knowledge about the most challenging targets. Würmstraße 4 D-82319 Starnberg Phone: +49 (0) 8151 959022-0 E-Mail: info@nanosaar.com Internet: www.nanosaar.com Flößergasse 4 D-81369 München Phone: +49 (0) 89 4522 895-0 E-Mail: info@nanotempertech.com Internet: www.nanotempertech.com BIOTECH IN BAVARIA - REPORT 2022|23 107

108

NDA Regulatory Service GmbH CRO Keywords: Pharmacovigiliance, Drug Development, Medical Writing, R&D Service, Regulatory Affairs NDA is a leading regulatory consultancy, supporting drug development companies of all sizes on the shortest and most economic path to approval and patient access. Our experienced team of 150 consultants (30 in Munich) provide advice on all phases of development and therapeutic areas, including procedure and submission man- agement, for both US and EU. Our specialist Advisory Board, consisting of very senior ex-regulators, provides independent strategic advice with an inside the agencies view. NEOVII Biotech GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Hematology, Immune Therapy, Antibody, Oncology Neovii Biotech GmbH develops, commercializes and manufactures immunologically active biopharmaceutical therapeutics, especially the medicinal product Grafalon®. Neovii is headquartered in Switzerland (Neovii Pharmaceuticals AG, Zürcherstrasse 19, 8640 Rapperswil, Switzerland (Phone: +41 55 210 05 00; Fax: +41 55 210 55 08; E-mail: info@neovii.com) and part of the Neopharm Group, Israel. NeuroProfile GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for drugs with new mechanisms of action and improved therapy of the diseases. nexttec GmbH BIOTECH DEVICES & REAGENTS Keywords: Laboratory, Devices, Genomics, Automation nexttec1-Step kits for rapid purification of plasmid and genomic DNA from tissue, cell cultures, blood, bacteria and plants. The nexttec1-Step DNA purification system consists of only one buffer system for the lysis of the corresponding samples and nexttecCleanColumns, or nextteccleanPlates96. The nexttec 1-Step DNA purification is a reversal of the usual, well-known DNA purification methods. Here, proteins and other inhibiting substances are adsorbed on a special sorbent surface. The DNA does not bind, passes through the adsorbent layer and is immediately available in the eluate for the applications. This allows purification of the DNA in just 4 minutes. Neumarkter Straße 18 D-81673 München Phone: +49 (0) 89 3585-4000 E-Mail: munich@ndareg.com Internet: www.ndareg.com Am Haag 6+7 D-82166 Gräfelfing Phone: +49 (0) 89 898888-0 E-Mail: Internet: www.neovii.com info.germany@neovii.com Keilsteiner Breiten 6 D-93055 Regensburg Phone: +49 (0) 941 785 369-0 E-Mail: info@neuroprofile.com Internet: www.neuroprofile.com Larezhausen 2 D-86567 Hilgertshausen Phone: +49 (0) 8250-92 790 32 E-Mail: Internet: www.nexttec.biz service@nexttec.biz 108 BIOTECH IN BAVARIA - REPORT 2022|23

109

NIGU Chemie GmbH c/o AlzChem AG PHARMA & CHEMICAL INDUSTRY Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics (test kits for viral RNA/DNA) is another integral part of the portfolio. Dr.-Albert-Frank-Straße 32 D-83308 Trostberg Phone: +49 (0) 8621 86-3029 E-Mail: Internet: www.nigu.de info@alzchem.com Novartis Pharma GmbH PHARMA Novartis is reimagining medicines to help improve and extend people’s lives. We use innovation and digital technologies to develop therapies in areas with high unmet medical need. We invest a high share of our turnover in research and development. Our products reach around 800 million people worldwide and we strive to expand access to them. In Germany Novartis employs around 7,400 people at 12 locations and around 109,000 worldwide. www.novartis.de and www.novartis.com Roonstraße 25 D-90429 Nürnberg Phone: +49 (0) 911 273-0 E-Mail: Internet: www.novartis.de angelika.gaufer@novartis.com YOUR DIAGNOSTICS YOUR DIAGNOSTICS STUDIES IN GOOD STUDIES IN GOOD HANDS. HANDS. TRIGA-S is a preferred CRO partner for the TRIGA-S is a preferred CRO partner for the planning and conduction of analytical and planning and conduction of analytical and clinical performance studies of in vitro clinical performance studies of in vitro diagnostics according to international regu- diagnostics according to international regu- lations (e.g. EU-IVDR, US-CFR). lations (e.g. EU-IVDR, US-CFR). Since 1998, our name stands for excellency Since 1998, our name stands for excellency and trustful collaboration. and trustful collaboration. TRIGA-S SCIENTIFIC SOLUTIONS TRIGA-S SCIENTIFIC SOLUTIONS Mühltal 5 • D-82392 Habach Mühltal 5 • D-82392 Habach Tel. +49 (0) 88 47 - 695 78 0 Tel. +49 (0) 88 47 - 695 78 0 info@triga-s.de info@triga-s.de www.triga-s.de www.triga-s.de BIOTECH IN BAVARIA - REPORT 2022|23 109 CONTRACT LABORATORY (BSL2) CONTRACT LABORATORY (BSL2) STUDY MANAGEMENT · CLINICAL MONITORING STUDY MANAGEMENT · CLINICAL MONITORING DATA MANAGEMENT · BIOSTATISTICS DATA MANAGEMENT · BIOSTATISTICS COMPLETE SAMPLE MANAGEMENT: COMPLETE SAMPLE MANAGEMENT: COLLECTION · LOGISTICS · PROCESSING · STORAGE COLLECTION · LOGISTICS · PROCESSING · STORAGE

110

Am Wildwechsel 7a D-82031 Grünwald Phone: +49 (0) 178 8087262 E-Mail: wb@nucleusmed.eu Internet: www.nucleusmed.eu Am BioPark 9 D-93053 Regensburg Phone: +49 (0) 941 280949-00 E-Mail: jobs@numares.com Internet: www.numares.com Nucleus Medical GmbH LIFE SCIENCE / BIOTECH Nucleus Medical GmbH has been founded in November 2019 by private investors. The company is focused on the development of innovative immune-modulating products in the field of transplantation medicine. Nucleus combines cutting-edge pharmaceutical technologies to ensure the intended therapeutic success of the later product. Nucleus works together with a network of service companies to ensure greatest possible flexibility and efficiency to achieve market authorization in a minimum of time. numares AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Develop ment, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases numares AG, based in Regensburg develops and markets innovative diagnostic tests based on NMR metabolomics. Essentially, our tests consist of metabolic constellations that are characteristic of certain diseases. To find these, we apply machine learning to clinical study cohorts measured with our AXINON® NMR system. We have a successful commercial base especially in laboratories in the USA. Nuvisan GmbH CRO Wegenerstraße 13 D-89231 Neu-Ulm Phone: +49 (0) 731 9840-0 E-Mail: bdinfo@nuvisan.com Internet: www.nuvisan.com Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA The NUVISAN Group is an international service provider in the field of clinical trials, laboratory services and contract manufacturing of drugs or their intermediates for the pharmaceutical industry. Headquartered in Neu-Ulm, NUVISAN operates several sites in Germany and France. Octamer GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Friedemann-Bach-Straße 95 D-82166 Gräfelfing Phone: +49 (0) 89 21538575 E-Mail: Internet: www.octamer.de support@octamer.com Epigenetic mechanisms promise to open new avenues to drug discovery because they allow interfering with the most basic processes of transcriptional regulation. We research nucleosomes for decades and offer the unique opportunity to provide disease-relevant substrates to epigenetic targets both for academic research and drug discovery. 110 BIOTECH IN BAVARIA - REPORT 2022|23

111

Omegametrix GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index® with a collaborator in 2004. In 2006, von Schacky founded the laboratory Omegametrix GmbH to deal with the ever-growing number of samples. Initially pro- posed as a risk factor for sudden cardiac death, the HS-Omega-3 Index also indicates risk for total mortality and cardiovascular disease. Other applications encompass, but are not limited to, athletes, cognition, psychiatric diseases or pregnancy and lactation. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 5506 300-7 E-Mail: info@omegametrix.eu Internet: www.omegametrix.eu OmicEra Diagnostics GmbH BIOTECH DNA/PROTEIN ANALYTICS Proteome scans become a universal diagnostic for health and disease. We anticipate that MS-based proteomics becomes a cornerstone of precision medicine over the coming years For broad applications, a new technology platformmust be developed including very large analytical capabilities. We aim to build the best performing plat- form with the highest capacity for precision medicine. Behringstraße 6 D-82152 Martinsried E-Mail: info@omicera.com Internet: www.omicera.com OmicScouts GmbH BIOTECH BIOINFORMATICS Keywords: Pharmacogenomics, Bioinformatics, Proteomics, Drug Development, Biomarker Discovery & Development OmicScouts is a chemical proteomics company focused on supporting drug and bio- marker discovery with its unique expertise and innovative technologies. We provide and develop proteome-wide assays that work with native proteins and enable the identifica- tion of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers. OmicScouts supports your drug and bio- marker discovery projects with end-to-end solutions tailored to project specific needs. Lise-Meitner-Straße 30 D-85354 Freising Phone: +49 (0) 8161-976289-0 E-Mail: info@omicScouts.com Internet: www.omicscouts.com OncoLead GmbH & Co. KG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Clinical Diagnostics, Oncology Oncolead is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents. Zugspitzstraße 5 D-85757 München-Karlsfeld Phone: +49 (0) 151 2062 1612 E-Mail: Internet: www.oncolead.com request4more@oncolead.com BIOTECH IN BAVARIA - REPORT 2022|23 111

112

Optores GmbH MEDTECH Gollierstraße 70 D-80339 München Phone: +49 (0) 89 927 78775 Internet: www.optores.com Optores GmbH provides the world’s fastest solutions for optical coherence tomog- raphy (OCT). With sweep rates of several million OCT A-scans per second, Optores founders coined the term “MHz-OCT”. These ultrahigh speeds are ideal for novel OCT applications, such as real-time surgical guidance, endoscopic OCT, large area surveys, visualization of blood flow, and high-throughput industrial inspection. Am Klopferspitz 19a D-82152 Martinsried Phone: +49 (0) 89 7801676-0 E-Mail: info@origenis.de Internet: www.origenis.de origenis GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules Origenis is a privately owned company based in Martinsried, Germany, and a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis runs its own patented drug discovery platform MOREsystem® which combines state-of- the-art drug design, patent analysis, chemical synthesis and biological characterization performed on 20.000 square feet of integrated lab space. We are currently focusing on anti-inflammatory and CNS drugs. Origenis runs research alliances as well as ac- tive in-house programs and is offering a variety of out-licensing opportunities via its proprietary patent database Cippix® - www.cippix.com. Oryx GmbH & Co. KG BIOTECH THERAPEUTICS & DIAGNOSTICS Marktplatz 1 D-85598 Baldham Phone: +49 (0) 8106 21 311-0 E-Mail: info@oryx-medicine.com Internet: www.oryx-medicine.com ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials. Otsuka Novel Products GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases Erika-Mann-Straße 21 D-80636 München Phone: +49 (0) 89 2060205 50 E-Mail: Internet: www.otsuka-onpg.com reception@otsuka-onpg.com Otsuka Novel Products GmbH (ONGP) est. 2011, is a subsidiary of Otsuka Group Company with an international network of 195 subsidiaries, 47,000 employees in 31 countries. With our corporate philosophy Otsuka-people creating new products for better health worldwide, ONPG focuses on fighting tuberculosis through innovative research and development, equitable access to medicines, collaborations, and capacity building programs that strengthen the quality and delivery of care. 112 BIOTECH IN BAVARIA - REPORT 2022|23

113

Oxford BioLabs Ltd. BIOTECH DEVICES & REAGENTS Oxford Biolabs is a science-routed company that develops and markets naturally-based nutraceuticals and cosmeceuticals aimed at helping people combat unwanted signs of ageing. This includes the areas of androgenetic alopecia, hair greying, skin ageing, immune support, or healthy ageing. Our goal is to create innovative products that are of high value for its users. Am BioPark 9 D-93053 Regensburg Phone: +49 (0) 941 640 791 02 E-Mail: Internet: www.oxbiolabs.com kontakt@oxfordbiolabs.com Panacea Biotec Germany GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection. Landwehrstr. 61 D-80336 München Phone: +49 (0) 89 411 123 414 E-Mail: info-de@panaceabiotec.com Internet: www.panaceabiotec.com/de BIOTECH IN BAVARIA - REPORT 2022|23 113

114

Am Gewerbepark 6 D-94501 Aidenbach Phone: +49 (0) 8543 6016-30 E-Mail: info@pan-biotech.de Internet: www.pan-biotech.de PANBiotech GmbH BIOTECH DEVICES & REAGENTS Keywords: Industrial Biotechnology, In-Vitro-Diagnostics, R&D Services PAN-Biotech GmbH, founded in 1988, is specialized in the manufacture of GMP com- pliant - cell culture solutions. The core strength is flexibility – this is why PAN-Biotech can offer customized solutions to partners both in research and industry. The focus of the product range includes both cell culture media and supplements for various cell cultures, as well as buffer solutions, WFI quality water and other reagents for the purification of cell culture-based products in industrial processes. PANSeratech GmbH PHARMA SUPPLIER AND TRADE Keywords: Fine Chemicals/Reagents Am Gewerbepark 13 D-94501 Aidenbach Phone: +49 (0) 8543 6016 30 E-Mail: info@pan-seratech.de Internet: www.pan-seratech.de PAN-Seratech is a modern, innovative company located in Germany. Together with our partners and distributors worldwide we have become a reliable supplier of serum prod- ucts for our customers in research and industry. Our products are produced with the highest standards made in Germany. We guarantee constant quality and full traceability. PARI Pharma GmbH MEDTECH Keywords: Antibiotics, Analytical Chemistry, Laboratory, Devices, Drug Delivery, Infectious Diseases, Respiratory Diseases PARI Pharma´s focus is the development and manufacturing of optimized eFlow® Technology nebulizers in cooperation with partners from the pharmaceutical industry. eFlow Technology is a platform suitable for a wide range of drug formulations and patient populations. It enables short development times for optimized drug-specific nebulizers. PARI has a committed team with a considerable track record. As of today, six commer- cial drug-specific eFlow Technology nebulizers administer inhaled drugs. Pelobiotech GmbH BIOTECH DEVICES & REAGENTS Keywords: Laboratory, Tissue Engineering/Cell Culture, Fine Chemicals/Reagents PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications (GMP). Tissue Dissociation Enzymes; Defined & Xeno-free Media; Human & Animal Primary & Stem Cells from healthy & diseased donors; Tagged Cells; ES/iPS Cells, Media, Reprogramming & Small Molecules; 2D/3D Cell Culture Systems. Moosstraße 3 D-82319 Starnberg Phone: +49 (0) 89 742846-0 E-Mail: Internet: www.pari.com/eflow-partnering eFlow-partnering@pari.com Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 51728659-0 E-Mail: info@pelobiotech.com Internet: www.pelobiotech.com 114 BIOTECH IN BAVARIA - REPORT 2022|23

115

Pharma Stulln GmbH PHARMA & CHEMICAL INDUSTRY; CMO Keywords: Ophtalmology, Respiratory Diseases Experience in manufacturing of eye drops in bottles and single-doses for almost 40 years. Specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions and Lens care products. A modern zone concept fulfills European and international standards in production of sterile fluid pharmaceuticals. Pharma Stulln has approx- imately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc. Pharmalog – Institut für klinische Forschung GmbH CRO Pharmalog (TÜV certified and BVMA member) offers full service with an excellent reputation for all phases of clinical trials since 1983. We operate in Germany and all EU/EEU-countries and have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products. PhaToCon (Pharm/Tox Concept) BIOTECH PRECLINICAL SERVICES Keywords: Antibody, Pharmacology, Regulatory Affairs, Toxicology, Drug Development, Drug Delivery, Tissue Engineering/Cell Culture Werksstraße 3 D-92551 Stulln Phone: +49 (0) 9435 3008-0 E-Mail: info@pharmastulln.de Internet: www.pharmastulln.de Oskar-Messter-Straße 29 D-85737 Ismaning Phone: +49 (0) 89 544637-0 E-Mail: pharmalog@pharmalog.com Internet: www.pharmalog.com Safety of Medical Device and Pharma for patients and manufacturers. Our compe- tence are toxicological Assessments (in vitro / in vivo) as well as biocompatibility evaluation and related preclinical study-management. Our support is customized, adapted from international standards like GLP/GMP, ISO, and we support “hands-on”, based on science, evidence, quality and pragmatism. With our network of competence and capabilities we mark the difference to your competitor on your way to success. Am Klopferspitz 19 D-82152 Planegg-Martinsried Phone: +49 (0) 89 444 899-41 E-Mail: info@phatocon.com Internet: www.phatocon.com Phytochem® Referenzsubstanzen GmbH BIOTECH DNA/PROTEIN ANALYTICS Phytochem (PC) develops, produces and markets pure reference substances for the pharmaceutical industry, research, analytics and authorities and synthesizes or isolates Impurities in remedies for customers needs with best equipment and experience. PC further develops analytical methods and new products mainly focussed on natural sources for Phytopharmaceuticals, Functional Foods as well as Cosmetics. The CEO has also the status of a qualified person acc. § 65 AMG for product release in Pharma. Krumbacher Straße 9 D-89335 Ichenhausen Phone: +49 (0) 731 9720 545 E-Mail: phytochem@t-online.de Internet: www.phytochem-standards.de BIOTECH IN BAVARIA - REPORT 2022|23 115

116

Zeppelinstrasse 3 D-85399 Hallbergmoos Phone: +49 (0) 811 12 447-0 E-Mail: info@pieris.com Internet: www.pieris.com Pieris Pharmaceuticals GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Oncology, Respiratory Diseases, Peptide/Protein, Drug Development, Immune Therapy Pieris Pharmaceuticals is an international Nasdaq-listed (TICKER: PIRS), clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia. PIKA Weihenstephan GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR Raiffeisenstraße 31a D-85276 Pfaffenhofen Phone: +49 (0) 8441 87948-30 E-Mail: info@pika-weihenstephan.de Internet: www.pika-weihenstephan.de PIKA Weihenstephan GmbH, a spin-off from TU München, is specialized in microbiology and DNA analyses for the food and beverage industries including breweries. Besides consultancy and lab service, our portfolio covers development, production and sales of products for on-site testing. Major products for quality control are FastOrange® enrichment media and 4everyone™ Detection kits, besides we supply fresh yeast from our HefeFarm®. PIKA Weihenstephan is certified according to DIN EN ISO 9001:2015. Industriestraße 1 D-93077 Bad Abbach Phone: +49 (0) 9405 96 999-10 E-Mail: info@polyquant.com Internet: www.polyquant.com PolyQuant GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Biomarker Discovery & Development, Peptide/Protein, Laboratory, Clinical Diagnostics, Proteomics, In-Vitro-Diagnostics, R&D Service PolyQuant provides ISO 9001:2015 certified products, services and bioinformatics support for protein analysis and proteomics covering: Stable isotope-labelled refer- ence standards for absolute protein quantification based on our proprietary QconCAT platform technology, Kits for LC and MS instrument calibration and standardization, entire assay development for proteomics workflows (quantitative/qualitative), com- prehensive support for protein analytics (Medtech, Biotech, Life Sciences, Pharma). Postnova Analytics GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices Rankinestrasse 1 D-86899 Landsberg a. L. Phone: +49 (0) 8191 985 688-0 E-Mail: info@postnova.com Internet: www.postnova.com Postnova is a manufacturer of analytical instruments based on Field-Flow Fractiona- tion. The application range of 1 nm-100 µm and 1000 Da up to many MDa, Postnova provides an analytical tool for the separation/characterization of particles, polymers, proteins, viruses, antibodies, liposomes or exosomes in complex aqueous/organic ma- trices. Postnova offers the complete range of FFF techniques as Electrical/Asymmetrical FlowFFF, CentriFFF and ThermalFFF along with detection as MALS, DLS, and ICP-MS. 116 BIOTECH IN BAVARIA - REPORT 2022|23

117

PPD Germany GmbH & Co. KG CRO Keywords: Medical Writing, Logistics, Devices, Drug Development PPD is a leading global contract research organization providing drug discovery, devel- opment and lifecycle management services. With offices in 46 countries and more than 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic ex- pertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. Visit www.ppdi.com. Hansastraße 32 D-80686 München Phone: +49 (0) 89 57877-0 E-Mail: genl.info@ppdi.com Internet: www.ppdi.com PreciPoint GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy, Automation, Devices PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoints core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Mi- croscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems. Alois-Steinecker-Straße 22 D-85354 Freising Phone: +49 (0) 8161 976979-0 E-Mail: vertrieb@precipoint.de Internet: www.precipoint.de Tel.: +49 (89) 85 89 63 - 0 kontakt@wander-immobilien.de You are looking for suitable laboratories? We are your specialist! www.wander-immobilien.de Ofﬁce, laboratories and production space from 250 sqm – 10.000 sqm We are looking forward to send you an attractive offer. BIOTECH IN BAVARIA - REPORT 2022|23 117

118

Am Klopferspitz 19 D-82152 Planegg/Martinsried Phone: +49 (0) 89 23 14 163-0 E-Mail: info@preomics.com Internet: www.preomics.com PreOmics GmbH BIOTECH DEVICES & REAGENTS Keywords: Molecular Diagnostics, Proteomics, Bioanalytics, Clinical Diagnostics The PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics. PreSens Precision Sensing GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry Am BioPark 11 D-93053 Regensburg Phone: +49 (0) 941 94272-100 E-Mail: info@presens.de Internet: www.presens.de PreSens is a world leader in the field of chemical-optical sensors and develops, manu- factures and distributes microsensors, 2D imaging and non-invasive sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices – with service all over the world. The out-of-box products and the engineering of customized sensors focus on parameters essential for life: oxygen, pH, CO2 and biomass. PreSens is certified EN ISO 13485:2016 and ISO 9001:2015. ProJect Pharmaceutics GmbH CRO Keywords: Drug Development, Drug Delivery, AntibodyDrugConjugate ADC, Antibody, Peptide/Protein, Small Molecules, Viruses ProJect Pharmaceutics transfers delicate pharmaceutical molecules into pioneering drugs with a deep expertise in formulation and pharmaceutical process development for liquid or lyophilized proteins, high-concentration products, ADCs / cytotoxics and live viral vaccines. We develop a quality product and its manufacturing process on a scientific rationale pursuant to international guidelines. Teamed up with manufac- turing CMOs, we smooth technology transfer from pre-clinical to large-scale supply. Proteros biostructures GmbH BIOTECH PRECLINICAL SERVICES Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis Proteros, Martinsried/Munich, Germany is a private biotechnology company aimed at drug discovery for technically demanding drug targets. Proteros is currently working for most of the big pharma and biotech companies in Europe, US and Japan in different types of service and collaborative relationships. For more information please visit www.proteros.com. Fraunhoferstraße 22 D-82152 Martinsried Phone: +49 (0) 89 452289-700 E-Mail: info@project-pharmaceutics.com Internet: www.project-pharmaceutics.com Bunsenstraße 7a D-82152 Martinsried Phone: +49 (0) 89 700761-0 E-Mail: business@proteros.com Internet: www.proteros.com 118 BIOTECH IN BAVARIA - REPORT 2022|23

119

PSI CRO Deutschland GmbH CRO PSI CRO Deutschland GmbH is a subsidiary of PSI CRO AG (Switzerland), a globally operating service provider specialized in clinical research and development services on behalf of the pharmaceutical and biotechnology industry. With more than 100 employees in Germany and over 2500 worldwide, we plan and execute clinical trials related to the global development of new therapies in many indications like Oncology, Gastroenterology, Haematology, Infectious Diseases, MS and other rare diseases. Behringstrasse 7 D-82152 Planegg-Steinkirchen Phone: +49 (0) 89 89996080 Internet: www.psi-cro.com PUREN Pharma Gmbh & Co. KG PHARMA & CHEMICAL INDUSTRY Already in the 1980s, PUREN Pharma had an important position in Germany thanks to high-quality, inexpensive generics and numerous branded drugs. Over time strategic takeovers have led to diverse company names. The range grew in the area of thera- py-relevant generics and branded medicines, the broadest parenteral portfolio for clinics in Germany and attractive OTC specialties. Actavis Germany has been part of the Actavis-Allergan group and belongs now to the globally operating AUROBINDO group. Willy-Brandt-Allee 2 D-81829 München Phone: +49 (0) 89 558909-0 E-Mail: info@puren-pharma.de Internet: www.puren-pharma.de quattro research GmbH BIOTECH BIOINFORMATICS quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the compound management solution quattro/CM or the ELN quattro/LJ. quattro research offers software development and consulting services to solve any data management challenges in life science R&D, e.g. Biologics registration. Fraunhoferstraße 18a D-82152 Martinsried Phone: +49 (0) 89 4132904-0 E-Mail: info@quattro-research.com Internet: www.quattro-research.com RAPID Biomedical GmbH BIOTECH DEVICES & REAGENTS Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies. Kettelerstraße 3-11 D-97222 Rimpar Phone: +49 (0) 9365 8826-43 E-Mail: info@rapidbiomed.de Internet: www.rapidbiomed.de BIOTECH IN BAVARIA - REPORT 2022|23 119

120

Ringstraße 3 D-85764 Oberschleißheim b. München +49 (0) 89 31577199 Phone: E-Mail: info@remark-pharma.de Internet: www.remark-pharma.de REMARK GmbH Pharmaservices & Consulting CRO Keywords: Drug Development, Medical Writing, Clinical Trial Management and Monitoring, R&D Service REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals we offer the following services: • Strategic Consulting • Project Management • Sponsor Representative • Medical Affairs Services • Quality Assurance Services • Medical Marketing For more information visit our web site at www.remark-pharma.com. res mechanica BIOTECH BIOINFORMATICS Ainmillerstraße 22 D-80801 München Internet: www.resmechanica.com res mechanica is a Munich-based company that develops hema.to, a software service for automatic and supportive diagnosis of leukemia based on flow cytometric data using artificial intelligence. hema.to has achieved a level of reliability in the diagnosis of mature B-cell neoplasms that is comparable to the judgment of an experienced diagnostician and is demonstrably world-class. Kaufbeurer Straße 55 D-86830 Schwabmünchen Phone: +49 (0) 8232 5003-0 E-Mail: medical@ritter-online.de Internet: www.ritter-medical.de Ritter GmbH, Medical BIOTECH DEVICES & REAGENTS Keywords: Genomics, PCR, Pharmacogenetics, Proteomics, Devices, Automation, ELISA/EIA Ritter GmbH was founded 1965. The company is established in Schwabmünchen, Bavaria. On 25,000 m² Ritter develops and produces with about 300 employees sterile and non-sterile laboratory equipment, high precision dispensers, tips and plates, certified according to the current DIN EN ISO 9001 and 13485 standards. In more than 70 countries, millions of Ritter medical products are used in clinical and biotech- nological applications every day. Products: Robotic Consumables, Liquid Handling, Clinical Products. 120 BIOTECH IN BAVARIA - REPORT 2022|23

121

rnatics GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS RNATICS develops first-in-class, carbohydrate-coupled RNA therapeutics to inhibit disease-causing RNAs in macrophages. This novel mode of delivery to immune cells enables access to organs previously not accessible to RNA therapy offering tremendous therapeutic opportunities for multiple diseases. The most advanced drug candidate, RCS-21, is currently in development for the treatment of lung inflammation originating from viral infections, such as SARS-CoV-2. We aim to begin first-in-human clinical trials within the next 12 months. Am Klopferspitz 19a D-82152 Martinsried E-Mail: info@rnatics.com Internet: www.rnatics.com Roche Diagnostics GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research-focused healthcare with combined strength in pharma and diagnostics. At Penzberg, Roche runs one of Europe’s largest biotechnology centers for research, development and production as well as a pioneer in digital health. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring as well as therapeutic proteins with focus on antibodies and biomarkers for oncology. Nonnenwald 2 D-82377 Penzberg Phone: +49 (0) 8856 60-0 E-Mail: penzberg.allgemein@roche.com Internet: www.roche.de RPharm Germany GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Automation, Logistics For many years we have been manufacturing and packaging pharmaceuticals for patients in over 150 countries. Innovative technologies and a highly motivated and competent team guarantee highest reliability and quality standards as well as an extraordinary price-performance ratio besides patient safety and customer satisfac- tion including personal contact. A company history of more than 150 years - both independent and historically within the global production network of Pfizer, Inc. is our pride. Heinrich-Mack-Straße 35 D-89257 Illertissen Phone: +49 (0) 7303 12-0 E-Mail: r-pharm-germany@r-pharm.com Internet: www.r-pharm.de SanoLiBio GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS SanoLiBio focuses on automated solutions in blood circulating rare cell enrichment and rare cell analysis. Cost-efficiency, accessibility, scalability, and diagnostic accu- racy drive our innovations. Our technology distincts itself from any existing rare cell enrichment platform by our no-loss enrichment of desired cells. SanoLiBios market priority is non-invasive prenatal testing and cancer diagnostics and ultimately, thriving to pioneer disease prevention by cell-based liquid biopsy. Walpurgisstraße 4 D-81677 München Phone: +49 (0) 89 20 333 292 E-Mail: info@sanolibio.com Internet: www.sanolibio.com BIOTECH IN BAVARIA - REPORT 2022|23 121

122

Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89-614241230 E-Mail: info@SciRhom.com Internet: www.SciRhom.com Am Klopferspitz 19 D-82152 Planegg/Martinsried Phone: +49 (0) 89 21546375 E-Mail: info@secarna.com Internet: www.secarna.com SciRhom GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Rheumatoid Arthritis, Inflammation, Autoimmune Diseases, Antibody, Drug Development SciRhom GmbH, a biopharmaceutical start-up company, develops first-in-class anti- bodies against iRhom2, a key modulator of several crucial pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the successful completion of antibody generation campaigns, SciRhom is now pursuing the preclinical and early clinical development of monoclonal antibodies against iRhom2 for the treatment of autoimmune and other serious diseases. Secarna Pharmaceuticals GmbH & Co. KG BIOTECH THERAPEUTICS & DIAGNOSTICS Secarna Pharmaceuticals is the leading independent European antisense drug discov- ery and development company. Leveraging its proprietary LNAplus platform, Secarna develops next generation antisense oligonucleotide (ASO) therapies addressing challenging or currently undruggable targets. LNAplus™ is fully validated by over 15 in-house programs and numerous industry collaborations focusing on immuno-oncol- ogy, immunology, fibrotic-, viral-, neurodegenerative- and cardiometabolic diseases. Securetec DetektionsSysteme AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Analytical Chemistry, R&D Service, In-Vitro-Diagnostics, Infectious Diseases, Antibody, Toxicology, Small Molecules Lilienthalstraße 7 D-85579 Neubiberg Phone: +49 (0) 89 2030 8016-51 E-Mail: info@securetec.net Internet: www.securetec.net Securetec Detektions-Systeme AG provides specific technologies for the detection of drugs and hazardous substances. We understand the worldwide demands of traffic safety, customs and enforcement authorities. Our competencies are the development and production of test solutions for a highly reliable day-to-day use for a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today`s world a safer one. SelectION Therapeutics GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases selectION is a privately owned biopharmaceutical company focused on the develop- ment of new peptide therapeutics for the treatment of severe autoimmune diseases and rare oncology indications. The Company has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The most advanced drug candidate is si-544, a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 547 2695-0 E-Mail: info@selectiontherapeutics.com Internet: www.selectiontherapeutics.com 122 BIOTECH IN BAVARIA - REPORT 2022|23

123

Sension GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medi- cal diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required. SERVIER Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Drug Development, Cardiovascular Diseases, Hematology, Neurology, Rheumatoid Arthritis, Oncology Servier is an international pharmaceutical company governed by a non-profit foun- dation, with its headquarters in France (Paris-Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excl. generics) in R&D. Five areas of excellence: cardiovascular, immune-inflammatory, neurodegenerative diseases, cancer, diabetes and generics. SigmaAldrich Chemie GmbH BIOTECH DEVICES & REAGENTS Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology man- ufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide. Provinostraße 52, Gebäude B14 D-86153 Augsburg Phone: +49 (0) 821 455799-0 E-Mail: info@sension.eu Internet: www.sension.eu Elsenheimerstraße 53 D-80687 München Phone: +49 (0) 89 57095-01 E-Mail: Internet: www.servier.de arnd.prilipp@servier.com Eschenstraße 5 D-82024 Taufkirchen Phone: +49 (0) 89 6513-0 E-Mail: deorders@sial.com Internet: www.sigma-aldrich.com Silantes GmbH BIOTECH DEVICES & REAGENTS Silantes GmbH, engages in development, manufacturing, marketing and distribution of stable isotopically labeled biomass and bio-molecules. By using a new patented technique for labelling S-isotopic bio-molecules, Silantes is able to offer improved quality and reduced costs for the customers in industrial and academic research fields at the same time. Additionally, international research projects with different scientific groups and close collaboration with NMR-specialists enable synergetic effects. Gollier Straße 70 C D-80339 München Phone: +49 (0) 89 500941-0 E-Mail: info@silantes.com Internet: www.silantes.com BIOTECH IN BAVARIA - REPORT 2022|23 123

124

Kurpromenade 2 D-95448 Bayreuth Phone: +49 (0) 921 730052-10 Internet: www.simfo.de Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 856625-55 E-Mail: info@sinatur.net Internet: www.sinatur.net SIMFO GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS simfo GmbH is a research and development facility with advanced expertise in per- sonalized medicine. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development. SiNatur GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Metabolic Diseases, Diabetics SiNatur owns the patent rights for the structure, preparation and medicinal applica- tions Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biological- ly active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity. SIRION BIOTECH GmbH BIOTECH DEVICES & REAGENTS Keywords: Gene Transfer, R&D Service, Viruses, Cell Therapy, Gene Therapy, Drug Development Am Haag 6 D-82166 Gräfelfing Phone: +49 (0) 89 700961-999 E-Mail: info@sirion-biotech.de Internet: www.sirion-biotech.com SIRION Biotech offers the world’s most comprehensive viral vector AAV-, Lentivirus-, and Adenovirus-based technologies to expedite gene and cell therapy and vaccine R&D. LentiBOOST transduction reagent is actively used to improve hematopoietic cell transductions in clinical trials (USA, Europe). Commercial arrangements range from fee-for-service, all the way to milestone & licensing. siTOOLs Biotech GmbH BIOTECH DEVICES & REAGENTS Keywords: RNAi & Antisense Lochhamer Straße 29a D-82152 Planegg Phone: +49 89 12501 4800 E-Mail: Internet: www.sitoolsbiotech.com info@sitools.de siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich‘s biotech cluster in Planegg/Martinsried. “siPools” are higly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects. 124 BIOTECH IN BAVARIA - REPORT 2022|23

125

Smart4Diagnostics GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices, Bioinformatics Smart4Diagnostics GmbH closes the data gap between blood collection and lab anal- ysis and enables a new quality standard for diagnostic decision making. We change medical diagnostics from a trust-based system into an evidence-based system. Our digital human sample fingerprint is a quantum leap forward for patient safety, the quality of medical decisions and sample turnaround time in the lab. We create a trustworthy and verifiably basis for the personalized medicine of the future. Rupert-Mayer-Straße 44 D-81379 München Phone: +49 (0) 89 724 018 40 E-Mail: Internet: www.smart4diagnostics.com contact@s4dx.com SmartBax GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, Medicinal Chemistry, Small Molecules smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens me- thicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Due to the increasing prevalence of resistance against marketed antibiotics, smartbax addresses an urgent medical need which is growing dramatically. SMARTEC IngenieurBüro BIOTECH DEVICES & REAGENTS Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/ Cell Culture Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engi- neering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Leopoldstraße 37 D-80802 München Phone: +49 (0) 151 5835 0852 E-Mail: info@smartbax.de Internet: www.smartbax.de Mühlthaler Straße 91c D-81475 München Phone: +49 (0) 89 854 665-13 E-Mail: ulrichschubert@smartecbio.de Internet: www.smartecbio.de Sourcia GmbH CRO Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices Sourcia is your high-experienced, flexible and independent partner in clinical develop- ment. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan. Lochhamer Strasse 31 D-82152 Martinsried Phone: +49 (0) 151 74403195 Internet: www.sourcia.eu BIOTECH IN BAVARIA - REPORT 2022|23 125

126

SSS International Clinical Research GmbH CRO Landsberger Straße 23/25 D-82110 Germering Phone: +49 (0) 89 800 650-0 E-Mail: info@cro-sss.de Internet: www.cro-sss.eu SSS International Clinical Research is a Service Provider for the pharmaceutical, bio- technological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania and Poland. We provide high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for more than 25 years and through many successful projects. Staburo GmbH – Statistical Consulting CRO Keywords: Oncology, Data Management and Biostatistics, Biomarker Discovery & Development, Bioinformatics, Data Management, Cardiovascular Diseases Staburo GmbH is a data science company, specialized in statistical consulting, pro- gramming and bioinformatics for healthcare projects. Our core competencies include Clinical Statistics, Translational Medicine & Biomarkers, Phase I & Pharmacokinetics/-Dy- namics, Data Transparency & Disclosure Services, Health Technology Assessment and Bioinformatics. Our customers are international pharmaceutical companies (7 of the top 20), CROs, biotech companies and medical device manufacturers. SÜDLABORBEDARF GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Devices SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield. Swedish Orphan Biovitrum GmbH, SOBI BIOTECH THERAPEUTICS & DIAGNOSTICS Swedish Orphan Biovitrum is an international company specializing in rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of these patients and their families. The Swedish Orphan Biovitrum GmbH (Sobi) has been active in Germany since 2017. The company is based in Martinsried, Bavaria. Behind the success of Sobi are the nearly 40 employees in Germany whose daily motivation is to help improve the lives of patients with rare diseases. Aschauer Straße 26b D-81549 München Phone: +49 (0) 89 5527 1520 E-Mail: info@staburo.de Internet: www.staburo.de Starnberger Straße 22 D-82131 Gauting Phone: +49 (0) 89 850 6527 E-Mail: info@suedlabor.de Internet: www.suedlabor.de Fraunhoferstraße 9a D-82152 Martinsried Phone: +49 (0) 89 550 66 760 E-Mail: mail.de@sobi.com Internet: www.sobi.com 126 BIOTECH IN BAVARIA - REPORT 2022|23

127

Syneos Health Germany GmbH CRO Keywords: CRO/CMO, Clinical Trial Management and Monitoring, Medical Writing The coming together of INC Research and inVentiv Health as one global company, called Syneos Health, has created the industry’s only true end-to-end solution. This one entity combines world-renowned clinical research and commercialization capa- bilities with today’s most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide. Stefan-George-Ring 6 D-81929 München Phone: +49 (0) 89 993913-0 E-Mail: reza.khosravani@syneoshealth.com Internet: www.syneoshealth.com Syntacoll GmbH PHARMA & CHEMICAL INDUSTRY Syntacoll is a subsidiary company and the only development and production site of Innocoll Pharmaceuticals Limited, an international pharmacy group. Since 1992, Syntacoll is developing and producing innovative, collagen-based ab- sorbable implants and wound dressings at our production site in Saal an der Donau. Our facility is GMP compliant and ISO 13485 certified. Additionally, Syntacoll holds a manufacturing license for collagen-based drugs. Donaustraße 24 D-93342 Saal/Donau Phone: +49 (0) 9441 6860-0 E-Mail: info@syntacoll.de Internet: www.syntacoll.de Synteract GmbH CRO Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain Synteract is an innovative mid-size CRO with European HQ in Munich. We are providing international, full-service, Phase I-III clinical trials services to biopharma companies. Over its nearly 35-year history, Synteract has contributed to more than 240 product approvals. Our core development areas are: oncology, dermatology, neuro sciences, general medicine and vaccination, rare/orphan disease, and pediatrics. Albrechtstraße 14 D-80636 München Phone: +49 (0) 89 126680-0 Internet: www.synteract.com Systasy Bioscience GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development Systasy Bioscience GmbH is a biopharma company, founded in 2012, engineering biology to decode the human complexity for discovering new drugs targeting mental disorders. Systasy’s game changing approach will disrupt the drug market by introduc- ing a scalable and unrivaled signalomics-based and AI-powered drug discovery en- gine, called Barcoded Drug Discovery Engine. Systasy combines its core technologies, molecular barcoding and human disease modelling, with phenogenomic compound screening and AI crawled-big data analysis to enable personalized medicine. Balanstraße 6 D-81669 München Phone: + 49 (0) 89 2155 3085 E-Mail: info@systasy.de Internet: www.systasy.de BIOTECH IN BAVARIA - REPORT 2022|23 127

128

Friedrich-Bergius-Ring 15 D-97076 Würzburg Phone: +49 (0) 931 250 99 712 E-Mail: info@t-curx.com Internet: www.t-curx.com TCURX GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Oncology, Hematology, Personalized Medicine, Cell Therapy, Drug Development T-CURX develops a new generation of CAR T cells for personalized cancer immunother- apy built on proprietary technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CAR T therapy. T cells are reprogrammed using virus-free gene transfer to destroy tumor cells. CAR T cells are living drugs that persist life-long and aim to provide continuous protection from relapse. T-CURX’s prod- uct pipeline addresses several cancer indications within hematology and oncology. TauroPharm GmbH PHARMA & CHEMICAL INDUSTRY August-Bebel-Straße 51 D-97297 Waldbüttelbrunn Phone: +49 (0) 931 40480511 E-Mail: infos@tauropharm.de Internet: www.tauropharm.de TauroPharm GmbH is a healthcare company founded in 2000 and based in Waldbüt- telbrunn, Germany. We want to minimize infection risks in global healthcare and thus increase patient safety worldwide.We manufacture products that prevent infections associated with central venous catheters and port systems in a variety of applications like administration of medication in the fields of oncology and haematology as well as other implanted medical devices. Propst-Hartl-Straße 8 D-82398 Polling Phone: +49 (0) 881-12123876 E-Mail: info@ncd-company.com Internet: www.ncd-company.com The NCD Company GmbH BIOTECH PRECLINICAL SERVICES Keywords: Toxicology The NCD Company is an independent project company and provides all services of a non-clinical development department for biotech and pharma companies with an experienced team at highest level. By outsourcing preclinical development, you will increase flexibility, save internal resources and ensure the access to a broad spec- trum of knowledge and experience. We provide Drug Development Planning and Management, Safety Testing/Toxicology, ADME/DMPK, Outsourcing, QA (GLP) and Regulatory Submission. Therawis Diagnostics GmbH PHARMA & CHEMICAL INDUSTRY Keywords: In-Vitro-Diagnostics, Oncology Grillparzerstrasse 14 D-81675 München Phone: +49 (0) 89 41 42 45 57-0 E-Mail: info@therawis.com Internet: www.therawis.com Therawis Diagnostics GmbH was founded by an experienced team with proven track record in oncology, diagnostics, corporate development, capital markets and devel- ops diagnostics to support and guide optimal therapy for cancer patients. Therawis Diagnostics and its partner Qjagen, Hilden, Germany, launched the therascreenPITX2 RGQ PCR Kit in 2018, a novel clinically validated biomarker test to predict outcome to anthracycline-based chemotherapy in high risk breast cancer patients. 128 BIOTECH IN BAVARIA - REPORT 2022|23

129

Thermo Fisher Scientific GENEART GmbH BIOTECH DEVICES & REAGENTS Keywords: Genomics, Combinatorics Thermo Fisher Scientific supplies innovative solutions for the world’s pharmaceutical and biopharmaceutical industries. With applications that span the drug development process - from drug discovery through large-scale commercial production - we provide a broad range of products and services including single-use technologies, customized fluid transfer systems, high-quality media and sera, freezing and storage equipment, and innovative consumables and reagents, purification, and analytics. Thermosome GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery Im Gewerbepark B35 D-93059 Regensburg Phone: +49 (0) 941 94276-0 E-Mail: geneart.info@lifetech.com Internet: www.thermofisher.com Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma. A m Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 7167 760-31 +49 (0) 89 7167 760-49 Fax: E-Mail: info@thermosome.com Internet: www.thermosome.com tilibit nanosystems GmbH BIOTECH DEVICES & REAGENTS Keywords: Nanobiotechnology, New Materials, R&D Service tilibit nanosystems is specialized in the development and production of functional DNA nanostructures. We offer the design of custom structures for research applica- tions, as well as collaborative development projects with industry partners for novel commercial applications. Nanostructure application fields comprise fields such as drug delivery, diagnostics, sensors, and analytical devices. Friedenstraße 18 D-81671 München E-Mail: info@tilibit.com Internet: www.tilibit.com TILL I.D. GmbH BIOTECH DEVICES & REAGENTS Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis TILL I.D. is a small, innovative company in between research and industry. We devel- op concepts and prototypes for all areas in light microscopy. Our projects focus on an innovative microscopy platform, which is entirely tailored for digitalization. Its versatility and flexibility does not stem from a number of attachable modules, but from a fundamental design to which different imaging techniques and illumination concepts have contributed right from the start. Am Klopferspitz 19a D-82152 Planegg/Martinsried Phone: +49 (0) 89 2032 4142-20 E-Mail: info@till-id.com Internet: www.till-id.com BIOTECH IN BAVARIA - REPORT 2022|23 129

130

TopLab GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Proteomics Fraunhoferstraße 18 a D-82152 Martinsried Phone: +49 (0) 89 2441 45412-81 E-Mail: info@toplab.de Internet: www.toplab.de TOPLAB GmbH is a leading ISO 9001/GMP certified and FDA registered service provider having outstanding expertise in proteome analysis, protein identification and charac- terization with more than 25 years of experience. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs. TRIGAS e.K. Scientific Solutions CRO Keywords: Laboratory, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Regulatory Affairs, In-Vitro-Diagnostics, Molecular Diagnostics TRIGA-S is a contract research institute and has stood for quality and reliability in clinical and analytical studies of in-vitro diagnostics for over 20 years. We offer manufacturers tailor-made performance studies according to EU-IVDR. In addition, we carry out contract measurements in our in-house laboratory. We are ISO 13485 certified and work according to the requirements of GCP/GCLP, GDP and GLP. TRION Research GmbH BIOTECH PRECLINICAL SERVICES Keywords: Drug Development, Immune Therapy, Antibody Production Service Our services comprise Liquid Biopsy diagnostics with the analysis of virus-infected cells and the detection of disseminated tumor cells in blood, urine and other body fluids. Moreover, we offer the full range of preclinical and clinical support from trial design over immunomonitoring and tumor biology analysis to data management and logistics solutions. We work together with our partners to elucidate the modes of action of new compounds. Tubulis GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Oncology, AntibodyDrugConjugate ADC, Drug Delivery, Drug Develop- ment Tubulis® generates uniquely matched protein-drug conjugates by combining pro- prietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlim- ited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets. Mühltal 5 D-82392 Habach Phone: +49 (0) 8847 695 78-0 E-Mail: info@triga-s.de Internet: www.triga-s.de Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 700 766-0 E-Mail: mail@trionresearch.de Internet: www.trionresearch.com Butenandtstraße 1 D-81377 München E-Mail: info@tubulis.com Internet: www.tubulis.com 130 BIOTECH IN BAVARIA - REPORT 2022|23

131

vasopharm GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/ cGMP signal cascade and its functional counterpart NOX. vasopharm’s drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral ves- sels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury. Vectura GmbH MEDTECH Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary for- mulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies. Friedrich-Bergius-Ring 15 D-97076 Würzburg Phone: +49 (0) 931 359099-0 E-Mail: office@vasopharm.com Internet: www.vasopharm.com Robert-Koch-Allee 29 D-82131 Gauting Phone: +49 (0) 89 897969-0 E-Mail: info@vectura.com Internet: www.vectura.com Velvio GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Velvio develops medicines to restore organ repair functions as treatment for Orphan Diseases in Neurodegeneration – first of all Amyotrophic Lateral Sclerosis (ALS). Further, Velvio is innovating new opportunities in Idiopathic Pulmonary Fibrosis (IPF) and treatment concepts in Immune-Oncology, Liver and Brain Tumors. From our broad compound pipeline, we are ready to go “first in man” with ALS and we are about to finish preclinical drug development in IPF. Am BioPark 11 D-93053 Regensburg Phone: +49 (0) 941 463 747 30 E-Mail: office@velvio.com Internet: www.velvio.com vermicon AG BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Microscopy, Laboratory, Bioanalytics, Other Diagnostics vermicon AG provides innovative technologies, specific microbiological expertise and cultivation-independent methods for the in-situ identification, quantification and vis- ualization of microorganisms. By using FISH (Fluorescence In Situ Hybridization), Flow Cytometry, qPCR, NGS and individually adapted solutions, vermicon provides deeper and holistic understanding of the microbial ecology within the samples. With satisfied customers worldwide, vermicon is driving the evolution of modern microbiology. Zeppelinstraße 3 D-85399 Hallbergmoos Phone: +49 (0) 811 1244940 E-Mail: info@vermicon.com Internet: www.vermicon.com BIOTECH IN BAVARIA - REPORT 2022|23 131

132

Vertex Pharmaceuticals (Germany) GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Sonnenstraße 19/Geb. 2, 2nd floor D-80331 München Phone: +49 (0) 89 20602-9900 Fax: +49 (0) 89 20602-9907 Internet: www.vrtx.com Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying cause of cystic fibrosis (CF) and has several ongoing clinical and research programs in CF. Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases, as well as a rapidly expanding pipeline of genetic and cell therapies. verum.de GmbH CRO Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases verum is a regional CRO specializing in clinical trials management in Germany, Austria as well as in Central and Eastern Europe. Since 2001 verum served 158 trials in different areas: neuroscience, oncology, cardiology, etc. During last years verum is also focused on biosamples (BS) collection studies, sponsored by developers and manufactures of integrated systems for the analysis of genetic variation and biological function. We are an expert in regulatory and ethic affairs for BS collection. vicron gmbh BIOTECH THERAPEUTICS & DIAGNOSTICS vicron applies its medical expertise to develop Decision Support Systems for doctors. Guideline-derived and proprietary algorithms as well as advanced data analytics are designed to facilitate data-based treatment decisions in real time. To ensure data integrity, vicron develops decentralized data management processes with on-site anonymization. Vifor Pharma Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Vifor Pharma is an internationally active pharma company, which researches, develops, produces and markets its own pharmaceutical products worldwide. The Company’s main area of focus is iron replacement therapy, Vifor Fresenius Medical Care Renal Pharma and infectious diseases. Kraillinger Straße 1 D-82152 Planegg Phone: +49 (0) 89 800777-60 E-Mail: Internet: www.verum.de verum@verum.de Föhrenstraße 12 D-85649 Brunnthal Internet: www.vicron.com Baierbrunner Straße 29 D-81379 München Phone: +49 (0) 89 324918 600 E-Mail: Internet: www.viforpharma.de info-de@viforpharma.com 132 BIOTECH IN BAVARIA - REPORT 2022|23

133

Biotechnologie 2023 (25. Jg.) GEDRUCKT + E-MAGAZIN + WEB Digitale Version: Erweitert um multimediale Inhalte und Funktionen – ideal zum mobilen Lesen! ) m o c . e b o d a . k c o t s e l l a ( i o d u t S y k S n e e r G i , t r e b G a n i r I , y k s y a n e S , r e n g i s e d e h t e i l l o , g s o t n a s a , t r a e n l i l r a t s , e b m o c n i i i , v o k z S i e g r e S , n o i t i d a r T r o t c e V , n o o t a d n u s © : r e d l i B ; n o i t i s o p m o K e n e g e : e g a i l l o c d l i B SAVE THE DATES! Die große Jubiläumsausgabe „25 Jahre Biotechnologie“ Erscheinungstermin: 30. September 2023 Buchungsschluss Partnerschaften & Anzeigen: 18. September 2023 9. Finance Day: 24. Oktober 2023, Faculty Club G2B (Gateway to Biotech), Innovations- und Gründerzentrum Biotechnologie (IZB), Martinsried; Halbtagesprogramm (ab ca. 13.00 Uhr) mit Keynotes, Panels und Diskussionen, Abendveranstaltung „25 Jahre Biotechnologie“ (ab ca. 18.00 Uhr) 10. Finance Day: 11. April 2024, im Rahmenprogramm der analytica (Messe München, 9.-12.4.2024), Ganztages programm & Networking Reception (ab ca. 17.00 Uhr) Ansprechpartner Karin Hofelich, Verlagsleiterin Life Sciences, hofelich@goingpublic.de, Tel.: +49 (0) 89-2000 339-54 Urs Moesenfechtel, Redakteur Life Sciences, moesenfechtel@goingpublic.de, Tel.: +49 (0) 89-2000 339-55 Plattform Life SciencesSeptember 2023 – 12,50 EUR (D) 3Technologie – Finanzierung – InvestmentJubiläumsausgabeJubiläumsausgabeBiotechnologie Biotechnologie (25. Jg.)(25. Jg.)WHAT‘SWHAT‘SNEXT?NEXT?Weitere Informationen zum Thema finden Sie unter:www.plattform-lifesciences.deinPlattform Life SciencesSeptember 2023 – 12,50 EUR (D) 3Technologie – Finanzierung – InvestmentJubiläumsausgabeJubiläumsausgabeBiotechnologie Biotechnologie (25. Jg.)(25. Jg.)WHAT‘SWHAT‘SNEXT?NEXT?Weitere Informationen zum Thema finden Sie unter:www.plattform-lifesciences.dein

134

Semmelweisstraße 3 D-82152 Planegg E-Mail: info@ViGeneron.com Internet: www.vigeneron.com Behringstraße 11 D-82152 Planegg-Steinkirchen Phone: +49 (0) 89 899336 E-Mail: Internet: www.viramed.de viramed@viramed.de ViGeneron Gmbh BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Neuro-Degeneration, Ophtalmology, Gene Therapy, Industrial Biotechnology, Orphan Drug ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharma- ceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. Viramed Biotech AG BIOTECH DEVICES & REAGENTS Keywords: ELISA/EIA, Clinical Diagnostics, In-Vitro-Diagnostics, Infectious Diseases, Chip/Array Technology Based on 40 years of experience in European and American markets Viramed® develops, produces and sells In-Vitro-Diagnostic test kits. Through proprietary research and develop- ment, the ViraChip® microarray product line is continuously expanding. Viramed® focuses on the serological detection of autoantibodies as well as antibodies against infectious disease parameters like Borrelia, Yersinia, Treponema, Helicobacter, Bordetella, SARS-CoV-2, EBV, CMV, Hepatitis E Virus, Parvovirus B19, Zika Virus, Dengue Virus, Chikungunya Virus and Toxoplasma. Software solutions, device design and manufacturing provide full automation for the ViraChip® technology in the diagnostic laboratory. vivoPharm Europe Ltd CRO Keywords: Bioanalytics, Pharmacokinetics, Oncology, Drug Development, Pharmacology, Toxicology, Vaccines Grillparzerstraße 25 D-81675 München Phone: + 49 (0) 89 122 287 6-90 E-Mail: Internet: www.vivoPharm.com info@vivopharm.eu vivoPharm is a successful and fast-growing precision research organization (CRO) that provides integrated preclinical services worldwide. Using our experience and knowledge, we assist in the planning and performance of tailored studies, from discovery stage through to clinical development and beyond. We’re a unique IO precision service organization, active in preclinical and clinical services. All work is carried in AAALAC accredited and GLP compliant facilities in Australia and the US. Wacker Chemie AG PHARMA & CHEMICAL INDUSTRY Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine. Hanns-Seidel-Platz 4 D-81737 München Phone: +49 (0) 89 6279-0 E-Mail: info@wacker.com Internet: www.wacker.com 134 BIOTECH IN BAVARIA - REPORT 2022|23

135

Winicker Norimed GmbH Medizinische Forschung CRO Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Manage- ment and Monitoring, Pharmacovigilance, Regulatory Affairs Winicker Norimed GmbH is an independent contract research organization. We man- age projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients SOPs. Winicker Norimed manages phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies. Deutschherrnstraße 15-19 D-90429 Nürnberg Phone: +49 (0) 911 92680-0 E-Mail: wn@winicker-norimed.com Internet: www.winicker-norimed.com XLprotein GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: AntibodyDrugConjugate ADC, Drug Development, Drug Delivery, Pharmaco- kinetics, Peptide/Protein, Oncology, Endocrinology, Inflammation, Rheumatoid Arthritis XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extend- ed plasma half-life as well as prolonged residence time in the eye. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in numerous partnerships with international pharmaceutical and biotech companies at various levels. Lise-Meitner-Straße 30 D-85354 Freising Phone: +49 (0) 8161 53730-90 E-Mail: info@xl-protein.com Internet: www.xl-protein.com XVir® Therapeutics GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS XVir Therapeutics GmbH is focusing on the clinical development of oncolytic adeno- viruses for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. XVir Therapeutics has completed preclinical development of its most advanced product candidate XVir and is preparing a Phase I clinical study in the indication glioblastoma. XVir’s therapeutic approach is covered by proprietary patents and patent applications, respectively. Nymphenburger Straße 1 D-80335 München Phone: +49 (0) 89 9931 7446 E-Mail: info@xvir.com Internet: www.xvir.com BIOTECH IN BAVARIA - REPORT 2022|23 135

136

Zeppelinstraße 1 D-85399 Hallbergmoos Phone: +49 (0) 8161 9656000 Mobil.: +49 (0) 172 73 50 948 E-Mail: manfred.seifert@zeta.com Internet: www.zeta.com Zeta GmbH BIOTECH & PHARMA PRODUCTION Keywords: Bioinformatics, Data Management and Biostatistics, Devices, Bioprocessing, Industrial Biotechnology, Automation The ZETA Group, with 800 highly qualified employees and 13 subsidiaries worldwide, specializes in planning, automation, digitization and maintenance of customized bio- pharmaceutical facilities for aseptic process solutions. ZETA acts as a one-stop shop, combining plant engineering with HVAC and cleanroom design. Zimmer BioTech GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Junkersstraße 9 D-89231 Neu-Ulm Phone: +49 (0) 7304 9283270 E-Mail: info@zimmer.de Internet: www.zimmer.de Zimmer BioTech, a Neu-Ulm, Germany-based start-up is advancing Alevin deep a drug based on 5-Aminolevulinic acid (ALA), used for treatment of actinic keratoses in photodynamic therapy (PDT). New developments show a huge upside potential as the drug could be used to treat Acne. Investors include Zimmer MedizinSysteme GmbH, the medical device producer, and High-Tech Gründerfonds. The company will use the funds to continue to develop a new therapy to combat skin cancer and Acne. 136 BIOTECH IN BAVARIA - REPORT 2022|23

138

About this Study: Data collection For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods/data. The biotechnology companies were classified according to the location of their headquarters inside or outside Bavaria as ‘international/national’ or ‘Bavarian (SME)’. The classification into OECD and non-OECD biotech companies as found in previous reports has been dispensed with, as this does not accurately portray the diversity of the biotech pharma ecosystem. Data were collected by our own survey between March and June 2023. The survey tool Surveymonkey was used for this. In this context it was also possible to obtain assessments of the business situation and international markets from a total of 78 companies in the industry. Other sources of data are personal communication and internet research. Possible deviations from previously published figures are the result of additional data gathered that also may refer to previous years. The period under review for this report is 2022. There are more than 300 company profiles listed in the appendix of this brochure. Not every company listed is also considered in this survey, for example some companies with very specific services. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in the appendix. More than 500 Bavarian companies in medical engineering are not included in this survey (by numbers or with profiles). Processing of data and estimation procedures For the assignment of the companies to branch areas and business fields, the answers of the companies, the classifications in the databases of BioM and BIO Deutschland e.V., the classification by the Chamber of Industry and Commerce as well as internet research were used. To determine the number of employees, the mean of the selected size ranges was used for companies for which no precise figures or additional information were given. In addition, the values were supplemented by annual financial statements and internet research as well as reported figures from the previous year. For the extrapolation of the total number of employees per group, the mean values of the respective branch areas (biotechnology, pharmaceuticals, CRO, others) were then calculated and multiplied by the total number of companies in the areas. The assignment and the estimates given were made with the greatest possible care; however, no liability is assumed for the completeness and correctness of the information. Published in June, 2023 IMPRINT Editorial Staff: Dr. Andreas Berghammer, Dr. Christina Grimm, Gabriele Klingner, Anja Kroke, Dr. Max Pöhlmann, Christiane Proll, Birgitta von Glass, Dr. Jens Wiehler Data collection and analysis: Dr. Andreas Berghammer, Dr. Christina Grimm, Nikolaus Repgen Company Profiles: Dr. Christina Grimm, Nikolaus Repgen Advertisement: Dr. Andreas Berghammer Podcast interviews were produced on behalf of BioM by Edmund Soutschek We thank the Bavarian companies and the regional organizations of the Bavarian Biotechnology Cluster for supporting this survey. CONTACT Prof. Dr. Ralf Huss, CEO BioM Managing Director and Spokesman of the Bavarian Biotechnology Cluster The Bavarian and the Munich Biotechnology Clusters are managed by: BioM Biotech Cluster Development GmbH Am Klopferspitz 19 a D-82152 Martinsried Phone: +49 (0)89 - 89 96 79-0 Fax: +49 (0)89 - 89 96 79-79 E-Mail: info@bio-m.org www.bio-m.org The layout, graphics and other contents of this brochure of the Bavarian Biotechnology Cluster are protected by copyright law. Layout-Design: GRAFIK·SL Stephanie Lüdeling, 83646 Wackersberg www.grafik-sl.de Pictures copyright as indicated Supported by the Bavarian Ministry of Economic Affairs, Regional Development and Energy https://www.stmwi.bayern.de

140

Fördergesellschaft IZB mbH Am Klopferspitz 19 82152 Planegg/Martinsried Tel. + 49 (0)89.55 279 48-0 Fax + 49 (0)89.55 279 48-29 info@izb-online.de www.izb-online.de YOU HAVE THE IDEA— WE HAVE THE LOCATION  Site: 26,000 m2, S1 laboratories  Real estate and facility management on site  Faculty Club and conference rooms for up to 100 people  Kindergarden (Bio Kids)  Hotel CAMPUS AT HOME  Restaurant SEVEN AND MORE, THE BOWL Food Lounge  On the Martinsried Campus: over 50 start -ups in the IZB, two Max Planck Institutes, ten faculties of the LMU, Clinic of the University Munich WHERE THE FUTURE BECOMES REALITY

Content

Greeting

Preface Prof. Dr. Ralf Huss

Company Development

Supporting the start-up scene is very close to my heart

MAxL – Munich Accelerator Life Sciences & Medicine

Next generation antimicrobials

Investments into biotech

We want to understand the language of cells and communicate with them

AI in radiology

DigiMed Bayern

Bavarian successes in CAR-T cell therapy

BIO-Europe 2023 in Munich

Life Science Centers in Bavaria

Development in Regensburg

Billion deal at the IZB

Company profiles

Imprint and contact